id	sid	tid	token	lemma	pos
dti-2343	1	1	dti	dti	PROPN
dti-2343	1	2	drug	drug	PROPN
dti-2343	1	3	target	target	NOUN
dti-2343	1	4	insights	insight	NOUN
dti-2343	1	5	2022	2022	NUM
dti-2343	1	6	;	;	PUNCT
dti-2343	1	7	16	16	NUM
dti-2343	1	8	:	:	SYM
dti-2343	1	9	6	6	NUM
dti-2343	1	10	-	-	SYM
dti-2343	1	11	11	11	NUM
dti-2343	1	12	issn	issn	PROPN
dti-2343	1	13	1177	1177	NUM
dti-2343	1	14	-	-	SYM
dti-2343	1	15	3928	3928	NUM
dti-2343	1	16	|	|	ADV
dti-2343	1	17	doi	doi	NOUN
dti-2343	1	18	:	:	PUNCT
dti-2343	1	19	10.33393	10.33393	NUM
dti-2343	1	20	/	/	SYM
dti-2343	1	21	dti.2022.2343	dti.2022.2343	NOUN
dti-2343	1	22	original	original	ADJ
dti-2343	1	23	research	research	NOUN
dti-2343	1	24	article	article	NOUN
dti-2343	1	25	drug	drug	NOUN
dti-2343	1	26	target	target	NOUN
dti-2343	1	27	insights	insight	NOUN
dti-2343	1	28	issn	issn	VERB
dti-2343	1	29	1177	1177	NUM
dti-2343	1	30	-	-	SYM
dti-2343	1	31	3928	3928	NUM
dti-2343	1	32	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2343	1	33	©	©	PROPN
dti-2343	1	34	2022	2022	NUM
dti-2343	1	35	the	the	DET
dti-2343	1	36	authors	author	NOUN
dti-2343	1	37	.	.	PUNCT
dti-2343	2	1	this	this	DET
dti-2343	2	2	article	article	NOUN
dti-2343	2	3	is	be	AUX
dti-2343	2	4	published	publish	VERB
dti-2343	2	5	by	by	ADP
dti-2343	2	6	aboutscience	aboutscience	NOUN
dti-2343	2	7	and	and	CCONJ
dti-2343	2	8	licensed	license	VERB
dti-2343	2	9	under	under	ADP
dti-2343	2	10	creative	creative	ADJ
dti-2343	2	11	commons	common	NOUN
dti-2343	2	12	attribution	attribution	NOUN
dti-2343	2	13	-	-	PUNCT
dti-2343	2	14	noncommercial	noncommercial	ADJ
dti-2343	2	15	4.0	4.0	NUM
dti-2343	2	16	international	international	NOUN
dti-2343	2	17	(	(	PUNCT
dti-2343	2	18	cc	cc	NOUN
dti-2343	2	19	by	by	ADP
dti-2343	2	20	-	-	PUNCT
dti-2343	2	21	nc	nc	PROPN
dti-2343	2	22	4.0	4.0	NUM
dti-2343	2	23	)	)	PUNCT
dti-2343	2	24	.	.	PUNCT
dti-2343	3	1	commercial	commercial	ADJ
dti-2343	3	2	use	use	NOUN
dti-2343	3	3	is	be	AUX
dti-2343	3	4	not	not	PART
dti-2343	3	5	permitted	permit	VERB
dti-2343	3	6	and	and	CCONJ
dti-2343	3	7	is	be	AUX
dti-2343	3	8	subject	subject	ADJ
dti-2343	3	9	to	to	ADP
dti-2343	3	10	publisher	publisher	NOUN
dti-2343	3	11	’s	’s	PART
dti-2343	3	12	permissions	permission	NOUN
dti-2343	3	13	.	.	PUNCT
dti-2343	4	1	full	full	ADJ
dti-2343	4	2	information	information	NOUN
dti-2343	4	3	is	be	AUX
dti-2343	4	4	available	available	ADJ
dti-2343	4	5	at	at	ADP
dti-2343	4	6	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2343	4	7	anatomical	anatomical	ADJ
dti-2343	4	8	and	and	CCONJ
dti-2343	4	9	functional	functional	ADJ
dti-2343	4	10	responses	response	NOUN
dti-2343	4	11	to	to	ADP
dti-2343	4	12	single	single	ADJ
dti-2343	4	13	brolucizumab	brolucizumab	NOUN
dti-2343	4	14	injection	injection	NOUN
dti-2343	4	15	in	in	ADP
dti-2343	4	16	neovascular	neovascular	NOUN
dti-2343	4	17	age	age	NOUN
dti-2343	4	18	-	-	PUNCT
dti-2343	4	19	related	relate	VERB
dti-2343	4	20	macular	macular	ADJ
dti-2343	4	21	degeneration	degeneration	NOUN
dti-2343	4	22	patients	patient	NOUN
dti-2343	4	23	not	not	PART
dti-2343	4	24	responding	respond	VERB
dti-2343	4	25	to	to	ADP
dti-2343	4	26	antiangiogenics	antiangiogenic	NOUN
dti-2343	4	27	:	:	PUNCT
dti-2343	4	28	a	a	DET
dti-2343	4	29	case	case	NOUN
dti-2343	4	30	series	series	PROPN
dti-2343	4	31	silvio	silvio	PROPN
dti-2343	4	32	zuccarini	zuccarini	PROPN
dti-2343	4	33	,	,	PUNCT
dti-2343	4	34	fabrizio	fabrizio	PROPN
dti-2343	4	35	puce	puce	PROPN
dti-2343	4	36	,	,	PUNCT
dti-2343	4	37	alessandro	alessandro	PROPN
dti-2343	4	38	crisà	crisà	PROPN
dti-2343	4	39	villa	villa	PROPN
dti-2343	4	40	donatello	donatello	PROPN
dti-2343	4	41	hospital	hospital	PROPN
dti-2343	4	42	,	,	PUNCT
dti-2343	4	43	department	department	NOUN
dti-2343	4	44	of	of	ADP
dti-2343	4	45	ophthalmology	ophthalmology	NOUN
dti-2343	4	46	,	,	PUNCT
dti-2343	4	47	florence	florence	PROPN
dti-2343	4	48	italy	italy	PROPN
dti-2343	4	49	abstract	abstract	ADJ
dti-2343	4	50	introduction	introduction	NOUN
dti-2343	4	51	:	:	PUNCT
dti-2343	4	52	neovascular	neovascular	NOUN
dti-2343	4	53	age	age	NOUN
dti-2343	4	54	-	-	PUNCT
dti-2343	4	55	related	relate	VERB
dti-2343	4	56	macular	macular	ADJ
dti-2343	4	57	degeneration	degeneration	NOUN
dti-2343	4	58	(	(	PUNCT
dti-2343	4	59	namd	namd	NOUN
dti-2343	4	60	)	)	PUNCT
dti-2343	4	61	is	be	AUX
dti-2343	4	62	treated	treat	VERB
dti-2343	4	63	with	with	ADP
dti-2343	4	64	antivascular	antivascular	ADJ
dti-2343	4	65	endothelial	endothelial	ADJ
dti-2343	4	66	growth	growth	NOUN
dti-2343	4	67	factor	factor	NOUN
dti-2343	4	68	(	(	PUNCT
dti-2343	4	69	anti	anti	ADJ
dti-2343	4	70	-	-	ADJ
dti-2343	4	71	vegf	vegf	ADJ
dti-2343	4	72	)	)	PUNCT
dti-2343	4	73	drugs	drug	NOUN
dti-2343	4	74	.	.	PUNCT
dti-2343	5	1	however	however	ADV
dti-2343	5	2	,	,	PUNCT
dti-2343	5	3	resistance	resistance	NOUN
dti-2343	5	4	to	to	ADP
dti-2343	5	5	anti	anti	ADJ
dti-2343	5	6	-	-	ADJ
dti-2343	5	7	vegf	vegf	ADJ
dti-2343	5	8	therapy	therapy	NOUN
dti-2343	5	9	is	be	AUX
dti-2343	5	10	observed	observe	VERB
dti-2343	5	11	in	in	ADP
dti-2343	5	12	some	some	DET
dti-2343	5	13	patients	patient	NOUN
dti-2343	5	14	.	.	PUNCT
dti-2343	6	1	brolucizumab	brolucizumab	PROPN
dti-2343	6	2	is	be	AUX
dti-2343	6	3	a	a	DET
dti-2343	6	4	new	new	ADJ
dti-2343	6	5	-	-	PUNCT
dti-2343	6	6	generation	generation	NOUN
dti-2343	6	7	anti	anti	ADJ
dti-2343	6	8	-	-	ADJ
dti-2343	6	9	vegf	vegf	ADJ
dti-2343	6	10	drug	drug	NOUN
dti-2343	6	11	for	for	ADP
dti-2343	6	12	the	the	DET
dti-2343	6	13	treatment	treatment	NOUN
dti-2343	6	14	of	of	ADP
dti-2343	6	15	namd	namd	NOUN
dti-2343	6	16	,	,	PUNCT
dti-2343	6	17	with	with	ADP
dti-2343	6	18	proven	prove	VERB
dti-2343	6	19	efficacy	efficacy	NOUN
dti-2343	6	20	in	in	ADP
dti-2343	6	21	fluid	fluid	ADJ
dti-2343	6	22	resolution	resolution	NOUN
dti-2343	6	23	and	and	CCONJ
dti-2343	6	24	long	long	ADV
dti-2343	6	25	-	-	PUNCT
dti-2343	6	26	lasting	last	VERB
dti-2343	6	27	effects	effect	NOUN
dti-2343	6	28	.	.	PUNCT
dti-2343	7	1	methods	method	NOUN
dti-2343	7	2	:	:	PUNCT
dti-2343	7	3	we	we	PRON
dti-2343	7	4	report	report	VERB
dti-2343	7	5	here	here	ADV
dti-2343	7	6	a	a	DET
dti-2343	7	7	case	case	NOUN
dti-2343	7	8	series	series	NOUN
dti-2343	7	9	of	of	ADP
dti-2343	7	10	namd	namd	ADJ
dti-2343	7	11	patients	patient	NOUN
dti-2343	7	12	not	not	PART
dti-2343	7	13	responding	respond	VERB
dti-2343	7	14	to	to	ADP
dti-2343	7	15	previous	previous	ADJ
dti-2343	7	16	anti	anti	ADJ
dti-2343	7	17	-	-	ADJ
dti-2343	7	18	vegf	vegf	ADJ
dti-2343	7	19	therapy	therapy	NOUN
dti-2343	7	20	showing	show	VERB
dti-2343	7	21	anatomical	anatomical	ADJ
dti-2343	7	22	and	and	CCONJ
dti-2343	7	23	functional	functional	ADJ
dti-2343	7	24	response	response	NOUN
dti-2343	7	25	to	to	ADP
dti-2343	7	26	a	a	DET
dti-2343	7	27	single	single	ADJ
dti-2343	7	28	intravitreal	intravitreal	NOUN
dti-2343	7	29	injection	injection	NOUN
dti-2343	7	30	of	of	ADP
dti-2343	7	31	brolucizumab	brolucizumab	NOUN
dti-2343	7	32	.	.	PUNCT
dti-2343	8	1	results	result	NOUN
dti-2343	8	2	:	:	PUNCT
dti-2343	8	3	nine	nine	NUM
dti-2343	8	4	patients	patient	NOUN
dti-2343	8	5	with	with	ADP
dti-2343	8	6	namd	namd	NOUN
dti-2343	8	7	,	,	PUNCT
dti-2343	8	8	undergoing	undergo	VERB
dti-2343	8	9	treatment	treatment	NOUN
dti-2343	8	10	with	with	ADP
dti-2343	8	11	anti	anti	ADJ
dti-2343	8	12	-	-	ADJ
dti-2343	8	13	vegf	vegf	ADJ
dti-2343	8	14	therapy	therapy	NOUN
dti-2343	8	15	(	(	PUNCT
dti-2343	8	16	aflibercept	aflibercept	PROPN
dti-2343	8	17	,	,	PUNCT
dti-2343	8	18	bevacizumab	bevacizumab	NOUN
dti-2343	8	19	,	,	PUNCT
dti-2343	8	20	or	or	CCONJ
dti-2343	8	21	ranibizumab	ranibizumab	NOUN
dti-2343	8	22	)	)	PUNCT
dti-2343	8	23	but	but	CCONJ
dti-2343	8	24	with	with	ADP
dti-2343	8	25	either	either	CCONJ
dti-2343	8	26	fluid	fluid	ADJ
dti-2343	8	27	persistence	persistence	NOUN
dti-2343	8	28	or	or	CCONJ
dti-2343	8	29	frequent	frequent	ADJ
dti-2343	8	30	fluid	fluid	ADJ
dti-2343	8	31	recurrences	recurrence	NOUN
dti-2343	8	32	in	in	ADP
dti-2343	8	33	retinal	retinal	ADJ
dti-2343	8	34	compartments	compartment	NOUN
dti-2343	8	35	,	,	PUNCT
dti-2343	8	36	were	be	AUX
dti-2343	8	37	switched	switch	VERB
dti-2343	8	38	to	to	PART
dti-2343	8	39	intravitreal	intravitreal	ADJ
dti-2343	8	40	brolucizumab	brolucizumab	NOUN
dti-2343	8	41	and	and	CCONJ
dti-2343	8	42	examined	examine	VERB
dti-2343	8	43	4	4	NUM
dti-2343	8	44	weeks	week	NOUN
dti-2343	8	45	postinjection	postinjection	NOUN
dti-2343	8	46	.	.	PUNCT
dti-2343	9	1	no	no	DET
dti-2343	9	2	signs	sign	NOUN
dti-2343	9	3	of	of	ADP
dti-2343	9	4	active	active	ADJ
dti-2343	9	5	disease	disease	NOUN
dti-2343	9	6	were	be	AUX
dti-2343	9	7	observed	observe	VERB
dti-2343	9	8	in	in	ADP
dti-2343	9	9	all	all	DET
dti-2343	9	10	but	but	SCONJ
dti-2343	9	11	one	one	NUM
dti-2343	9	12	patient	patient	NOUN
dti-2343	9	13	,	,	PUNCT
dti-2343	9	14	with	with	ADP
dti-2343	9	15	complete	complete	ADJ
dti-2343	9	16	retinal	retinal	ADJ
dti-2343	9	17	fluid	fluid	NOUN
dti-2343	9	18	resolution	resolution	NOUN
dti-2343	9	19	in	in	ADP
dti-2343	9	20	seven	seven	NUM
dti-2343	9	21	patients	patient	NOUN
dti-2343	9	22	.	.	PUNCT
dti-2343	10	1	central	central	ADJ
dti-2343	10	2	macular	macular	ADJ
dti-2343	10	3	thickness	thickness	NOUN
dti-2343	10	4	and	and	CCONJ
dti-2343	10	5	visual	visual	ADJ
dti-2343	10	6	acuity	acuity	NOUN
dti-2343	10	7	significantly	significantly	ADV
dti-2343	10	8	improved	improve	VERB
dti-2343	10	9	,	,	PUNCT
dti-2343	10	10	and	and	CCONJ
dti-2343	10	11	changes	change	NOUN
dti-2343	10	12	were	be	AUX
dti-2343	10	13	sustained	sustain	VERB
dti-2343	10	14	for	for	ADP
dti-2343	10	15	up	up	ADP
dti-2343	10	16	to	to	PART
dti-2343	10	17	12	12	NUM
dti-2343	10	18	weeks	week	NOUN
dti-2343	10	19	in	in	ADP
dti-2343	10	20	a	a	DET
dti-2343	10	21	subset	subset	NOUN
dti-2343	10	22	of	of	ADP
dti-2343	10	23	three	three	NUM
dti-2343	10	24	patients	patient	NOUN
dti-2343	10	25	.	.	PUNCT
dti-2343	11	1	no	no	DET
dti-2343	11	2	adverse	adverse	ADJ
dti-2343	11	3	reactions	reaction	NOUN
dti-2343	11	4	were	be	AUX
dti-2343	11	5	observed	observe	VERB
dti-2343	11	6	.	.	PUNCT
dti-2343	12	1	conclusions	conclusion	NOUN
dti-2343	12	2	:	:	PUNCT
dti-2343	12	3	this	this	DET
dti-2343	12	4	new	new	ADJ
dti-2343	12	5	anti	anti	ADJ
dti-2343	12	6	-	-	ADJ
dti-2343	12	7	vegf	vegf	ADJ
dti-2343	12	8	drug	drug	NOUN
dti-2343	12	9	showed	show	VERB
dti-2343	12	10	great	great	ADJ
dti-2343	12	11	efficacy	efficacy	NOUN
dti-2343	12	12	since	since	SCONJ
dti-2343	12	13	the	the	DET
dti-2343	12	14	first	first	ADJ
dti-2343	12	15	week	week	NOUN
dti-2343	12	16	from	from	ADP
dti-2343	12	17	the	the	DET
dti-2343	12	18	injection	injection	NOUN
dti-2343	12	19	with	with	ADP
dti-2343	12	20	a	a	DET
dti-2343	12	21	significative	significative	ADJ
dti-2343	12	22	reduction	reduction	NOUN
dti-2343	12	23	of	of	ADP
dti-2343	12	24	subretinal	subretinal	ADJ
dti-2343	12	25	fluid	fluid	NOUN
dti-2343	12	26	and	and	CCONJ
dti-2343	12	27	rapid	rapid	ADJ
dti-2343	12	28	improvement	improvement	NOUN
dti-2343	12	29	of	of	ADP
dti-2343	12	30	visual	visual	ADJ
dti-2343	12	31	acuity	acuity	NOUN
dti-2343	12	32	.	.	PUNCT
dti-2343	13	1	in	in	ADP
dti-2343	13	2	conclusion	conclusion	NOUN
dti-2343	13	3	,	,	PUNCT
dti-2343	13	4	brolucizumab	brolucizumab	NOUN
dti-2343	13	5	administered	administer	VERB
dti-2343	13	6	intravitreally	intravitreally	ADV
dti-2343	13	7	appears	appear	VERB
dti-2343	13	8	to	to	PART
dti-2343	13	9	be	be	AUX
dti-2343	13	10	an	an	DET
dti-2343	13	11	effective	effective	ADJ
dti-2343	13	12	treatment	treatment	NOUN
dti-2343	13	13	in	in	ADP
dti-2343	13	14	namd	namd	ADJ
dti-2343	13	15	patients	patient	NOUN
dti-2343	13	16	,	,	PUNCT
dti-2343	13	17	leading	lead	VERB
dti-2343	13	18	to	to	ADP
dti-2343	13	19	both	both	DET
dti-2343	13	20	early	early	ADJ
dti-2343	13	21	anatomical	anatomical	ADJ
dti-2343	13	22	and	and	CCONJ
dti-2343	13	23	functional	functional	ADJ
dti-2343	13	24	improvements	improvement	NOUN
dti-2343	13	25	.	.	PUNCT
dti-2343	14	1	keywords	keyword	NOUN
dti-2343	14	2	:	:	PUNCT
dti-2343	14	3	anti	anti	ADJ
dti-2343	14	4	-	-	NOUN
dti-2343	14	5	vegf	vegf	ADJ
dti-2343	14	6	,	,	PUNCT
dti-2343	14	7	brolucizumab	brolucizumab	NOUN
dti-2343	14	8	,	,	PUNCT
dti-2343	14	9	case	case	NOUN
dti-2343	14	10	series	series	NOUN
dti-2343	14	11	,	,	PUNCT
dti-2343	14	12	neovascular	neovascular	PROPN
dti-2343	14	13	age	age	NOUN
dti-2343	14	14	-	-	PUNCT
dti-2343	14	15	related	relate	VERB
dti-2343	14	16	macular	macular	ADJ
dti-2343	14	17	degeneration	degeneration	NOUN
dti-2343	14	18	(	(	PUNCT
dti-2343	14	19	namd	namd	NOUN
dti-2343	14	20	)	)	PUNCT
dti-2343	14	21	received	receive	VERB
dti-2343	14	22	:	:	PUNCT
dti-2343	14	23	september	september	PROPN
dti-2343	14	24	24	24	NUM
dti-2343	14	25	,	,	PUNCT
dti-2343	14	26	2021	2021	NUM
dti-2343	14	27	accepted	accept	VERB
dti-2343	14	28	:	:	PUNCT
dti-2343	14	29	march	march	PROPN
dti-2343	14	30	16	16	NUM
dti-2343	14	31	,	,	PUNCT
dti-2343	14	32	2022	2022	NUM
dti-2343	14	33	published	publish	VERB
dti-2343	14	34	online	online	ADV
dti-2343	14	35	:	:	PUNCT
dti-2343	14	36	march	march	PROPN
dti-2343	14	37	24	24	NUM
dti-2343	14	38	,	,	PUNCT
dti-2343	14	39	2022	2022	NUM
dti-2343	14	40	corresponding	correspond	VERB
dti-2343	14	41	author	author	NOUN
dti-2343	14	42	:	:	PUNCT
dti-2343	14	43	silvio	silvio	NOUN
dti-2343	14	44	zuccarini	zuccarini	PROPN
dti-2343	14	45	villa	villa	PROPN
dti-2343	14	46	donatello	donatello	PROPN
dti-2343	14	47	hospital	hospital	PROPN
dti-2343	14	48	via	via	ADP
dti-2343	14	49	attilio	attilio	PROPN
dti-2343	14	50	ragionieri	ragionieri	PROPN
dti-2343	14	51	,	,	PUNCT
dti-2343	14	52	101	101	NUM
dti-2343	14	53	50019	50019	NUM
dti-2343	14	54	,	,	PUNCT
dti-2343	14	55	sesto	sesto	PROPN
dti-2343	14	56	fiorentino	fiorentino	PROPN
dti-2343	14	57	,	,	PUNCT
dti-2343	14	58	firenze	firenze	PROPN
dti-2343	14	59	italy	italy	PROPN
dti-2343	14	60	silvio.zuccarini@virgilio.it	silvio.zuccarini@virgilio.it	PROPN
dti-2343	14	61	(	(	PUNCT
dti-2343	14	62	i.e.	i.e.	X
dti-2343	14	63	,	,	PUNCT
dti-2343	14	64	intraretinal	intraretinal	ADJ
dti-2343	14	65	fluid	fluid	NOUN
dti-2343	14	66	[	[	X
dti-2343	14	67	irf	irf	NOUN
dti-2343	14	68	]	]	X
dti-2343	14	69	,	,	PUNCT
dti-2343	14	70	subretinal	subretinal	ADJ
dti-2343	14	71	fluid	fluid	NOUN
dti-2343	14	72	[	[	X
dti-2343	14	73	srf	srf	NOUN
dti-2343	14	74	]	]	X
dti-2343	14	75	,	,	PUNCT
dti-2343	14	76	or	or	CCONJ
dti-2343	14	77	fluid	fluid	NOUN
dti-2343	14	78	accumulating	accumulate	VERB
dti-2343	14	79	in	in	ADP
dti-2343	14	80	the	the	DET
dti-2343	14	81	subretinal	subretinal	ADJ
dti-2343	14	82	pigment	pigment	NOUN
dti-2343	14	83	epithelium	epithelium	NOUN
dti-2343	14	84	[	[	X
dti-2343	14	85	sub	sub	NOUN
dti-2343	14	86	-	-	ADJ
dti-2343	14	87	rpe	rpe	ADJ
dti-2343	14	88	]	]	PUNCT
dti-2343	14	89	space	space	NOUN
dti-2343	14	90	)	)	PUNCT
dti-2343	14	91	are	be	AUX
dti-2343	14	92	used	use	VERB
dti-2343	14	93	as	as	ADP
dti-2343	14	94	biomarkers	biomarker	NOUN
dti-2343	14	95	for	for	ADP
dti-2343	14	96	disease	disease	NOUN
dti-2343	14	97	activity	activity	NOUN
dti-2343	14	98	.	.	PUNCT
dti-2343	15	1	treatment	treatment	NOUN
dti-2343	15	2	of	of	ADP
dti-2343	15	3	namd	namd	NOUN
dti-2343	15	4	is	be	AUX
dti-2343	15	5	based	base	VERB
dti-2343	15	6	on	on	ADP
dti-2343	15	7	the	the	DET
dti-2343	15	8	use	use	NOUN
dti-2343	15	9	of	of	ADP
dti-2343	15	10	antivascular	antivascular	ADJ
dti-2343	15	11	endothelial	endothelial	ADJ
dti-2343	15	12	growth	growth	NOUN
dti-2343	15	13	factor	factor	NOUN
dti-2343	15	14	(	(	PUNCT
dti-2343	15	15	anti	anti	ADJ
dti-2343	15	16	-	-	ADJ
dti-2343	15	17	vegf	vegf	ADJ
dti-2343	15	18	)	)	PUNCT
dti-2343	15	19	drugs	drug	NOUN
dti-2343	15	20	,	,	PUNCT
dti-2343	15	21	with	with	ADP
dti-2343	15	22	the	the	DET
dti-2343	15	23	objective	objective	NOUN
dti-2343	15	24	of	of	ADP
dti-2343	15	25	controlling	control	VERB
dti-2343	15	26	the	the	DET
dti-2343	15	27	exudation	exudation	NOUN
dti-2343	15	28	from	from	ADP
dti-2343	15	29	the	the	DET
dti-2343	15	30	vessels	vessel	NOUN
dti-2343	15	31	to	to	PART
dti-2343	15	32	minimize	minimize	VERB
dti-2343	15	33	disease	disease	NOUN
dti-2343	15	34	activity	activity	NOUN
dti-2343	15	35	and	and	CCONJ
dti-2343	15	36	consequently	consequently	ADV
dti-2343	15	37	avoid	avoid	VERB
dti-2343	15	38	va	va	NOUN
dti-2343	15	39	loss	loss	NOUN
dti-2343	15	40	(	(	PUNCT
dti-2343	15	41	3,4	3,4	NUM
dti-2343	15	42	)	)	PUNCT
dti-2343	15	43	.	.	PUNCT
dti-2343	16	1	appropriate	appropriate	ADJ
dti-2343	16	2	treatment	treatment	NOUN
dti-2343	16	3	intervals	interval	NOUN
dti-2343	16	4	maintain	maintain	VERB
dti-2343	16	5	and	and	CCONJ
dti-2343	16	6	sometimes	sometimes	ADV
dti-2343	16	7	improve	improve	VERB
dti-2343	16	8	patients	patient	NOUN
dti-2343	16	9	’	'	PUNCT
dti-2343	16	10	vision	vision	NOUN
dti-2343	16	11	in	in	ADP
dti-2343	16	12	the	the	DET
dti-2343	16	13	long	long	ADJ
dti-2343	16	14	term	term	NOUN
dti-2343	16	15	(	(	PUNCT
dti-2343	16	16	3,5	3,5	NUM
dti-2343	16	17	-	-	SYM
dti-2343	16	18	9	9	NUM
dti-2343	16	19	)	)	PUNCT
dti-2343	16	20	.	.	PUNCT
dti-2343	17	1	macular	macular	ADJ
dti-2343	17	2	neovascularization	neovascularization	NOUN
dti-2343	17	3	secondary	secondary	ADJ
dti-2343	17	4	to	to	ADP
dti-2343	17	5	namd	namd	NOUN
dti-2343	17	6	requires	require	VERB
dti-2343	17	7	continuous	continuous	ADJ
dti-2343	17	8	treatment	treatment	NOUN
dti-2343	17	9	because	because	SCONJ
dti-2343	17	10	it	it	PRON
dti-2343	17	11	remains	remain	VERB
dti-2343	17	12	active	active	ADJ
dti-2343	17	13	for	for	ADP
dti-2343	17	14	years	year	NOUN
dti-2343	17	15	(	(	PUNCT
dti-2343	17	16	10	10	NUM
dti-2343	17	17	)	)	PUNCT
dti-2343	17	18	.	.	PUNCT
dti-2343	18	1	randomized	randomize	VERB
dti-2343	18	2	controlled	control	VERB
dti-2343	18	3	trials	trial	NOUN
dti-2343	18	4	showed	show	VERB
dti-2343	18	5	that	that	SCONJ
dti-2343	18	6	srf	srf	PROPN
dti-2343	18	7	and/or	and/or	CCONJ
dti-2343	18	8	irf	irf	PROPN
dti-2343	18	9	is	be	AUX
dti-2343	18	10	still	still	ADV
dti-2343	18	11	present	present	ADJ
dti-2343	18	12	after	after	ADP
dti-2343	18	13	two	two	NUM
dti-2343	18	14	years	year	NOUN
dti-2343	18	15	of	of	ADP
dti-2343	18	16	treatment	treatment	NOUN
dti-2343	18	17	in	in	ADP
dti-2343	18	18	around	around	ADP
dti-2343	18	19	40%-50	40%-50	NUM
dti-2343	18	20	%	%	NOUN
dti-2343	18	21	of	of	ADP
dti-2343	18	22	patients	patient	NOUN
dti-2343	18	23	(	(	PUNCT
dti-2343	18	24	3,11,12	3,11,12	NUM
dti-2343	18	25	)	)	PUNCT
dti-2343	18	26	.	.	PUNCT
dti-2343	19	1	long	long	ADJ
dti-2343	19	2	-	-	PUNCT
dti-2343	19	3	term	term	NOUN
dti-2343	19	4	retrospective	retrospective	ADJ
dti-2343	19	5	observational	observational	ADJ
dti-2343	19	6	studies	study	NOUN
dti-2343	19	7	have	have	AUX
dti-2343	19	8	also	also	ADV
dti-2343	19	9	reported	report	VERB
dti-2343	19	10	around	around	ADP
dti-2343	19	11	40	40	NUM
dti-2343	19	12	%	%	NOUN
dti-2343	19	13	of	of	ADP
dti-2343	19	14	patients	patient	NOUN
dti-2343	19	15	with	with	ADP
dti-2343	19	16	detectable	detectable	ADJ
dti-2343	19	17	active	active	ADJ
dti-2343	19	18	disease	disease	NOUN
dti-2343	19	19	at	at	ADP
dti-2343	19	20	the	the	DET
dti-2343	19	21	end	end	NOUN
dti-2343	19	22	of	of	ADP
dti-2343	19	23	the	the	DET
dti-2343	19	24	study	study	NOUN
dti-2343	19	25	,	,	PUNCT
dti-2343	19	26	after	after	ADP
dti-2343	19	27	3	3	NUM
dti-2343	19	28	and	and	CCONJ
dti-2343	19	29	10	10	NUM
dti-2343	19	30	years	year	NOUN
dti-2343	19	31	,	,	PUNCT
dti-2343	19	32	respectively	respectively	ADV
dti-2343	19	33	(	(	PUNCT
dti-2343	19	34	9,13	9,13	NUM
dti-2343	19	35	)	)	PUNCT
dti-2343	19	36	.	.	PUNCT
dti-2343	20	1	the	the	DET
dti-2343	20	2	activity	activity	NOUN
dti-2343	20	3	pattern	pattern	NOUN
dti-2343	20	4	of	of	ADP
dti-2343	20	5	namd	namd	NOUN
dti-2343	20	6	is	be	AUX
dti-2343	20	7	often	often	ADV
dti-2343	20	8	unpredictable	unpredictable	ADJ
dti-2343	20	9	and	and	CCONJ
dti-2343	20	10	patients	patient	NOUN
dti-2343	20	11	must	must	AUX
dti-2343	20	12	be	be	AUX
dti-2343	20	13	continuously	continuously	ADV
dti-2343	20	14	monitored	monitor	VERB
dti-2343	20	15	and	and	CCONJ
dti-2343	20	16	treated	treat	VERB
dti-2343	20	17	to	to	PART
dti-2343	20	18	avoid	avoid	VERB
dti-2343	20	19	permanent	permanent	ADJ
dti-2343	20	20	va	va	NOUN
dti-2343	20	21	loss	loss	NOUN
dti-2343	20	22	introduction	introduction	NOUN
dti-2343	20	23	neovascular	neovascular	NOUN
dti-2343	20	24	age	age	NOUN
dti-2343	20	25	-	-	PUNCT
dti-2343	20	26	related	relate	VERB
dti-2343	20	27	macular	macular	ADJ
dti-2343	20	28	degeneration	degeneration	NOUN
dti-2343	20	29	(	(	PUNCT
dti-2343	20	30	namd	namd	NOUN
dti-2343	20	31	)	)	PUNCT
dti-2343	20	32	is	be	AUX
dti-2343	20	33	a	a	DET
dti-2343	20	34	chronic	chronic	ADJ
dti-2343	20	35	degenerative	degenerative	ADJ
dti-2343	20	36	disease	disease	NOUN
dti-2343	20	37	characterized	characterize	VERB
dti-2343	20	38	by	by	ADP
dti-2343	20	39	the	the	DET
dti-2343	20	40	pathological	pathological	ADJ
dti-2343	20	41	growth	growth	NOUN
dti-2343	20	42	of	of	ADP
dti-2343	20	43	vessels	vessel	NOUN
dti-2343	20	44	,	,	PUNCT
dti-2343	20	45	which	which	PRON
dti-2343	20	46	leak	leak	VERB
dti-2343	20	47	blood	blood	NOUN
dti-2343	20	48	and	and	CCONJ
dti-2343	20	49	fluids	fluid	NOUN
dti-2343	20	50	in	in	ADP
dti-2343	20	51	the	the	DET
dti-2343	20	52	various	various	ADJ
dti-2343	20	53	retinal	retinal	ADJ
dti-2343	20	54	compartments	compartment	NOUN
dti-2343	20	55	,	,	PUNCT
dti-2343	20	56	leading	lead	VERB
dti-2343	20	57	to	to	ADP
dti-2343	20	58	loss	loss	NOUN
dti-2343	20	59	of	of	ADP
dti-2343	20	60	visual	visual	ADJ
dti-2343	20	61	acuity	acuity	NOUN
dti-2343	20	62	(	(	PUNCT
dti-2343	20	63	va	va	NOUN
dti-2343	20	64	)	)	PUNCT
dti-2343	20	65	(	(	PUNCT
dti-2343	20	66	1,2	1,2	NUM
dti-2343	20	67	)	)	PUNCT
dti-2343	20	68	.	.	PUNCT
dti-2343	21	1	fluids	fluid	NOUN
dti-2343	21	2	accumulating	accumulate	VERB
dti-2343	21	3	in	in	ADP
dti-2343	21	4	retinal	retinal	ADJ
dti-2343	21	5	compartments	compartment	NOUN
dti-2343	21	6	https://doi.org/10.33393/dti.2022.2343	https://doi.org/10.33393/dti.2022.2343	NOUN
dti-2343	21	7	https://creativecommons.org/licenses/by-nc/4.0/legalcode	https://creativecommons.org/licenses/by-nc/4.0/legalcode	PROPN
dti-2343	21	8	zuccarini	zuccarini	NOUN
dti-2343	21	9	et	et	PROPN
dti-2343	21	10	al	al	PROPN
dti-2343	21	11	drug	drug	PROPN
dti-2343	21	12	target	target	NOUN
dti-2343	21	13	insights	insight	NOUN
dti-2343	21	14	2022	2022	NUM
dti-2343	21	15	;	;	PUNCT
dti-2343	21	16	16	16	NUM
dti-2343	21	17	:	:	SYM
dti-2343	21	18	7	7	NUM
dti-2343	21	19	©	©	ADP
dti-2343	21	20	2022	2022	NUM
dti-2343	21	21	the	the	DET
dti-2343	21	22	authors	author	NOUN
dti-2343	21	23	.	.	PUNCT
dti-2343	22	1	published	publish	VERB
dti-2343	22	2	by	by	ADP
dti-2343	22	3	aboutscience	aboutscience	NOUN
dti-2343	22	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2343	22	5	(	(	PUNCT
dti-2343	22	6	14	14	NUM
dti-2343	22	7	-	-	SYM
dti-2343	22	8	16	16	NUM
dti-2343	22	9	)	)	PUNCT
dti-2343	22	10	,	,	PUNCT
dti-2343	22	11	thus	thus	ADV
dti-2343	22	12	representing	represent	VERB
dti-2343	22	13	an	an	DET
dti-2343	22	14	important	important	ADJ
dti-2343	22	15	burden	burden	NOUN
dti-2343	22	16	for	for	ADP
dti-2343	22	17	both	both	DET
dti-2343	22	18	patients	patient	NOUN
dti-2343	22	19	and	and	CCONJ
dti-2343	22	20	clinicians	clinician	NOUN
dti-2343	22	21	(	(	PUNCT
dti-2343	22	22	4,17	4,17	NOUN
dti-2343	22	23	)	)	PUNCT
dti-2343	22	24	.	.	PUNCT
dti-2343	23	1	in	in	ADP
dti-2343	23	2	clinical	clinical	ADJ
dti-2343	23	3	practice	practice	NOUN
dti-2343	23	4	,	,	PUNCT
dti-2343	23	5	patients	patient	NOUN
dti-2343	23	6	are	be	AUX
dti-2343	23	7	treated	treat	VERB
dti-2343	23	8	in	in	ADP
dti-2343	23	9	a	a	DET
dti-2343	23	10	personalized	personalized	ADJ
dti-2343	23	11	way	way	NOUN
dti-2343	23	12	with	with	ADP
dti-2343	23	13	the	the	DET
dti-2343	23	14	aim	aim	NOUN
dti-2343	23	15	of	of	ADP
dti-2343	23	16	controlling	control	VERB
dti-2343	23	17	recurrences	recurrence	NOUN
dti-2343	23	18	,	,	PUNCT
dti-2343	23	19	but	but	CCONJ
dti-2343	23	20	over	over	ADP
dti-2343	23	21	time	time	NOUN
dti-2343	23	22	anti	anti	ADJ
dti-2343	23	23	-	-	ADJ
dti-2343	23	24	vegf	vegf	ADJ
dti-2343	23	25	therapies	therapy	NOUN
dti-2343	23	26	may	may	AUX
dti-2343	23	27	experience	experience	VERB
dti-2343	23	28	reduced	reduced	ADJ
dti-2343	23	29	effectiveness	effectiveness	NOUN
dti-2343	23	30	:	:	PUNCT
dti-2343	23	31	after	after	ADP
dti-2343	23	32	5	5	NUM
dti-2343	23	33	and	and	CCONJ
dti-2343	23	34	10	10	NUM
dti-2343	23	35	years	year	NOUN
dti-2343	23	36	of	of	ADP
dti-2343	23	37	treatment	treatment	NOUN
dti-2343	23	38	,	,	PUNCT
dti-2343	23	39	41	41	NUM
dti-2343	23	40	%	%	NOUN
dti-2343	23	41	and	and	CCONJ
dti-2343	23	42	42	42	NUM
dti-2343	23	43	%	%	NOUN
dti-2343	23	44	of	of	ADP
dti-2343	23	45	patients	patient	NOUN
dti-2343	23	46	,	,	PUNCT
dti-2343	23	47	respectively	respectively	ADV
dti-2343	23	48	,	,	PUNCT
dti-2343	23	49	made	make	VERB
dti-2343	23	50	at	at	ADP
dti-2343	23	51	least	least	ADV
dti-2343	23	52	one	one	NUM
dti-2343	23	53	switch	switch	NOUN
dti-2343	23	54	to	to	ADP
dti-2343	23	55	other	other	ADJ
dti-2343	23	56	anti	anti	ADJ
dti-2343	23	57	-	-	ADJ
dti-2343	23	58	vegfs	vegfs	ADJ
dti-2343	23	59	(	(	PUNCT
dti-2343	23	60	9,18	9,18	NUM
dti-2343	23	61	)	)	PUNCT
dti-2343	23	62	.	.	PUNCT
dti-2343	24	1	the	the	DET
dti-2343	24	2	poor	poor	ADJ
dti-2343	24	3	response	response	NOUN
dti-2343	24	4	(	(	PUNCT
dti-2343	24	5	with	with	ADP
dti-2343	24	6	either	either	CCONJ
dti-2343	24	7	fluid	fluid	ADJ
dti-2343	24	8	persistence	persistence	NOUN
dti-2343	24	9	or	or	CCONJ
dti-2343	24	10	recurrences	recurrence	NOUN
dti-2343	24	11	)	)	PUNCT
dti-2343	24	12	may	may	AUX
dti-2343	24	13	be	be	AUX
dti-2343	24	14	due	due	ADJ
dti-2343	24	15	to	to	ADP
dti-2343	24	16	tachyphylaxis	tachyphylaxis	ADJ
dti-2343	24	17	,	,	PUNCT
dti-2343	24	18	changes	change	NOUN
dti-2343	24	19	in	in	ADP
dti-2343	24	20	the	the	DET
dti-2343	24	21	neovascular	neovascular	ADJ
dti-2343	24	22	membrane	membrane	NOUN
dti-2343	24	23	characteristics	characteristic	NOUN
dti-2343	24	24	(	(	PUNCT
dti-2343	24	25	e.g.	e.g.	ADV
dti-2343	24	26	,	,	PUNCT
dti-2343	24	27	increased	increase	VERB
dti-2343	24	28	fibrosis	fibrosis	NOUN
dti-2343	24	29	acting	act	VERB
dti-2343	24	30	like	like	ADP
dti-2343	24	31	a	a	DET
dti-2343	24	32	resorption	resorption	NOUN
dti-2343	24	33	barrier	barrier	NOUN
dti-2343	24	34	)	)	PUNCT
dti-2343	24	35	,	,	PUNCT
dti-2343	24	36	chronic	chronic	ADJ
dti-2343	24	37	changes	change	NOUN
dti-2343	24	38	in	in	ADP
dti-2343	24	39	vessel	vessel	NOUN
dti-2343	24	40	walls	wall	NOUN
dti-2343	24	41	,	,	PUNCT
dti-2343	24	42	changes	change	NOUN
dti-2343	24	43	in	in	ADP
dti-2343	24	44	the	the	DET
dti-2343	24	45	type	type	NOUN
dti-2343	24	46	of	of	ADP
dti-2343	24	47	lesion	lesion	NOUN
dti-2343	24	48	evolving	evolve	VERB
dti-2343	24	49	over	over	ADP
dti-2343	24	50	time	time	NOUN
dti-2343	24	51	,	,	PUNCT
dti-2343	24	52	or	or	CCONJ
dti-2343	24	53	an	an	DET
dti-2343	24	54	inadequate	inadequate	ADJ
dti-2343	24	55	treatment	treatment	NOUN
dti-2343	24	56	frequency	frequency	NOUN
dti-2343	24	57	(	(	PUNCT
dti-2343	24	58	19,20	19,20	NOUN
dti-2343	24	59	)	)	PUNCT
dti-2343	24	60	.	.	PUNCT
dti-2343	25	1	as	as	ADP
dti-2343	25	2	a	a	DET
dti-2343	25	3	consequence	consequence	NOUN
dti-2343	25	4	,	,	PUNCT
dti-2343	25	5	switching	switch	VERB
dti-2343	25	6	treatment	treatment	NOUN
dti-2343	25	7	becomes	become	VERB
dti-2343	25	8	necessary	necessary	ADJ
dti-2343	25	9	and	and	CCONJ
dti-2343	25	10	it	it	PRON
dti-2343	25	11	is	be	AUX
dti-2343	25	12	important	important	ADJ
dti-2343	25	13	to	to	PART
dti-2343	25	14	re	re	VERB
dti-2343	25	15	-	-	VERB
dti-2343	25	16	establish	establish	VERB
dti-2343	25	17	control	control	NOUN
dti-2343	25	18	of	of	ADP
dti-2343	25	19	the	the	DET
dti-2343	25	20	disease	disease	NOUN
dti-2343	25	21	.	.	PUNCT
dti-2343	26	1	while	while	SCONJ
dti-2343	26	2	va	va	PROPN
dti-2343	26	3	is	be	AUX
dti-2343	26	4	not	not	PART
dti-2343	26	5	usually	usually	ADV
dti-2343	26	6	regained	regain	VERB
dti-2343	26	7	,	,	PUNCT
dti-2343	26	8	treatment	treatment	NOUN
dti-2343	26	9	switch	switch	NOUN
dti-2343	26	10	is	be	AUX
dti-2343	26	11	consistently	consistently	ADV
dti-2343	26	12	associated	associate	VERB
dti-2343	26	13	with	with	ADP
dti-2343	26	14	anatomical	anatomical	ADJ
dti-2343	26	15	improvement	improvement	NOUN
dti-2343	26	16	(	(	PUNCT
dti-2343	26	17	20,21	20,21	NUM
dti-2343	26	18	)	)	PUNCT
dti-2343	26	19	.	.	PUNCT
dti-2343	27	1	in	in	ADP
dti-2343	27	2	patients	patient	NOUN
dti-2343	27	3	showing	show	VERB
dti-2343	27	4	fluid	fluid	ADJ
dti-2343	27	5	persistence	persistence	NOUN
dti-2343	27	6	despite	despite	SCONJ
dti-2343	27	7	at	at	ADV
dti-2343	27	8	least	least	ADV
dti-2343	27	9	three	three	NUM
dti-2343	27	10	-	-	PUNCT
dti-2343	27	11	monthly	monthly	ADJ
dti-2343	27	12	injections	injection	NOUN
dti-2343	27	13	with	with	ADP
dti-2343	27	14	bevacizumab	bevacizumab	NOUN
dti-2343	27	15	,	,	PUNCT
dti-2343	27	16	switching	switch	VERB
dti-2343	27	17	to	to	ADP
dti-2343	27	18	either	either	CCONJ
dti-2343	27	19	aflibercept	aflibercept	NOUN
dti-2343	27	20	or	or	CCONJ
dti-2343	27	21	ranibizumab	ranibizumab	NOUN
dti-2343	27	22	showed	show	VERB
dti-2343	27	23	comparable	comparable	ADJ
dti-2343	27	24	efficacy	efficacy	NOUN
dti-2343	27	25	,	,	PUNCT
dti-2343	27	26	with	with	ADP
dti-2343	27	27	anatomical	anatomical	ADJ
dti-2343	27	28	improvement	improvement	NOUN
dti-2343	27	29	noticeable	noticeable	ADJ
dti-2343	27	30	after	after	ADP
dti-2343	27	31	a	a	DET
dti-2343	27	32	single	single	ADJ
dti-2343	27	33	injection	injection	NOUN
dti-2343	27	34	(	(	PUNCT
dti-2343	27	35	22	22	NUM
dti-2343	27	36	)	)	PUNCT
dti-2343	27	37	.	.	PUNCT
dti-2343	28	1	brolucizumab	brolucizumab	PROPN
dti-2343	28	2	6	6	NUM
dti-2343	28	3	mg	mg	PROPN
dti-2343	28	4	(	(	PUNCT
dti-2343	28	5	beovu	beovu	ADJ
dti-2343	28	6	®	®	PROPN
dti-2343	28	7	,	,	PUNCT
dti-2343	28	8	novartis	novartis	PROPN
dti-2343	28	9	ag	ag	PROPN
dti-2343	28	10	,	,	PUNCT
dti-2343	28	11	basel	basel	PROPN
dti-2343	28	12	,	,	PUNCT
dti-2343	28	13	switzerland	switzerland	PROPN
dti-2343	28	14	)	)	PUNCT
dti-2343	28	15	,	,	PUNCT
dti-2343	28	16	a	a	DET
dti-2343	28	17	monoclonal	monoclonal	ADJ
dti-2343	28	18	single	single	ADJ
dti-2343	28	19	-	-	PUNCT
dti-2343	28	20	chain	chain	NOUN
dti-2343	28	21	variable	variable	ADJ
dti-2343	28	22	domain	domain	NOUN
dti-2343	28	23	antibody	antibody	NOUN
dti-2343	28	24	fragment	fragment	NOUN
dti-2343	28	25	,	,	PUNCT
dti-2343	28	26	is	be	AUX
dti-2343	28	27	a	a	DET
dti-2343	28	28	new	new	ADJ
dti-2343	28	29	-	-	PUNCT
dti-2343	28	30	generation	generation	NOUN
dti-2343	28	31	anti	anti	ADJ
dti-2343	28	32	-	-	ADJ
dti-2343	28	33	vegf	vegf	ADJ
dti-2343	28	34	drug	drug	NOUN
dti-2343	28	35	approved	approve	VERB
dti-2343	28	36	for	for	ADP
dti-2343	28	37	the	the	DET
dti-2343	28	38	treatment	treatment	NOUN
dti-2343	28	39	of	of	ADP
dti-2343	28	40	namd	namd	NOUN
dti-2343	28	41	,	,	PUNCT
dti-2343	28	42	with	with	ADP
dti-2343	28	43	proven	prove	VERB
dti-2343	28	44	efficacy	efficacy	NOUN
dti-2343	28	45	in	in	ADP
dti-2343	28	46	fluid	fluid	ADJ
dti-2343	28	47	resolution	resolution	NOUN
dti-2343	28	48	and	and	CCONJ
dti-2343	28	49	long	long	ADV
dti-2343	28	50	-	-	PUNCT
dti-2343	28	51	lasting	last	VERB
dti-2343	28	52	effects	effect	NOUN
dti-2343	28	53	(	(	PUNCT
dti-2343	28	54	23	23	NUM
dti-2343	28	55	)	)	PUNCT
dti-2343	28	56	.	.	PUNCT
dti-2343	29	1	brolucizumab	brolucizumab	PROPN
dti-2343	29	2	shows	show	VERB
dti-2343	29	3	great	great	ADJ
dti-2343	29	4	promise	promise	NOUN
dti-2343	29	5	in	in	ADP
dti-2343	29	6	reducing	reduce	VERB
dti-2343	29	7	the	the	DET
dti-2343	29	8	risk	risk	NOUN
dti-2343	29	9	of	of	ADP
dti-2343	29	10	undertreatment	undertreatment	ADJ
dti-2343	29	11	and	and	CCONJ
dti-2343	29	12	permanent	permanent	ADJ
dti-2343	29	13	va	va	NOUN
dti-2343	29	14	loss	loss	NOUN
dti-2343	29	15	.	.	PUNCT
dti-2343	30	1	results	result	NOUN
dti-2343	30	2	from	from	ADP
dti-2343	30	3	the	the	DET
dti-2343	30	4	hawk	hawk	NOUN
dti-2343	30	5	and	and	CCONJ
dti-2343	30	6	harrier	harrier	NOUN
dti-2343	30	7	studies	study	NOUN
dti-2343	30	8	(	(	PUNCT
dti-2343	30	9	24	24	NUM
dti-2343	30	10	)	)	PUNCT
dti-2343	30	11	showed	show	VERB
dti-2343	30	12	that	that	SCONJ
dti-2343	30	13	patients	patient	NOUN
dti-2343	30	14	treated	treat	VERB
dti-2343	30	15	with	with	ADP
dti-2343	30	16	brolucizumab	brolucizumab	NOUN
dti-2343	30	17	(	(	PUNCT
dti-2343	30	18	administered	administer	VERB
dti-2343	30	19	at	at	ADP
dti-2343	30	20	8and	8and	NUM
dti-2343	30	21	12	12	NUM
dti-2343	30	22	-	-	PUNCT
dti-2343	30	23	week	week	NOUN
dti-2343	30	24	intervals	interval	NOUN
dti-2343	30	25	after	after	ADP
dti-2343	30	26	three	three	NUM
dti-2343	30	27	-	-	PUNCT
dti-2343	30	28	monthly	monthly	ADJ
dti-2343	30	29	loading	loading	NOUN
dti-2343	30	30	doses	dose	NOUN
dti-2343	30	31	)	)	PUNCT
dti-2343	30	32	had	have	VERB
dti-2343	30	33	a	a	DET
dti-2343	30	34	significantly	significantly	ADV
dti-2343	30	35	higher	high	ADJ
dti-2343	30	36	reduction	reduction	NOUN
dti-2343	30	37	in	in	ADP
dti-2343	30	38	retinal	retinal	ADJ
dti-2343	30	39	central	central	ADJ
dti-2343	30	40	subfield	subfield	NOUN
dti-2343	30	41	thickness	thickness	NOUN
dti-2343	30	42	(	(	PUNCT
dti-2343	30	43	cst	cst	PROPN
dti-2343	30	44	)	)	PUNCT
dti-2343	30	45	and	and	CCONJ
dti-2343	30	46	absence	absence	NOUN
dti-2343	30	47	of	of	ADP
dti-2343	30	48	srf	srf	PROPN
dti-2343	30	49	/	/	SYM
dti-2343	30	50	irf	irf	PROPN
dti-2343	30	51	at	at	ADP
dti-2343	30	52	48	48	NUM
dti-2343	30	53	and	and	CCONJ
dti-2343	30	54	95	95	NUM
dti-2343	30	55	weeks	week	NOUN
dti-2343	30	56	postinjection	postinjection	NOUN
dti-2343	30	57	,	,	PUNCT
dti-2343	30	58	compared	compare	VERB
dti-2343	30	59	with	with	ADP
dti-2343	30	60	those	those	PRON
dti-2343	30	61	treated	treat	VERB
dti-2343	30	62	with	with	ADP
dti-2343	30	63	aflibercept	aflibercept	NOUN
dti-2343	30	64	(	(	PUNCT
dti-2343	30	65	23	23	NUM
dti-2343	30	66	)	)	PUNCT
dti-2343	30	67	.	.	PUNCT
dti-2343	31	1	these	these	DET
dti-2343	31	2	data	datum	NOUN
dti-2343	31	3	also	also	ADV
dti-2343	31	4	showed	show	VERB
dti-2343	31	5	that	that	SCONJ
dti-2343	31	6	disease	disease	NOUN
dti-2343	31	7	activity	activity	NOUN
dti-2343	31	8	was	be	AUX
dti-2343	31	9	controlled	control	VERB
dti-2343	31	10	in	in	ADP
dti-2343	31	11	a	a	DET
dti-2343	31	12	shorter	short	ADJ
dti-2343	31	13	timeframe	timeframe	NOUN
dti-2343	31	14	after	after	ADP
dti-2343	31	15	diagnosis	diagnosis	NOUN
dti-2343	31	16	when	when	SCONJ
dti-2343	31	17	using	use	VERB
dti-2343	31	18	brolucizumab	brolucizumab	NOUN
dti-2343	31	19	compared	compare	VERB
dti-2343	31	20	with	with	ADP
dti-2343	31	21	aflibercept	aflibercept	NOUN
dti-2343	31	22	(	(	PUNCT
dti-2343	31	23	24	24	NUM
dti-2343	31	24	)	)	PUNCT
dti-2343	31	25	.	.	PUNCT
dti-2343	32	1	the	the	DET
dti-2343	32	2	use	use	NOUN
dti-2343	32	3	of	of	ADP
dti-2343	32	4	brolucizumab	brolucizumab	NOUN
dti-2343	32	5	in	in	ADP
dti-2343	32	6	patients	patient	NOUN
dti-2343	32	7	showing	show	VERB
dti-2343	32	8	no	no	DET
dti-2343	32	9	response	response	NOUN
dti-2343	32	10	to	to	ADP
dti-2343	32	11	other	other	ADJ
dti-2343	32	12	anti	anti	ADJ
dti-2343	32	13	-	-	ADJ
dti-2343	32	14	vegfs	vegfs	ADJ
dti-2343	32	15	offers	offer	VERB
dti-2343	32	16	a	a	DET
dti-2343	32	17	valuable	valuable	ADJ
dti-2343	32	18	therapeutic	therapeutic	ADJ
dti-2343	32	19	option	option	NOUN
dti-2343	32	20	to	to	PART
dti-2343	32	21	maintain	maintain	VERB
dti-2343	32	22	disease	disease	NOUN
dti-2343	32	23	control	control	NOUN
dti-2343	32	24	and	and	CCONJ
dti-2343	32	25	va	va	NOUN
dti-2343	32	26	while	while	SCONJ
dti-2343	32	27	reducing	reduce	VERB
dti-2343	32	28	treatment	treatment	NOUN
dti-2343	32	29	burden	burden	NOUN
dti-2343	32	30	.	.	PUNCT
dti-2343	33	1	preliminary	preliminary	ADJ
dti-2343	33	2	observations	observation	NOUN
dti-2343	33	3	on	on	ADP
dti-2343	33	4	patients	patient	NOUN
dti-2343	33	5	switched	switch	VERB
dti-2343	33	6	to	to	PART
dti-2343	33	7	brolucizumab	brolucizumab	NOUN
dti-2343	33	8	have	have	AUX
dti-2343	33	9	recently	recently	ADV
dti-2343	33	10	been	be	AUX
dti-2343	33	11	published	publish	VERB
dti-2343	33	12	(	(	PUNCT
dti-2343	33	13	25,26	25,26	NOUN
dti-2343	33	14	)	)	PUNCT
dti-2343	33	15	,	,	PUNCT
dti-2343	33	16	confirming	confirm	VERB
dti-2343	33	17	its	its	PRON
dti-2343	33	18	efficacy	efficacy	NOUN
dti-2343	33	19	in	in	ADP
dti-2343	33	20	controlling	control	VERB
dti-2343	33	21	fluid	fluid	ADJ
dti-2343	33	22	accumulation	accumulation	NOUN
dti-2343	33	23	.	.	PUNCT
dti-2343	34	1	however	however	ADV
dti-2343	34	2	,	,	PUNCT
dti-2343	34	3	more	more	ADJ
dti-2343	34	4	data	datum	NOUN
dti-2343	34	5	are	be	AUX
dti-2343	34	6	needed	need	VERB
dti-2343	34	7	to	to	PART
dti-2343	34	8	further	far	ADV
dti-2343	34	9	characterize	characterize	VERB
dti-2343	34	10	brolucizumab	brolucizumab	NOUN
dti-2343	34	11	efficacy	efficacy	NOUN
dti-2343	34	12	and	and	CCONJ
dti-2343	34	13	rapidity	rapidity	NOUN
dti-2343	34	14	in	in	ADP
dti-2343	34	15	obtaining	obtain	VERB
dti-2343	34	16	complete	complete	ADJ
dti-2343	34	17	fluid	fluid	ADJ
dti-2343	34	18	resolution	resolution	NOUN
dti-2343	34	19	and	and	CCONJ
dti-2343	34	20	the	the	DET
dti-2343	34	21	impact	impact	NOUN
dti-2343	34	22	on	on	ADP
dti-2343	34	23	functional	functional	ADJ
dti-2343	34	24	outcomes	outcome	NOUN
dti-2343	34	25	.	.	PUNCT
dti-2343	35	1	we	we	PRON
dti-2343	35	2	report	report	VERB
dti-2343	35	3	here	here	ADV
dti-2343	35	4	the	the	DET
dti-2343	35	5	anatomical	anatomical	ADJ
dti-2343	35	6	and	and	CCONJ
dti-2343	35	7	functional	functional	ADJ
dti-2343	35	8	responses	response	NOUN
dti-2343	35	9	observed	observe	VERB
dti-2343	35	10	in	in	ADP
dti-2343	35	11	a	a	DET
dti-2343	35	12	group	group	NOUN
dti-2343	35	13	of	of	ADP
dti-2343	35	14	namd	namd	ADJ
dti-2343	35	15	patients	patient	NOUN
dti-2343	35	16	with	with	ADP
dti-2343	35	17	persistent	persistent	ADJ
dti-2343	35	18	or	or	CCONJ
dti-2343	35	19	recurrent	recurrent	ADJ
dti-2343	35	20	fluids	fluid	NOUN
dti-2343	35	21	1	1	NUM
dti-2343	35	22	month	month	NOUN
dti-2343	35	23	after	after	ADP
dti-2343	35	24	a	a	DET
dti-2343	35	25	single	single	ADJ
dti-2343	35	26	injection	injection	NOUN
dti-2343	35	27	of	of	ADP
dti-2343	35	28	brolucizumab	brolucizumab	NOUN
dti-2343	35	29	,	,	PUNCT
dti-2343	35	30	as	as	SCONJ
dti-2343	35	31	assessed	assess	VERB
dti-2343	35	32	retrospectively	retrospectively	ADV
dti-2343	35	33	in	in	ADP
dti-2343	35	34	a	a	DET
dti-2343	35	35	center	center	NOUN
dti-2343	35	36	in	in	ADP
dti-2343	35	37	italy	italy	PROPN
dti-2343	35	38	.	.	PUNCT
dti-2343	36	1	materials	material	NOUN
dti-2343	36	2	and	and	CCONJ
dti-2343	36	3	methods	method	NOUN
dti-2343	36	4	study	study	NOUN
dti-2343	36	5	design	design	NOUN
dti-2343	36	6	we	we	PRON
dti-2343	36	7	retrospectively	retrospectively	ADV
dti-2343	36	8	analyzed	analyze	VERB
dti-2343	36	9	data	datum	NOUN
dti-2343	36	10	from	from	ADP
dti-2343	36	11	nine	nine	NUM
dti-2343	36	12	patients	patient	NOUN
dti-2343	36	13	with	with	ADP
dti-2343	36	14	namd	namd	NOUN
dti-2343	36	15	who	who	PRON
dti-2343	36	16	were	be	AUX
dti-2343	36	17	switched	switch	VERB
dti-2343	36	18	to	to	PART
dti-2343	36	19	brolucizumab	brolucizumab	VERB
dti-2343	36	20	6	6	NUM
dti-2343	36	21	mg	mg	NOUN
dti-2343	36	22	because	because	SCONJ
dti-2343	36	23	they	they	PRON
dti-2343	36	24	were	be	AUX
dti-2343	36	25	not	not	PART
dti-2343	36	26	responsive	responsive	ADJ
dti-2343	36	27	to	to	ADP
dti-2343	36	28	other	other	ADJ
dti-2343	36	29	anti	anti	ADJ
dti-2343	36	30	-	-	ADJ
dti-2343	36	31	vegfs	vegfs	ADJ
dti-2343	36	32	.	.	PUNCT
dti-2343	37	1	all	all	DET
dti-2343	37	2	recruited	recruit	VERB
dti-2343	37	3	patients	patient	NOUN
dti-2343	37	4	were	be	AUX
dti-2343	37	5	followed	follow	VERB
dti-2343	37	6	and	and	CCONJ
dti-2343	37	7	treated	treat	VERB
dti-2343	37	8	at	at	ADP
dti-2343	37	9	villa	villa	PROPN
dti-2343	37	10	donatello	donatello	PROPN
dti-2343	37	11	hospital	hospital	PROPN
dti-2343	37	12	,	,	PUNCT
dti-2343	37	13	florence	florence	NOUN
dti-2343	37	14	,	,	PUNCT
dti-2343	37	15	italy	italy	PROPN
dti-2343	37	16	.	.	PUNCT
dti-2343	38	1	the	the	DET
dti-2343	38	2	use	use	NOUN
dti-2343	38	3	of	of	ADP
dti-2343	38	4	brolucizumab	brolucizumab	NOUN
dti-2343	38	5	for	for	ADP
dti-2343	38	6	treating	treat	VERB
dti-2343	38	7	namd	namd	NOUN
dti-2343	38	8	was	be	AUX
dti-2343	38	9	officially	officially	ADV
dti-2343	38	10	introduced	introduce	VERB
dti-2343	38	11	in	in	ADP
dti-2343	38	12	october	october	PROPN
dti-2343	38	13	2020	2020	NUM
dti-2343	38	14	.	.	PUNCT
dti-2343	39	1	patient	patient	ADJ
dti-2343	39	2	demographic	demographic	ADJ
dti-2343	39	3	and	and	CCONJ
dti-2343	39	4	clinical	clinical	ADJ
dti-2343	39	5	information	information	NOUN
dti-2343	39	6	collected	collect	VERB
dti-2343	39	7	at	at	ADP
dti-2343	39	8	baseline	baseline	PROPN
dti-2343	39	9	(	(	PUNCT
dti-2343	39	10	i.e.	i.e.	X
dti-2343	39	11	,	,	PUNCT
dti-2343	39	12	before	before	ADP
dti-2343	39	13	the	the	DET
dti-2343	39	14	brolucizumab	brolucizumab	NOUN
dti-2343	39	15	injection	injection	NOUN
dti-2343	39	16	)	)	PUNCT
dti-2343	39	17	included	include	VERB
dti-2343	39	18	:	:	PUNCT
dti-2343	39	19	age	age	NOUN
dti-2343	39	20	;	;	PUNCT
dti-2343	39	21	gender	gender	NOUN
dti-2343	39	22	;	;	PUNCT
dti-2343	39	23	treatment	treatment	NOUN
dti-2343	39	24	prior	prior	ADV
dti-2343	39	25	to	to	ADP
dti-2343	39	26	brolucizumab	brolucizumab	NOUN
dti-2343	39	27	injection	injection	NOUN
dti-2343	39	28	(	(	PUNCT
dti-2343	39	29	anti	anti	ADJ
dti-2343	39	30	-	-	ADJ
dti-2343	39	31	vegf	vegf	NOUN
dti-2343	39	32	used	use	VERB
dti-2343	39	33	,	,	PUNCT
dti-2343	39	34	treatment	treatment	NOUN
dti-2343	39	35	duration	duration	NOUN
dti-2343	39	36	,	,	PUNCT
dti-2343	39	37	number	number	NOUN
dti-2343	39	38	of	of	ADP
dti-2343	39	39	injections	injection	NOUN
dti-2343	39	40	,	,	PUNCT
dti-2343	39	41	last	last	ADJ
dti-2343	39	42	interval	interval	NOUN
dti-2343	39	43	between	between	ADP
dti-2343	39	44	injections	injection	NOUN
dti-2343	39	45	,	,	PUNCT
dti-2343	39	46	time	time	NOUN
dti-2343	39	47	from	from	ADP
dti-2343	39	48	last	last	ADJ
dti-2343	39	49	injection	injection	NOUN
dti-2343	39	50	to	to	ADP
dti-2343	39	51	the	the	DET
dti-2343	39	52	first	first	ADJ
dti-2343	39	53	brolucizumab	brolucizumab	NOUN
dti-2343	39	54	injection	injection	NOUN
dti-2343	39	55	)	)	PUNCT
dti-2343	39	56	;	;	PUNCT
dti-2343	40	1	va	va	PROPN
dti-2343	40	2	;	;	PUNCT
dti-2343	40	3	cst	cst	PROPN
dti-2343	40	4	;	;	PUNCT
dti-2343	40	5	type	type	NOUN
dti-2343	40	6	of	of	ADP
dti-2343	40	7	lesion	lesion	NOUN
dti-2343	40	8	;	;	PUNCT
dti-2343	40	9	and	and	CCONJ
dti-2343	40	10	the	the	DET
dti-2343	40	11	presence	presence	NOUN
dti-2343	40	12	of	of	ADP
dti-2343	40	13	irf	irf	PROPN
dti-2343	40	14	,	,	PUNCT
dti-2343	40	15	srf	srf	PROPN
dti-2343	40	16	,	,	PUNCT
dti-2343	40	17	or	or	CCONJ
dti-2343	40	18	sub	sub	ADJ
dti-2343	40	19	-	-	ADJ
dti-2343	40	20	rpe	rpe	ADJ
dti-2343	40	21	fluid	fluid	NOUN
dti-2343	40	22	,	,	PUNCT
dti-2343	40	23	fibrosis	fibrosis	NOUN
dti-2343	40	24	,	,	PUNCT
dti-2343	40	25	subretinal	subretinal	ADJ
dti-2343	40	26	fibrosis	fibrosis	NOUN
dti-2343	40	27	,	,	PUNCT
dti-2343	40	28	and	and	CCONJ
dti-2343	40	29	subretinal	subretinal	ADJ
dti-2343	40	30	hyperreflective	hyperreflective	ADJ
dti-2343	40	31	material	material	NOUN
dti-2343	40	32	(	(	PUNCT
dti-2343	40	33	shrm	shrm	PROPN
dti-2343	40	34	)	)	PUNCT
dti-2343	40	35	.	.	PUNCT
dti-2343	41	1	following	follow	VERB
dti-2343	41	2	the	the	DET
dti-2343	41	3	first	first	ADJ
dti-2343	41	4	brolucizumab	brolucizumab	NOUN
dti-2343	41	5	injection	injection	NOUN
dti-2343	41	6	,	,	PUNCT
dti-2343	41	7	patients	patient	NOUN
dti-2343	41	8	were	be	AUX
dti-2343	41	9	examined	examine	VERB
dti-2343	41	10	at	at	ADP
dti-2343	41	11	two	two	NUM
dti-2343	41	12	time	time	NOUN
dti-2343	41	13	points	point	NOUN
dti-2343	41	14	(	(	PUNCT
dti-2343	41	15	t1	t1	NOUN
dti-2343	41	16	=	=	SYM
dti-2343	41	17	1	1	NUM
dti-2343	41	18	±	±	NUM
dti-2343	41	19	1	1	NUM
dti-2343	41	20	weeks	week	NOUN
dti-2343	41	21	and	and	CCONJ
dti-2343	41	22	t2	t2	NOUN
dti-2343	41	23	=	=	SYM
dti-2343	41	24	4	4	NUM
dti-2343	41	25	±	±	NUM
dti-2343	41	26	1	1	NUM
dti-2343	41	27	weeks	week	NOUN
dti-2343	41	28	)	)	PUNCT
dti-2343	41	29	to	to	PART
dti-2343	41	30	determine	determine	VERB
dti-2343	41	31	the	the	DET
dti-2343	41	32	presence	presence	NOUN
dti-2343	41	33	of	of	ADP
dti-2343	41	34	anatomical	anatomical	ADJ
dti-2343	41	35	and	and	CCONJ
dti-2343	41	36	functional	functional	ADJ
dti-2343	41	37	changes	change	NOUN
dti-2343	41	38	using	use	VERB
dti-2343	41	39	slit	slit	ADJ
dti-2343	41	40	-	-	PUNCT
dti-2343	41	41	lamp	lamp	NOUN
dti-2343	41	42	ophthalmoscopy	ophthalmoscopy	NOUN
dti-2343	41	43	,	,	PUNCT
dti-2343	41	44	spectral	spectral	ADJ
dti-2343	41	45	domain	domain	NOUN
dti-2343	41	46	optical	optical	ADJ
dti-2343	41	47	coherence	coherence	NOUN
dti-2343	41	48	tomography	tomography	NOUN
dti-2343	41	49	(	(	PUNCT
dti-2343	41	50	sd	sd	NOUN
dti-2343	41	51	-	-	PUNCT
dti-2343	41	52	oct	oct	NOUN
dti-2343	41	53	)	)	PUNCT
dti-2343	41	54	,	,	PUNCT
dti-2343	41	55	fundus	fundus	NOUN
dti-2343	41	56	examination	examination	NOUN
dti-2343	41	57	,	,	PUNCT
dti-2343	41	58	and	and	CCONJ
dti-2343	41	59	va	va	NOUN
dti-2343	41	60	assessment	assessment	NOUN
dti-2343	41	61	(	(	PUNCT
dti-2343	41	62	etdrs	etdr	NOUN
dti-2343	41	63	scoring	scoring	NOUN
dti-2343	41	64	)	)	PUNCT
dti-2343	41	65	.	.	PUNCT
dti-2343	42	1	three	three	NUM
dti-2343	42	2	patients	patient	NOUN
dti-2343	42	3	had	have	VERB
dti-2343	42	4	further	further	ADJ
dti-2343	42	5	assessments	assessment	NOUN
dti-2343	42	6	at	at	ADP
dti-2343	42	7	a	a	DET
dti-2343	42	8	longer	long	ADV
dti-2343	42	9	follow	follow	NOUN
dti-2343	42	10	-	-	PUNCT
dti-2343	42	11	up	up	NOUN
dti-2343	42	12	.	.	PUNCT
dti-2343	43	1	due	due	ADP
dti-2343	43	2	to	to	ADP
dti-2343	43	3	the	the	DET
dti-2343	43	4	possibility	possibility	NOUN
dti-2343	43	5	of	of	ADP
dti-2343	43	6	intraocular	intraocular	ADJ
dti-2343	43	7	inflammation	inflammation	NOUN
dti-2343	43	8	(	(	PUNCT
dti-2343	43	9	ioi	ioi	PROPN
dti-2343	43	10	)	)	PUNCT
dti-2343	43	11	,	,	PUNCT
dti-2343	43	12	vasculitis	vasculitis	NOUN
dti-2343	43	13	,	,	PUNCT
dti-2343	43	14	or	or	CCONJ
dti-2343	43	15	retinal	retinal	ADJ
dti-2343	43	16	vascular	vascular	ADJ
dti-2343	43	17	occlusion	occlusion	NOUN
dti-2343	43	18	,	,	PUNCT
dti-2343	43	19	all	all	DET
dti-2343	43	20	patients	patient	NOUN
dti-2343	43	21	were	be	AUX
dti-2343	43	22	informed	inform	VERB
dti-2343	43	23	and	and	CCONJ
dti-2343	43	24	instructed	instruct	VERB
dti-2343	43	25	to	to	PART
dti-2343	43	26	report	report	VERB
dti-2343	43	27	,	,	PUNCT
dti-2343	43	28	within	within	ADP
dti-2343	43	29	24	24	NUM
dti-2343	43	30	hours	hour	NOUN
dti-2343	43	31	of	of	ADP
dti-2343	43	32	the	the	DET
dti-2343	43	33	injection	injection	NOUN
dti-2343	43	34	,	,	PUNCT
dti-2343	43	35	any	any	PRON
dti-2343	43	36	of	of	ADP
dti-2343	43	37	the	the	DET
dti-2343	43	38	following	follow	VERB
dti-2343	43	39	symptoms	symptom	NOUN
dti-2343	43	40	:	:	PUNCT
dti-2343	43	41	redness	redness	NOUN
dti-2343	43	42	,	,	PUNCT
dti-2343	43	43	reduction	reduction	NOUN
dti-2343	43	44	of	of	ADP
dti-2343	43	45	viscous	viscous	ADJ
dti-2343	43	46	,	,	PUNCT
dti-2343	43	47	floaters	floater	NOUN
dti-2343	43	48	,	,	PUNCT
dti-2343	43	49	eye	eye	NOUN
dti-2343	43	50	pain	pain	NOUN
dti-2343	43	51	or	or	CCONJ
dti-2343	43	52	pressure	pressure	NOUN
dti-2343	43	53	,	,	PUNCT
dti-2343	43	54	scotoma	scotoma	NOUN
dti-2343	43	55	,	,	PUNCT
dti-2343	43	56	or	or	CCONJ
dti-2343	43	57	blurred	blurred	ADJ
dti-2343	43	58	vision	vision	NOUN
dti-2343	43	59	.	.	PUNCT
dti-2343	44	1	a	a	DET
dti-2343	44	2	notification	notification	NOUN
dti-2343	44	3	letter	letter	NOUN
dti-2343	44	4	was	be	AUX
dti-2343	44	5	sent	send	VERB
dti-2343	44	6	to	to	ADP
dti-2343	44	7	the	the	DET
dti-2343	44	8	local	local	ADJ
dti-2343	44	9	ethical	ethical	ADJ
dti-2343	44	10	committee	committee	NOUN
dti-2343	44	11	,	,	PUNCT
dti-2343	44	12	according	accord	VERB
dti-2343	44	13	to	to	ADP
dti-2343	44	14	italian	italian	ADJ
dti-2343	44	15	regulations	regulation	NOUN
dti-2343	44	16	.	.	PUNCT
dti-2343	45	1	all	all	DET
dti-2343	45	2	patients	patient	NOUN
dti-2343	45	3	provided	provide	VERB
dti-2343	45	4	written	write	VERB
dti-2343	45	5	informed	inform	VERB
dti-2343	45	6	consent	consent	NOUN
dti-2343	45	7	prior	prior	ADV
dti-2343	45	8	to	to	ADP
dti-2343	45	9	receiving	receive	VERB
dti-2343	45	10	the	the	DET
dti-2343	45	11	brolucizumab	brolucizumab	NOUN
dti-2343	45	12	injection	injection	NOUN
dti-2343	45	13	.	.	PUNCT
dti-2343	46	1	patient	patient	ADJ
dti-2343	46	2	inclusion	inclusion	NOUN
dti-2343	46	3	and	and	CCONJ
dti-2343	46	4	exclusion	exclusion	NOUN
dti-2343	46	5	criteria	criterion	NOUN
dti-2343	46	6	the	the	DET
dti-2343	46	7	study	study	NOUN
dti-2343	46	8	only	only	ADV
dti-2343	46	9	included	include	VERB
dti-2343	46	10	patients	patient	NOUN
dti-2343	46	11	with	with	ADP
dti-2343	46	12	namd	namd	NOUN
dti-2343	46	13	not	not	PART
dti-2343	46	14	responsive	responsive	ADJ
dti-2343	46	15	anymore	anymore	ADV
dti-2343	46	16	to	to	ADP
dti-2343	46	17	other	other	ADJ
dti-2343	46	18	anti	anti	ADJ
dti-2343	46	19	-	-	ADJ
dti-2343	46	20	vegfs	vegfs	ADJ
dti-2343	46	21	(	(	PUNCT
dti-2343	46	22	i.e.	i.e.	X
dti-2343	46	23	,	,	PUNCT
dti-2343	46	24	showing	show	VERB
dti-2343	46	25	either	either	CCONJ
dti-2343	46	26	fluid	fluid	ADJ
dti-2343	46	27	persistence	persistence	NOUN
dti-2343	46	28	or	or	CCONJ
dti-2343	46	29	frequent	frequent	ADJ
dti-2343	46	30	fluid	fluid	ADJ
dti-2343	46	31	recurrences	recurrence	NOUN
dti-2343	46	32	)	)	PUNCT
dti-2343	46	33	,	,	PUNCT
dti-2343	46	34	who	who	PRON
dti-2343	46	35	were	be	AUX
dti-2343	46	36	first	first	ADV
dti-2343	46	37	injected	inject	VERB
dti-2343	46	38	with	with	ADP
dti-2343	46	39	brolucizumab	brolucizumab	NOUN
dti-2343	46	40	by	by	ADP
dti-2343	46	41	december	december	PROPN
dti-2343	46	42	2020	2020	NUM
dti-2343	46	43	,	,	PUNCT
dti-2343	46	44	and	and	CCONJ
dti-2343	46	45	had	have	VERB
dti-2343	46	46	a	a	DET
dti-2343	46	47	visit	visit	NOUN
dti-2343	46	48	1	1	NUM
dti-2343	46	49	month	month	NOUN
dti-2343	46	50	(	(	PUNCT
dti-2343	46	51	t2	t2	NOUN
dti-2343	46	52	range	range	NOUN
dti-2343	46	53	4±1	4±1	NUM
dti-2343	46	54	weeks	week	NOUN
dti-2343	46	55	)	)	PUNCT
dti-2343	46	56	after	after	ADP
dti-2343	46	57	the	the	DET
dti-2343	46	58	injection	injection	NOUN
dti-2343	46	59	.	.	PUNCT
dti-2343	47	1	patients	patient	NOUN
dti-2343	47	2	with	with	ADP
dti-2343	47	3	a	a	DET
dti-2343	47	4	maculopathy	maculopathy	ADJ
dti-2343	47	5	other	other	ADJ
dti-2343	47	6	than	than	ADP
dti-2343	47	7	namd	namd	NOUN
dti-2343	47	8	or	or	CCONJ
dti-2343	47	9	who	who	PRON
dti-2343	47	10	received	receive	VERB
dti-2343	47	11	brolucizumab	brolucizumab	NOUN
dti-2343	47	12	injection	injection	NOUN
dti-2343	47	13	after	after	ADP
dti-2343	47	14	december	december	PROPN
dti-2343	47	15	2020	2020	NUM
dti-2343	47	16	were	be	AUX
dti-2343	47	17	excluded	exclude	VERB
dti-2343	47	18	.	.	PUNCT
dti-2343	48	1	study	study	NOUN
dti-2343	48	2	outcomes	outcome	NOUN
dti-2343	48	3	the	the	DET
dti-2343	48	4	main	main	ADJ
dti-2343	48	5	outcome	outcome	NOUN
dti-2343	48	6	measured	measure	VERB
dti-2343	48	7	was	be	AUX
dti-2343	48	8	the	the	DET
dti-2343	48	9	proportion	proportion	NOUN
dti-2343	48	10	of	of	ADP
dti-2343	48	11	patients	patient	NOUN
dti-2343	48	12	without	without	ADP
dti-2343	48	13	srf	srf	PROPN
dti-2343	48	14	and	and	CCONJ
dti-2343	48	15	irf	irf	PROPN
dti-2343	48	16	1	1	NUM
dti-2343	48	17	month	month	NOUN
dti-2343	48	18	after	after	ADP
dti-2343	48	19	brolucizumab	brolucizumab	NOUN
dti-2343	48	20	injection	injection	NOUN
dti-2343	48	21	.	.	PUNCT
dti-2343	49	1	secondary	secondary	ADJ
dti-2343	49	2	outcomes	outcome	NOUN
dti-2343	49	3	were	be	AUX
dti-2343	49	4	the	the	DET
dti-2343	49	5	proportion	proportion	NOUN
dti-2343	49	6	of	of	ADP
dti-2343	49	7	patients	patient	NOUN
dti-2343	49	8	with	with	ADP
dti-2343	49	9	reduced	reduced	ADJ
dti-2343	49	10	(	(	PUNCT
dti-2343	49	11	or	or	CCONJ
dti-2343	49	12	absent	absent	ADJ
dti-2343	49	13	)	)	PUNCT
dti-2343	49	14	srf	srf	PROPN
dti-2343	49	15	/	/	SYM
dti-2343	49	16	irf	irf	PROPN
dti-2343	49	17	1	1	NUM
dti-2343	49	18	month	month	NOUN
dti-2343	49	19	after	after	ADP
dti-2343	49	20	injection	injection	NOUN
dti-2343	49	21	,	,	PUNCT
dti-2343	49	22	the	the	DET
dti-2343	49	23	proportion	proportion	NOUN
dti-2343	49	24	of	of	ADP
dti-2343	49	25	sub	sub	ADJ
dti-2343	49	26	-	-	ADJ
dti-2343	49	27	rpe	rpe	ADJ
dti-2343	49	28	fluid	fluid	NOUN
dti-2343	49	29	resolution	resolution	NOUN
dti-2343	49	30	1	1	NUM
dti-2343	49	31	month	month	NOUN
dti-2343	49	32	after	after	ADP
dti-2343	49	33	injection	injection	NOUN
dti-2343	49	34	in	in	ADP
dti-2343	49	35	patients	patient	NOUN
dti-2343	49	36	with	with	ADP
dti-2343	49	37	sub	sub	ADJ
dti-2343	49	38	-	-	ADJ
dti-2343	49	39	rpe	rpe	ADJ
dti-2343	49	40	fluid	fluid	NOUN
dti-2343	49	41	at	at	ADP
dti-2343	49	42	baseline	baseline	NOUN
dti-2343	49	43	,	,	PUNCT
dti-2343	49	44	the	the	DET
dti-2343	49	45	proportion	proportion	NOUN
dti-2343	49	46	of	of	ADP
dti-2343	49	47	patients	patient	NOUN
dti-2343	49	48	without	without	ADP
dti-2343	49	49	active	active	ADJ
dti-2343	49	50	disease	disease	NOUN
dti-2343	49	51	1	1	NUM
dti-2343	49	52	month	month	NOUN
dti-2343	49	53	after	after	ADP
dti-2343	49	54	injection	injection	NOUN
dti-2343	49	55	,	,	PUNCT
dti-2343	49	56	the	the	DET
dti-2343	49	57	mean	mean	ADJ
dti-2343	49	58	time	time	NOUN
dti-2343	49	59	to	to	ADP
dti-2343	49	60	first	first	ADJ
dti-2343	49	61	disease	disease	NOUN
dti-2343	49	62	inactivation	inactivation	NOUN
dti-2343	49	63	,	,	PUNCT
dti-2343	49	64	and	and	CCONJ
dti-2343	49	65	the	the	DET
dti-2343	49	66	mean	mean	ADJ
dti-2343	49	67	difference	difference	NOUN
dti-2343	49	68	of	of	ADP
dti-2343	49	69	cst	cst	PROPN
dti-2343	49	70	and	and	CCONJ
dti-2343	49	71	va	va	PROPN
dti-2343	49	72	between	between	ADP
dti-2343	49	73	baseline	baseline	PROPN
dti-2343	49	74	and	and	CCONJ
dti-2343	49	75	1	1	NUM
dti-2343	49	76	-	-	PUNCT
dti-2343	49	77	month	month	NOUN
dti-2343	49	78	postinjection	postinjection	NOUN
dti-2343	49	79	.	.	PUNCT
dti-2343	50	1	statistical	statistical	ADJ
dti-2343	50	2	analysis	analysis	NOUN
dti-2343	50	3	descriptive	descriptive	ADJ
dti-2343	50	4	statistics	statistic	NOUN
dti-2343	50	5	were	be	AUX
dti-2343	50	6	used	use	VERB
dti-2343	50	7	to	to	PART
dti-2343	50	8	summarize	summarize	VERB
dti-2343	50	9	demographic	demographic	ADJ
dti-2343	50	10	and	and	CCONJ
dti-2343	50	11	clinical	clinical	ADJ
dti-2343	50	12	data	datum	NOUN
dti-2343	50	13	at	at	ADP
dti-2343	50	14	baseline	baseline	NOUN
dti-2343	50	15	and	and	CCONJ
dti-2343	50	16	successive	successive	ADJ
dti-2343	50	17	time	time	NOUN
dti-2343	50	18	points	point	NOUN
dti-2343	50	19	,	,	PUNCT
dti-2343	50	20	as	as	ADP
dti-2343	50	21	appropriate	appropriate	ADJ
dti-2343	50	22	.	.	PUNCT
dti-2343	51	1	continuous	continuous	ADJ
dti-2343	51	2	data	datum	NOUN
dti-2343	51	3	were	be	AUX
dti-2343	51	4	described	describe	VERB
dti-2343	51	5	using	use	VERB
dti-2343	51	6	the	the	DET
dti-2343	51	7	mean	mean	ADJ
dti-2343	51	8	,	,	PUNCT
dti-2343	51	9	standard	standard	ADJ
dti-2343	51	10	deviation	deviation	NOUN
dti-2343	51	11	(	(	PUNCT
dti-2343	51	12	sd	sd	NOUN
dti-2343	51	13	)	)	PUNCT
dti-2343	51	14	,	,	PUNCT
dti-2343	51	15	and	and	CCONJ
dti-2343	51	16	range	range	NOUN
dti-2343	51	17	,	,	PUNCT
dti-2343	51	18	while	while	SCONJ
dti-2343	51	19	categorical	categorical	ADJ
dti-2343	51	20	data	datum	NOUN
dti-2343	51	21	were	be	AUX
dti-2343	51	22	expressed	express	VERB
dti-2343	51	23	as	as	ADP
dti-2343	51	24	percentages	percentage	NOUN
dti-2343	51	25	.	.	PUNCT
dti-2343	52	1	the	the	DET
dti-2343	52	2	difference	difference	NOUN
dti-2343	52	3	in	in	ADP
dti-2343	52	4	cst	cst	PROPN
dti-2343	52	5	and	and	CCONJ
dti-2343	52	6	va	va	PROPN
dti-2343	52	7	between	between	ADP
dti-2343	52	8	baseline	baseline	PROPN
dti-2343	52	9	and	and	CCONJ
dti-2343	52	10	the	the	DET
dti-2343	52	11	assessment	assessment	NOUN
dti-2343	52	12	at	at	ADP
dti-2343	52	13	1	1	NUM
dti-2343	52	14	month	month	NOUN
dti-2343	52	15	was	be	AUX
dti-2343	52	16	tested	test	VERB
dti-2343	52	17	using	use	VERB
dti-2343	52	18	the	the	DET
dti-2343	52	19	nonparametric	nonparametric	NOUN
dti-2343	52	20	wilcoxon	wilcoxon	VERB
dti-2343	52	21	single	single	ADJ
dti-2343	52	22	brolucizumab	brolucizumab	NOUN
dti-2343	52	23	intravitreal	intravitreal	ADJ
dti-2343	52	24	injection	injection	NOUN
dti-2343	52	25	for	for	ADP
dti-2343	52	26	namd	namd	NOUN
dti-2343	52	27	treatment8	treatment8	NOUN
dti-2343	53	1	©	©	ADP
dti-2343	53	2	2022	2022	NUM
dti-2343	54	1	the	the	DET
dti-2343	54	2	authors	author	NOUN
dti-2343	54	3	.	.	PUNCT
dti-2343	55	1	drug	drug	NOUN
dti-2343	55	2	target	target	NOUN
dti-2343	55	3	insights	insight	NOUN
dti-2343	55	4	issn	issn	VERB
dti-2343	55	5	1177	1177	NUM
dti-2343	55	6	-	-	SYM
dti-2343	55	7	3928	3928	NUM
dti-2343	55	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-2343	55	9	signed	sign	VERB
dti-2343	55	10	-	-	PUNCT
dti-2343	55	11	rank	rank	NOUN
dti-2343	55	12	test	test	NOUN
dti-2343	55	13	,	,	PUNCT
dti-2343	55	14	with	with	ADP
dti-2343	55	15	statistical	statistical	ADJ
dti-2343	55	16	significance	significance	NOUN
dti-2343	55	17	set	set	VERB
dti-2343	55	18	at	at	ADP
dti-2343	55	19	p	p	NOUN
dti-2343	55	20	<	<	X
dti-2343	55	21	0.05	0.05	NUM
dti-2343	55	22	.	.	PUNCT
dti-2343	56	1	the	the	DET
dti-2343	56	2	time	time	NOUN
dti-2343	56	3	to	to	ADP
dti-2343	56	4	first	first	ADJ
dti-2343	56	5	disease	disease	NOUN
dti-2343	56	6	inactivation	inactivation	NOUN
dti-2343	56	7	was	be	AUX
dti-2343	56	8	determined	determine	VERB
dti-2343	56	9	using	use	VERB
dti-2343	56	10	kaplan	kaplan	PROPN
dti-2343	56	11	-	-	PUNCT
dti-2343	56	12	meier	meier	PROPN
dti-2343	56	13	survival	survival	NOUN
dti-2343	56	14	analysis	analysis	NOUN
dti-2343	56	15	using	use	VERB
dti-2343	56	16	the	the	DET
dti-2343	56	17	two	two	NUM
dti-2343	56	18	available	available	ADJ
dti-2343	56	19	observation	observation	NOUN
dti-2343	56	20	time	time	NOUN
dti-2343	56	21	points	point	NOUN
dti-2343	56	22	,	,	PUNCT
dti-2343	56	23	t1	t1	NOUN
dti-2343	56	24	and	and	CCONJ
dti-2343	56	25	t2	t2	NOUN
dti-2343	56	26	.	.	PUNCT
dti-2343	57	1	analyses	analysis	NOUN
dti-2343	57	2	were	be	AUX
dti-2343	57	3	performed	perform	VERB
dti-2343	57	4	using	use	VERB
dti-2343	57	5	ibm	ibm	PROPN
dti-2343	57	6	®	®	NOUN
dti-2343	57	7	spss	spss	PROPN
dti-2343	57	8	®	®	PROPN
dti-2343	57	9	version	version	NOUN
dti-2343	57	10	26	26	NUM
dti-2343	57	11	.	.	PUNCT
dti-2343	58	1	results	result	VERB
dti-2343	58	2	patient	patient	ADJ
dti-2343	58	3	characteristics	characteristic	NOUN
dti-2343	58	4	at	at	ADP
dti-2343	58	5	baseline	baseline	NOUN
dti-2343	58	6	a	a	DET
dti-2343	58	7	total	total	NOUN
dti-2343	58	8	of	of	ADP
dti-2343	58	9	nine	nine	NUM
dti-2343	58	10	patients	patient	NOUN
dti-2343	58	11	were	be	AUX
dti-2343	58	12	eligible	eligible	ADJ
dti-2343	58	13	and	and	CCONJ
dti-2343	58	14	included	include	VERB
dti-2343	58	15	in	in	ADP
dti-2343	58	16	the	the	DET
dti-2343	58	17	study	study	NOUN
dti-2343	58	18	.	.	PUNCT
dti-2343	59	1	none	none	NOUN
dti-2343	59	2	of	of	ADP
dti-2343	59	3	the	the	DET
dti-2343	59	4	patients	patient	NOUN
dti-2343	59	5	had	have	VERB
dti-2343	59	6	signs	sign	NOUN
dti-2343	59	7	of	of	ADP
dti-2343	59	8	ioi	ioi	NOUN
dti-2343	59	9	at	at	ADP
dti-2343	59	10	baseline	baseline	NOUN
dti-2343	59	11	or	or	CCONJ
dti-2343	59	12	study	study	NOUN
dti-2343	59	13	end	end	NOUN
dti-2343	59	14	.	.	PUNCT
dti-2343	60	1	patient	patient	ADJ
dti-2343	60	2	demographics	demographic	NOUN
dti-2343	60	3	and	and	CCONJ
dti-2343	60	4	clinical	clinical	ADJ
dti-2343	60	5	and	and	CCONJ
dti-2343	60	6	treatment	treatment	NOUN
dti-2343	60	7	history	history	NOUN
dti-2343	60	8	at	at	ADP
dti-2343	60	9	baseline	baseline	NOUN
dti-2343	60	10	are	be	AUX
dti-2343	60	11	summarized	summarize	VERB
dti-2343	60	12	in	in	ADP
dti-2343	60	13	table	table	NOUN
dti-2343	60	14	i.	i.	NOUN
dti-2343	60	15	before	before	ADP
dti-2343	60	16	switching	switch	VERB
dti-2343	60	17	to	to	PART
dti-2343	60	18	brolucizumab	brolucizumab	VERB
dti-2343	60	19	,	,	PUNCT
dti-2343	60	20	six	six	NUM
dti-2343	60	21	patients	patient	NOUN
dti-2343	60	22	were	be	AUX
dti-2343	60	23	treated	treat	VERB
dti-2343	60	24	with	with	ADP
dti-2343	60	25	a	a	DET
dti-2343	60	26	single	single	ADJ
dti-2343	60	27	anti	anti	ADJ
dti-2343	60	28	-	-	NOUN
dti-2343	60	29	vegf	vegf	ADJ
dti-2343	60	30	:	:	PUNCT
dti-2343	60	31	aflibercept	aflibercept	PROPN
dti-2343	60	32	(	(	PUNCT
dti-2343	60	33	n	n	NOUN
dti-2343	60	34	=	=	SYM
dti-2343	60	35	2	2	NUM
dti-2343	60	36	)	)	PUNCT
dti-2343	60	37	or	or	CCONJ
dti-2343	60	38	bevacizumab	bevacizumab	NOUN
dti-2343	60	39	(	(	PUNCT
dti-2343	60	40	n	n	NOUN
dti-2343	60	41	=	=	SYM
dti-2343	60	42	2	2	NUM
dti-2343	60	43	)	)	PUNCT
dti-2343	60	44	or	or	CCONJ
dti-2343	60	45	ranibizumab	ranibizumab	NOUN
dti-2343	60	46	(	(	PUNCT
dti-2343	60	47	n	n	NOUN
dti-2343	60	48	=	=	SYM
dti-2343	60	49	2	2	NUM
dti-2343	60	50	)	)	PUNCT
dti-2343	60	51	.	.	PUNCT
dti-2343	61	1	the	the	DET
dti-2343	61	2	remaining	remain	VERB
dti-2343	61	3	patients	patient	NOUN
dti-2343	61	4	switched	switch	VERB
dti-2343	61	5	from	from	ADP
dti-2343	61	6	aflibercept	aflibercept	PRON
dti-2343	61	7	to	to	ADP
dti-2343	61	8	bevacizumab	bevacizumab	NOUN
dti-2343	61	9	(	(	PUNCT
dti-2343	61	10	n	n	NOUN
dti-2343	61	11	=	=	SYM
dti-2343	61	12	1	1	NUM
dti-2343	61	13	)	)	PUNCT
dti-2343	61	14	,	,	PUNCT
dti-2343	61	15	from	from	ADP
dti-2343	61	16	bevacizumab	bevacizumab	NOUN
dti-2343	61	17	to	to	ADP
dti-2343	61	18	aflibercept	aflibercept	PROPN
dti-2343	61	19	(	(	PUNCT
dti-2343	61	20	n	n	NOUN
dti-2343	61	21	=	=	SYM
dti-2343	61	22	1	1	NUM
dti-2343	61	23	)	)	PUNCT
dti-2343	61	24	,	,	PUNCT
dti-2343	61	25	and	and	CCONJ
dti-2343	61	26	from	from	ADP
dti-2343	61	27	bevacizumab	bevacizumab	NOUN
dti-2343	61	28	to	to	PART
dti-2343	61	29	ranibizumab	ranibizumab	VERB
dti-2343	61	30	to	to	ADP
dti-2343	61	31	aflibercept	aflibercept	NOUN
dti-2343	61	32	(	(	PUNCT
dti-2343	61	33	n	n	NOUN
dti-2343	61	34	=	=	SYM
dti-2343	61	35	1	1	NUM
dti-2343	61	36	)	)	PUNCT
dti-2343	61	37	.	.	PUNCT
dti-2343	62	1	anatomical	anatomical	ADJ
dti-2343	62	2	and	and	CCONJ
dti-2343	62	3	functional	functional	ADJ
dti-2343	62	4	outcomes	outcome	NOUN
dti-2343	62	5	at	at	ADP
dti-2343	62	6	1	1	NUM
dti-2343	62	7	-	-	PUNCT
dti-2343	62	8	month	month	NOUN
dti-2343	62	9	postinjection	postinjection	NOUN
dti-2343	62	10	patients	patient	NOUN
dti-2343	62	11	were	be	AUX
dti-2343	62	12	assessed	assess	VERB
dti-2343	62	13	within	within	ADP
dti-2343	62	14	1	1	NUM
dti-2343	62	15	week	week	NOUN
dti-2343	62	16	and	and	CCONJ
dti-2343	62	17	1	1	NUM
dti-2343	62	18	month	month	NOUN
dti-2343	62	19	(	(	PUNCT
dti-2343	62	20	mean	mean	NOUN
dti-2343	62	21	29.1	29.1	NUM
dti-2343	62	22	±	±	NUM
dti-2343	62	23	4.6	4.6	NUM
dti-2343	62	24	days	day	NOUN
dti-2343	62	25	,	,	PUNCT
dti-2343	62	26	range	range	NOUN
dti-2343	62	27	24	24	NUM
dti-2343	62	28	-	-	SYM
dti-2343	62	29	35	35	NUM
dti-2343	62	30	)	)	PUNCT
dti-2343	62	31	after	after	ADP
dti-2343	62	32	the	the	DET
dti-2343	62	33	first	first	ADJ
dti-2343	62	34	brolucizumab	brolucizumab	NOUN
dti-2343	62	35	injection	injection	NOUN
dti-2343	62	36	.	.	PUNCT
dti-2343	63	1	no	no	DET
dti-2343	63	2	signs	sign	NOUN
dti-2343	63	3	of	of	ADP
dti-2343	63	4	active	active	ADJ
dti-2343	63	5	disease	disease	NOUN
dti-2343	63	6	were	be	AUX
dti-2343	63	7	observed	observe	VERB
dti-2343	63	8	in	in	ADP
dti-2343	63	9	eight	eight	NUM
dti-2343	63	10	(	(	PUNCT
dti-2343	63	11	88.9	88.9	NUM
dti-2343	63	12	%	%	NOUN
dti-2343	63	13	)	)	PUNCT
dti-2343	63	14	patients	patient	NOUN
dti-2343	63	15	:	:	PUNCT
dti-2343	63	16	in	in	ADP
dti-2343	63	17	seven	seven	NUM
dti-2343	63	18	patients	patient	NOUN
dti-2343	63	19	(	(	PUNCT
dti-2343	63	20	77.8	77.8	NUM
dti-2343	63	21	%	%	NOUN
dti-2343	63	22	)	)	PUNCT
dti-2343	63	23	srf	srf	PROPN
dti-2343	63	24	and	and	CCONJ
dti-2343	63	25	irf	irf	PROPN
dti-2343	63	26	were	be	AUX
dti-2343	63	27	absent	absent	ADJ
dti-2343	63	28	,	,	PUNCT
dti-2343	63	29	while	while	SCONJ
dti-2343	63	30	in	in	ADP
dti-2343	63	31	one	one	NUM
dti-2343	63	32	patient	patient	NOUN
dti-2343	63	33	(	(	PUNCT
dti-2343	63	34	11.1	11.1	NUM
dti-2343	63	35	%	%	NOUN
dti-2343	63	36	)	)	PUNCT
dti-2343	63	37	fluid	fluid	NOUN
dti-2343	63	38	was	be	AUX
dti-2343	63	39	only	only	ADV
dti-2343	63	40	partially	partially	ADV
dti-2343	63	41	reabsorbed	reabsorb	VERB
dti-2343	63	42	.	.	PUNCT
dti-2343	64	1	all	all	DET
dti-2343	64	2	three	three	NUM
dti-2343	64	3	patients	patient	NOUN
dti-2343	64	4	presenting	present	VERB
dti-2343	64	5	with	with	ADP
dti-2343	64	6	sub	sub	ADJ
dti-2343	64	7	-	-	ADJ
dti-2343	64	8	rpe	rpe	ADJ
dti-2343	64	9	fluid	fluid	NOUN
dti-2343	64	10	at	at	ADP
dti-2343	64	11	baseline	baseline	PROPN
dti-2343	64	12	showed	show	VERB
dti-2343	64	13	complete	complete	ADJ
dti-2343	64	14	resolution	resolution	NOUN
dti-2343	64	15	.	.	PUNCT
dti-2343	65	1	the	the	DET
dti-2343	65	2	cst	cst	PROPN
dti-2343	65	3	showed	show	VERB
dti-2343	65	4	a	a	DET
dti-2343	65	5	significant	significant	ADJ
dti-2343	65	6	reduction	reduction	NOUN
dti-2343	65	7	from	from	ADP
dti-2343	65	8	398.4	398.4	NUM
dti-2343	65	9	(	(	PUNCT
dti-2343	65	10	97.5	97.5	NUM
dti-2343	65	11	sd	sd	NOUN
dti-2343	65	12	)	)	PUNCT
dti-2343	65	13	μm	μm	NOUN
dti-2343	65	14	at	at	ADP
dti-2343	65	15	baseline	baseline	NOUN
dti-2343	65	16	to	to	ADP
dti-2343	65	17	258.3	258.3	NUM
dti-2343	65	18	(	(	PUNCT
dti-2343	65	19	32.4	32.4	NUM
dti-2343	65	20	sd	sd	NOUN
dti-2343	65	21	)	)	PUNCT
dti-2343	65	22	μm	μm	NOUN
dti-2343	65	23	at	at	ADP
dti-2343	65	24	1	1	NUM
dti-2343	65	25	month	month	NOUN
dti-2343	65	26	postinjection	postinjection	NOUN
dti-2343	65	27	(	(	PUNCT
dti-2343	65	28	mean	mean	INTJ
dti-2343	65	29	difference	difference	NOUN
dti-2343	65	30	131.1	131.1	NUM
dti-2343	65	31	μm	μm	NOUN
dti-2343	65	32	,	,	PUNCT
dti-2343	65	33	95	95	NUM
dti-2343	65	34	%	%	NOUN
dti-2343	65	35	confidence	confidence	NOUN
dti-2343	65	36	interval	interval	NOUN
dti-2343	65	37	[	[	X
dti-2343	65	38	ci	ci	X
dti-2343	65	39	]	]	X
dti-2343	65	40	46.4	46.4	NUM
dti-2343	65	41	-	-	SYM
dti-2343	65	42	215.8	215.8	NUM
dti-2343	65	43	;	;	PUNCT
dti-2343	65	44	related	relate	VERB
dti-2343	65	45	-	-	PUNCT
dti-2343	65	46	samples	sample	NOUN
dti-2343	65	47	wilcoxon	wilcoxon	VERB
dti-2343	65	48	signed	sign	VERB
dti-2343	65	49	-	-	PUNCT
dti-2343	65	50	rank	rank	NOUN
dti-2343	65	51	test	test	NOUN
dti-2343	65	52	p	p	NOUN
dti-2343	65	53	=	=	NOUN
dti-2343	65	54	0.007	0.007	NUM
dti-2343	65	55	)	)	PUNCT
dti-2343	65	56	.	.	PUNCT
dti-2343	66	1	in	in	ADP
dti-2343	66	2	parallel	parallel	NOUN
dti-2343	66	3	,	,	PUNCT
dti-2343	66	4	va	va	PROPN
dti-2343	66	5	improved	improve	VERB
dti-2343	66	6	significantly	significantly	ADV
dti-2343	66	7	from	from	ADP
dti-2343	66	8	54.4	54.4	NUM
dti-2343	66	9	(	(	PUNCT
dti-2343	66	10	20.1	20.1	NUM
dti-2343	66	11	sd	sd	NOUN
dti-2343	66	12	)	)	PUNCT
dti-2343	66	13	letters	letter	NOUN
dti-2343	66	14	at	at	ADP
dti-2343	66	15	baseline	baseline	NOUN
dti-2343	66	16	to	to	ADP
dti-2343	66	17	72.8	72.8	NUM
dti-2343	66	18	(	(	PUNCT
dti-2343	66	19	16	16	NUM
dti-2343	66	20	sd	sd	NOUN
dti-2343	66	21	)	)	PUNCT
dti-2343	66	22	letters	letter	NOUN
dti-2343	66	23	at	at	ADP
dti-2343	66	24	1	1	NUM
dti-2343	66	25	month	month	NOUN
dti-2343	66	26	postinjection	postinjection	NOUN
dti-2343	66	27	(	(	PUNCT
dti-2343	66	28	mean	mean	INTJ
dti-2343	66	29	difference	difference	NOUN
dti-2343	66	30	18.3	18.3	NUM
dti-2343	66	31	letters	letter	NOUN
dti-2343	66	32	,	,	PUNCT
dti-2343	66	33	95	95	NUM
dti-2343	66	34	%	%	NOUN
dti-2343	66	35	ci	ci	NOUN
dti-2343	66	36	6.64	6.64	NUM
dti-2343	66	37	-	-	SYM
dti-2343	66	38	30.02	30.02	NUM
dti-2343	66	39	;	;	PUNCT
dti-2343	66	40	related	relate	VERB
dti-2343	66	41	-	-	PUNCT
dti-2343	66	42	samples	sample	NOUN
dti-2343	66	43	wilcoxon	wilcoxon	VERB
dti-2343	66	44	signed	sign	VERB
dti-2343	66	45	-	-	PUNCT
dti-2343	66	46	rank	rank	NOUN
dti-2343	66	47	test	test	NOUN
dti-2343	66	48	p	p	NOUN
dti-2343	66	49	=	=	NOUN
dti-2343	66	50	0.011	0.011	NUM
dti-2343	66	51	)	)	PUNCT
dti-2343	66	52	.	.	PUNCT
dti-2343	67	1	the	the	DET
dti-2343	67	2	estimated	estimate	VERB
dti-2343	67	3	mean	mean	NOUN
dti-2343	67	4	and	and	CCONJ
dti-2343	67	5	median	median	ADJ
dti-2343	67	6	time	time	NOUN
dti-2343	67	7	to	to	ADP
dti-2343	67	8	disease	disease	NOUN
dti-2343	67	9	inactivation	inactivation	NOUN
dti-2343	67	10	were	be	AUX
dti-2343	67	11	14.2	14.2	NUM
dti-2343	67	12	(	(	PUNCT
dti-2343	67	13	range	range	NOUN
dti-2343	67	14	5	5	NUM
dti-2343	67	15	-	-	SYM
dti-2343	67	16	23.4	23.4	NUM
dti-2343	67	17	)	)	PUNCT
dti-2343	67	18	days	day	NOUN
dti-2343	67	19	and	and	CCONJ
dti-2343	67	20	3	3	NUM
dti-2343	67	21	(	(	PUNCT
dti-2343	67	22	range	range	VERB
dti-2343	67	23	2.03	2.03	NUM
dti-2343	67	24	-	-	SYM
dti-2343	67	25	3.97	3.97	NUM
dti-2343	67	26	)	)	PUNCT
dti-2343	67	27	days	day	NOUN
dti-2343	67	28	,	,	PUNCT
dti-2343	67	29	respectively	respectively	ADV
dti-2343	67	30	(	(	PUNCT
dti-2343	67	31	shown	show	VERB
dti-2343	67	32	in	in	ADP
dti-2343	67	33	fig	fig	NOUN
dti-2343	67	34	.	.	PUNCT
dti-2343	68	1	1	1	NUM
dti-2343	68	2	)	)	PUNCT
dti-2343	68	3	.	.	PUNCT
dti-2343	69	1	in	in	ADP
dti-2343	69	2	the	the	DET
dti-2343	69	3	three	three	NUM
dti-2343	69	4	patients	patient	NOUN
dti-2343	69	5	who	who	PRON
dti-2343	69	6	were	be	AUX
dti-2343	69	7	further	far	ADV
dti-2343	69	8	examined	examine	VERB
dti-2343	69	9	at	at	ADP
dti-2343	69	10	60	60	NUM
dti-2343	69	11	,	,	PUNCT
dti-2343	69	12	62	62	NUM
dti-2343	69	13	,	,	PUNCT
dti-2343	69	14	and	and	CCONJ
dti-2343	69	15	92	92	NUM
dti-2343	69	16	days	day	NOUN
dti-2343	69	17	,	,	PUNCT
dti-2343	69	18	respectively	respectively	ADV
dti-2343	69	19	,	,	PUNCT
dti-2343	69	20	from	from	ADP
dti-2343	69	21	the	the	DET
dti-2343	69	22	injection	injection	NOUN
dti-2343	69	23	,	,	PUNCT
dti-2343	69	24	no	no	DET
dti-2343	69	25	sign	sign	NOUN
dti-2343	69	26	of	of	ADP
dti-2343	69	27	disease	disease	NOUN
dti-2343	69	28	reactivation	reactivation	NOUN
dti-2343	69	29	or	or	CCONJ
dti-2343	69	30	fluid	fluid	NOUN
dti-2343	69	31	recurrence	recurrence	NOUN
dti-2343	69	32	was	be	AUX
dti-2343	69	33	observed	observe	VERB
dti-2343	69	34	,	,	PUNCT
dti-2343	69	35	and	and	CCONJ
dti-2343	69	36	the	the	DET
dti-2343	69	37	va	va	NOUN
dti-2343	69	38	remained	remain	VERB
dti-2343	69	39	stable	stable	ADJ
dti-2343	69	40	;	;	PUNCT
dti-2343	69	41	thus	thus	ADV
dti-2343	69	42	,	,	PUNCT
dti-2343	69	43	there	there	PRON
dti-2343	69	44	was	be	VERB
dti-2343	69	45	no	no	DET
dti-2343	69	46	need	need	NOUN
dti-2343	69	47	for	for	ADP
dti-2343	69	48	additional	additional	ADJ
dti-2343	69	49	injections	injection	NOUN
dti-2343	69	50	.	.	PUNCT
dti-2343	70	1	as	as	ADP
dti-2343	70	2	a	a	DET
dti-2343	70	3	case	case	NOUN
dti-2343	70	4	example	example	NOUN
dti-2343	70	5	,	,	PUNCT
dti-2343	70	6	the	the	DET
dti-2343	70	7	retinal	retinal	ADJ
dti-2343	70	8	sd	sd	NOUN
dti-2343	70	9	-	-	PUNCT
dti-2343	70	10	oct	oct	NOUN
dti-2343	70	11	b	b	PROPN
dti-2343	70	12	-	-	PUNCT
dti-2343	70	13	scans	scan	NOUN
dti-2343	70	14	of	of	ADP
dti-2343	70	15	one	one	NUM
dti-2343	70	16	of	of	ADP
dti-2343	70	17	the	the	DET
dti-2343	70	18	patients	patient	NOUN
dti-2343	70	19	at	at	ADP
dti-2343	70	20	different	different	ADJ
dti-2343	70	21	time	time	NOUN
dti-2343	70	22	points	point	NOUN
dti-2343	70	23	following	follow	VERB
dti-2343	70	24	brolucizumab	brolucizumab	NOUN
dti-2343	70	25	injection	injection	NOUN
dti-2343	70	26	are	be	AUX
dti-2343	70	27	shown	show	VERB
dti-2343	70	28	in	in	ADP
dti-2343	70	29	figure	figure	NOUN
dti-2343	70	30	2	2	NUM
dti-2343	70	31	.	.	PUNCT
dti-2343	71	1	ioi	ioi	PROPN
dti-2343	71	2	,	,	PUNCT
dti-2343	71	3	vasculitis	vasculitis	NOUN
dti-2343	71	4	,	,	PUNCT
dti-2343	71	5	or	or	CCONJ
dti-2343	71	6	retinal	retinal	ADJ
dti-2343	71	7	vascular	vascular	ADJ
dti-2343	71	8	occlusion	occlusion	NOUN
dti-2343	71	9	was	be	AUX
dti-2343	71	10	not	not	PART
dti-2343	71	11	reported	report	VERB
dti-2343	71	12	for	for	ADP
dti-2343	71	13	any	any	DET
dti-2343	71	14	patient	patient	NOUN
dti-2343	71	15	in	in	ADP
dti-2343	71	16	the	the	DET
dti-2343	71	17	follow	follow	NOUN
dti-2343	71	18	-	-	PUNCT
dti-2343	71	19	up	up	NOUN
dti-2343	71	20	period	period	NOUN
dti-2343	71	21	under	under	ADP
dti-2343	71	22	consideration	consideration	NOUN
dti-2343	71	23	.	.	PUNCT
dti-2343	72	1	discussion	discussion	NOUN
dti-2343	72	2	significant	significant	ADJ
dti-2343	72	3	anatomical	anatomical	ADJ
dti-2343	72	4	improvements	improvement	NOUN
dti-2343	72	5	were	be	AUX
dti-2343	72	6	observed	observe	VERB
dti-2343	72	7	in	in	ADP
dti-2343	72	8	patients	patient	NOUN
dti-2343	72	9	switching	switch	VERB
dti-2343	72	10	to	to	PART
dti-2343	72	11	brolucizumab	brolucizumab	VERB
dti-2343	72	12	,	,	PUNCT
dti-2343	72	13	as	as	SCONJ
dti-2343	72	14	expected	expect	VERB
dti-2343	72	15	according	accord	VERB
dti-2343	72	16	to	to	ADP
dti-2343	72	17	the	the	DET
dti-2343	72	18	available	available	ADJ
dti-2343	72	19	data	datum	NOUN
dti-2343	72	20	(	(	PUNCT
dti-2343	72	21	25,27,28	25,27,28	NUM
dti-2343	72	22	)	)	PUNCT
dti-2343	72	23	.	.	PUNCT
dti-2343	73	1	these	these	PRON
dti-2343	73	2	included	include	VERB
dti-2343	73	3	a	a	DET
dti-2343	73	4	significant	significant	ADJ
dti-2343	73	5	reduction	reduction	NOUN
dti-2343	73	6	in	in	ADP
dti-2343	73	7	cst	cst	PROPN
dti-2343	73	8	and	and	CCONJ
dti-2343	73	9	almost	almost	ADV
dti-2343	73	10	complete	complete	ADJ
dti-2343	73	11	resolution	resolution	NOUN
dti-2343	73	12	of	of	ADP
dti-2343	73	13	fluids	fluid	NOUN
dti-2343	73	14	in	in	ADP
dti-2343	73	15	most	most	ADJ
dti-2343	73	16	patients	patient	NOUN
dti-2343	73	17	.	.	PUNCT
dti-2343	74	1	although	although	SCONJ
dti-2343	74	2	the	the	DET
dti-2343	74	3	most	most	ADV
dti-2343	74	4	frequent	frequent	ADJ
dti-2343	74	5	timepoint	timepoint	NOUN
dti-2343	74	6	used	use	VERB
dti-2343	74	7	to	to	PART
dti-2343	74	8	evaluate	evaluate	VERB
dti-2343	74	9	the	the	DET
dti-2343	74	10	postinjection	postinjection	NOUN
dti-2343	74	11	anatomical	anatomical	ADJ
dti-2343	74	12	response	response	NOUN
dti-2343	74	13	is	be	AUX
dti-2343	74	14	approximately	approximately	ADV
dti-2343	74	15	1	1	NUM
dti-2343	74	16	month	month	NOUN
dti-2343	74	17	,	,	PUNCT
dti-2343	74	18	in	in	ADP
dti-2343	74	19	the	the	DET
dti-2343	74	20	case	case	NOUN
dti-2343	74	21	of	of	ADP
dti-2343	74	22	no	no	DET
dti-2343	74	23	response	response	NOUN
dti-2343	74	24	it	it	PRON
dti-2343	74	25	would	would	AUX
dti-2343	74	26	be	be	AUX
dti-2343	74	27	useful	useful	ADJ
dti-2343	74	28	to	to	PART
dti-2343	74	29	have	have	VERB
dti-2343	74	30	an	an	DET
dti-2343	74	31	earlier	early	ADJ
dti-2343	74	32	assessment	assessment	NOUN
dti-2343	74	33	since	since	SCONJ
dti-2343	74	34	there	there	PRON
dti-2343	74	35	is	be	VERB
dti-2343	74	36	a	a	DET
dti-2343	74	37	correlation	correlation	NOUN
dti-2343	74	38	between	between	ADP
dti-2343	74	39	cst	cst	PROPN
dti-2343	74	40	reduction	reduction	NOUN
dti-2343	74	41	and	and	CCONJ
dti-2343	74	42	the	the	DET
dti-2343	74	43	time	time	NOUN
dti-2343	74	44	passed	pass	VERB
dti-2343	74	45	from	from	ADP
dti-2343	74	46	the	the	DET
dti-2343	74	47	last	last	ADJ
dti-2343	74	48	injection	injection	NOUN
dti-2343	74	49	(	(	PUNCT
dti-2343	74	50	29,30	29,30	NUM
dti-2343	74	51	)	)	PUNCT
dti-2343	74	52	.	.	PUNCT
dti-2343	75	1	in	in	ADP
dti-2343	75	2	the	the	DET
dti-2343	75	3	group	group	NOUN
dti-2343	75	4	of	of	ADP
dti-2343	75	5	patients	patient	NOUN
dti-2343	75	6	we	we	PRON
dti-2343	75	7	described	describe	VERB
dti-2343	75	8	,	,	PUNCT
dti-2343	75	9	the	the	DET
dti-2343	75	10	response	response	NOUN
dti-2343	75	11	to	to	PART
dti-2343	75	12	brolucizumab	brolucizumab	VERB
dti-2343	75	13	treatment	treatment	NOUN
dti-2343	75	14	was	be	AUX
dti-2343	75	15	rapid	rapid	ADJ
dti-2343	75	16	according	accord	VERB
dti-2343	75	17	to	to	ADP
dti-2343	75	18	anatomical	anatomical	ADJ
dti-2343	75	19	improvement	improvement	NOUN
dti-2343	75	20	,	,	PUNCT
dti-2343	75	21	which	which	PRON
dti-2343	75	22	occurred	occur	VERB
dti-2343	75	23	on	on	ADP
dti-2343	75	24	average	average	ADJ
dti-2343	75	25	2	2	NUM
dti-2343	75	26	weeks	week	NOUN
dti-2343	75	27	after	after	ADP
dti-2343	75	28	the	the	DET
dti-2343	75	29	injection	injection	NOUN
dti-2343	75	30	.	.	PUNCT
dti-2343	76	1	furthermore	furthermore	ADV
dti-2343	76	2	,	,	PUNCT
dti-2343	76	3	in	in	ADP
dti-2343	76	4	the	the	DET
dti-2343	76	5	subgroup	subgroup	NOUN
dti-2343	76	6	of	of	ADP
dti-2343	76	7	patients	patient	NOUN
dti-2343	76	8	followed	follow	VERB
dti-2343	76	9	for	for	ADP
dti-2343	76	10	more	more	ADJ
dti-2343	76	11	than	than	ADP
dti-2343	76	12	4	4	NUM
dti-2343	76	13	weeks	week	NOUN
dti-2343	76	14	,	,	PUNCT
dti-2343	76	15	the	the	DET
dti-2343	76	16	improvements	improvement	NOUN
dti-2343	76	17	were	be	AUX
dti-2343	76	18	stable	stable	ADJ
dti-2343	76	19	for	for	ADP
dti-2343	76	20	at	at	ADV
dti-2343	76	21	least	least	ADV
dti-2343	76	22	8	8	NUM
dti-2343	76	23	to	to	PART
dti-2343	76	24	12	12	NUM
dti-2343	76	25	weeks	week	NOUN
dti-2343	76	26	after	after	ADP
dti-2343	76	27	injection	injection	NOUN
dti-2343	76	28	.	.	PUNCT
dti-2343	77	1	despite	despite	SCONJ
dti-2343	77	2	these	these	DET
dti-2343	77	3	results	result	NOUN
dti-2343	77	4	being	be	AUX
dti-2343	77	5	obtained	obtain	VERB
dti-2343	77	6	in	in	ADP
dti-2343	77	7	non	non	ADJ
dti-2343	77	8	-	-	ADJ
dti-2343	77	9	treatment	treatment	ADJ
dti-2343	77	10	-	-	PUNCT
dti-2343	77	11	naïve	naïve	ADJ
dti-2343	77	12	patients	patient	NOUN
dti-2343	77	13	,	,	PUNCT
dti-2343	77	14	they	they	PRON
dti-2343	77	15	seem	seem	VERB
dti-2343	77	16	to	to	PART
dti-2343	77	17	be	be	AUX
dti-2343	77	18	in	in	ADP
dti-2343	77	19	line	line	NOUN
dti-2343	77	20	with	with	ADP
dti-2343	77	21	those	those	PRON
dti-2343	77	22	from	from	ADP
dti-2343	77	23	the	the	DET
dti-2343	77	24	hawk	hawk	NOUN
dti-2343	77	25	and	and	CCONJ
dti-2343	77	26	harrier	harrier	NOUN
dti-2343	77	27	studies	study	NOUN
dti-2343	77	28	,	,	PUNCT
dti-2343	77	29	which	which	PRON
dti-2343	77	30	showed	show	VERB
dti-2343	77	31	that	that	SCONJ
dti-2343	77	32	namd	namd	NOUN
dti-2343	77	33	was	be	AUX
dti-2343	77	34	controlled	control	VERB
dti-2343	77	35	for	for	ADP
dti-2343	77	36	at	at	ADV
dti-2343	77	37	least	least	ADV
dti-2343	77	38	12	12	NUM
dti-2343	77	39	weeks	week	NOUN
dti-2343	77	40	in	in	ADP
dti-2343	77	41	more	more	ADJ
dti-2343	77	42	than	than	ADP
dti-2343	77	43	50	50	NUM
dti-2343	77	44	%	%	NOUN
dti-2343	77	45	of	of	ADP
dti-2343	77	46	naïve	naïve	ADJ
dti-2343	77	47	patients	patient	NOUN
dti-2343	77	48	injected	inject	VERB
dti-2343	77	49	with	with	ADP
dti-2343	77	50	brolucizumab	brolucizumab	NOUN
dti-2343	77	51	(	(	PUNCT
dti-2343	77	52	24	24	NUM
dti-2343	77	53	)	)	PUNCT
dti-2343	77	54	.	.	PUNCT
dti-2343	78	1	such	such	ADJ
dti-2343	78	2	long	long	ADJ
dti-2343	78	3	-	-	PUNCT
dti-2343	78	4	term	term	NOUN
dti-2343	78	5	effects	effect	NOUN
dti-2343	78	6	suggest	suggest	VERB
dti-2343	78	7	patients	patient	NOUN
dti-2343	78	8	may	may	AUX
dti-2343	78	9	be	be	AUX
dti-2343	78	10	stabilized	stabilize	VERB
dti-2343	78	11	with	with	ADP
dti-2343	78	12	an	an	DET
dti-2343	78	13	interval	interval	NOUN
dti-2343	78	14	of	of	ADP
dti-2343	78	15	12	12	NUM
dti-2343	78	16	weeks	week	NOUN
dti-2343	78	17	between	between	ADP
dti-2343	78	18	injections	injection	NOUN
dti-2343	78	19	,	,	PUNCT
dti-2343	78	20	thus	thus	ADV
dti-2343	78	21	table	table	NOUN
dti-2343	78	22	i	i	PRON
dti-2343	78	23	baseline	baseline	VERB
dti-2343	78	24	characteristics	characteristic	NOUN
dti-2343	78	25	characteristic	characteristic	ADJ
dti-2343	78	26	data	datum	NOUN
dti-2343	78	27	age	age	NOUN
dti-2343	78	28	(	(	PUNCT
dti-2343	78	29	years	year	NOUN
dti-2343	78	30	)	)	PUNCT
dti-2343	78	31	,	,	PUNCT
dti-2343	78	32	mean	mean	INTJ
dti-2343	78	33	(	(	PUNCT
dti-2343	78	34	sd	sd	NOUN
dti-2343	78	35	;	;	PUNCT
dti-2343	78	36	range	range	NOUN
dti-2343	78	37	)	)	PUNCT
dti-2343	78	38	77.2	77.2	NUM
dti-2343	78	39	(	(	PUNCT
dti-2343	78	40	11.6	11.6	NUM
dti-2343	78	41	;	;	PUNCT
dti-2343	78	42	58	58	NUM
dti-2343	78	43	-	-	SYM
dti-2343	78	44	90	90	NUM
dti-2343	78	45	)	)	PUNCT
dti-2343	78	46	female	female	ADJ
dti-2343	78	47	gender	gender	NOUN
dti-2343	78	48	,	,	PUNCT
dti-2343	78	49	no	no	INTJ
dti-2343	78	50	.	.	PUNCT
dti-2343	79	1	(	(	PUNCT
dti-2343	79	2	%	%	NOUN
dti-2343	79	3	)	)	PUNCT
dti-2343	79	4	7	7	NUM
dti-2343	79	5	(	(	PUNCT
dti-2343	79	6	77.8	77.8	NUM
dti-2343	79	7	)	)	PUNCT
dti-2343	79	8	clinical	clinical	ADJ
dti-2343	79	9	profile	profile	NOUN
dti-2343	79	10	,	,	PUNCT
dti-2343	79	11	mean	mean	INTJ
dti-2343	79	12	(	(	PUNCT
dti-2343	79	13	sd	sd	NOUN
dti-2343	79	14	)	)	PUNCT
dti-2343	79	15	va	va	NOUN
dti-2343	79	16	(	(	PUNCT
dti-2343	79	17	letters	letters	PROPN
dti-2343	79	18	)	)	PUNCT
dti-2343	79	19	54.4	54.4	NUM
dti-2343	79	20	(	(	PUNCT
dti-2343	79	21	20.1	20.1	NUM
dti-2343	79	22	)	)	PUNCT
dti-2343	79	23	cst	cst	PROPN
dti-2343	79	24	(	(	PUNCT
dti-2343	79	25	μm	μm	PROPN
dti-2343	79	26	)	)	PUNCT
dti-2343	79	27	386.4	386.4	NUM
dti-2343	79	28	(	(	PUNCT
dti-2343	79	29	97.5	97.5	NUM
dti-2343	79	30	)	)	PUNCT
dti-2343	79	31	angiographic	angiographic	ADJ
dti-2343	79	32	lesion	lesion	NOUN
dti-2343	79	33	type	type	NOUN
dti-2343	79	34	,	,	PUNCT
dti-2343	79	35	no	no	INTJ
dti-2343	79	36	.	.	PUNCT
dti-2343	80	1	(	(	PUNCT
dti-2343	80	2	%	%	INTJ
dti-2343	80	3	)	)	PUNCT
dti-2343	80	4	1	1	NUM
dti-2343	80	5	4	4	NUM
dti-2343	80	6	(	(	PUNCT
dti-2343	80	7	44.4	44.4	NUM
dti-2343	80	8	)	)	PUNCT
dti-2343	80	9	2	2	NUM
dti-2343	80	10	5	5	NUM
dti-2343	80	11	(	(	PUNCT
dti-2343	80	12	55.6	55.6	NUM
dti-2343	80	13	)	)	PUNCT
dti-2343	80	14	with	with	ADP
dti-2343	80	15	irf	irf	PROPN
dti-2343	80	16	6	6	NUM
dti-2343	80	17	(	(	PUNCT
dti-2343	80	18	66.7	66.7	NUM
dti-2343	80	19	)	)	PUNCT
dti-2343	80	20	with	with	ADP
dti-2343	80	21	srf	srf	PROPN
dti-2343	80	22	7	7	NUM
dti-2343	80	23	(	(	PUNCT
dti-2343	80	24	77.8	77.8	NUM
dti-2343	80	25	)	)	PUNCT
dti-2343	80	26	with	with	ADP
dti-2343	80	27	sub	sub	ADJ
dti-2343	80	28	-	-	ADJ
dti-2343	80	29	rpe	rpe	ADJ
dti-2343	80	30	fluid	fluid	NOUN
dti-2343	80	31	3	3	NUM
dti-2343	80	32	(	(	PUNCT
dti-2343	80	33	33.3	33.3	NUM
dti-2343	80	34	)	)	PUNCT
dti-2343	80	35	with	with	ADP
dti-2343	80	36	fibrosis	fibrosis	NOUN
dti-2343	80	37	3	3	NUM
dti-2343	80	38	(	(	PUNCT
dti-2343	80	39	33.3	33.3	NUM
dti-2343	80	40	)	)	PUNCT
dti-2343	80	41	with	with	ADP
dti-2343	80	42	subretinal	subretinal	ADJ
dti-2343	80	43	fibrosis	fibrosis	NOUN
dti-2343	80	44	1	1	NUM
dti-2343	80	45	(	(	PUNCT
dti-2343	80	46	11.1	11.1	NUM
dti-2343	80	47	)	)	PUNCT
dti-2343	80	48	with	with	ADP
dti-2343	80	49	shrm	shrm	PROPN
dti-2343	80	50	1	1	NUM
dti-2343	80	51	(	(	PUNCT
dti-2343	80	52	11.1	11.1	NUM
dti-2343	80	53	)	)	PUNCT
dti-2343	80	54	anti	anti	ADJ
dti-2343	80	55	-	-	ADJ
dti-2343	80	56	vegf	vegf	ADJ
dti-2343	80	57	treatment	treatment	NOUN
dti-2343	80	58	prior	prior	ADV
dti-2343	80	59	to	to	ADP
dti-2343	80	60	brolucizumab	brolucizumab	NOUN
dti-2343	80	61	injection	injection	NOUN
dti-2343	80	62	,	,	PUNCT
dti-2343	80	63	mean	mean	NOUN
dti-2343	80	64	(	(	PUNCT
dti-2343	80	65	sd	sd	NOUN
dti-2343	80	66	;	;	PUNCT
dti-2343	80	67	min	min	PROPN
dti-2343	80	68	-	-	PUNCT
dti-2343	80	69	max	max	ADJ
dti-2343	80	70	)	)	PUNCT
dti-2343	80	71	treatment	treatment	NOUN
dti-2343	80	72	length	length	NOUN
dti-2343	80	73	(	(	PUNCT
dti-2343	80	74	months	month	NOUN
dti-2343	80	75	)	)	PUNCT
dti-2343	80	76	9.9	9.9	NUM
dti-2343	80	77	(	(	PUNCT
dti-2343	80	78	5.8	5.8	NUM
dti-2343	80	79	;	;	PUNCT
dti-2343	80	80	3	3	NUM
dti-2343	80	81	-	-	SYM
dti-2343	80	82	18	18	NUM
dti-2343	80	83	)	)	PUNCT
dti-2343	80	84	no	no	NOUN
dti-2343	80	85	.	.	NOUN
dti-2343	80	86	of	of	ADP
dti-2343	80	87	injections	injection	NOUN
dti-2343	80	88	5.7	5.7	NUM
dti-2343	80	89	(	(	PUNCT
dti-2343	80	90	3.5	3.5	NUM
dti-2343	80	91	;	;	PUNCT
dti-2343	80	92	2	2	NUM
dti-2343	80	93	-	-	SYM
dti-2343	80	94	12	12	NUM
dti-2343	80	95	)	)	PUNCT
dti-2343	80	96	last	last	ADJ
dti-2343	80	97	administration	administration	NOUN
dti-2343	80	98	interval	interval	NOUN
dti-2343	80	99	(	(	PUNCT
dti-2343	80	100	months	month	NOUN
dti-2343	80	101	)	)	PUNCT
dti-2343	80	102	2	2	NUM
dti-2343	80	103	(	(	PUNCT
dti-2343	80	104	0.7	0.7	NUM
dti-2343	80	105	;	;	PUNCT
dti-2343	80	106	1	1	NUM
dti-2343	80	107	-	-	SYM
dti-2343	80	108	3	3	NUM
dti-2343	80	109	)	)	PUNCT
dti-2343	80	110	months	month	NOUN
dti-2343	80	111	from	from	ADP
dti-2343	80	112	last	last	ADJ
dti-2343	80	113	injection	injection	NOUN
dti-2343	80	114	to	to	PART
dti-2343	80	115	brolucizumab	brolucizumab	NOUN
dti-2343	80	116	switch	switch	VERB
dti-2343	80	117	3.1	3.1	NUM
dti-2343	80	118	(	(	PUNCT
dti-2343	80	119	1.2	1.2	NUM
dti-2343	80	120	;	;	PUNCT
dti-2343	80	121	2	2	NUM
dti-2343	80	122	-	-	SYM
dti-2343	80	123	6	6	NUM
dti-2343	80	124	)	)	PUNCT
dti-2343	80	125	reason	reason	NOUN
dti-2343	80	126	for	for	ADP
dti-2343	80	127	switching	switch	VERB
dti-2343	80	128	to	to	PART
dti-2343	80	129	brolucizumab	brolucizumab	VERB
dti-2343	80	130	,	,	PUNCT
dti-2343	80	131	no	no	INTJ
dti-2343	80	132	.	.	PUNCT
dti-2343	81	1	(	(	PUNCT
dti-2343	81	2	%	%	INTJ
dti-2343	81	3	)	)	PUNCT
dti-2343	81	4	fluid	fluid	ADJ
dti-2343	81	5	persistence	persistence	NOUN
dti-2343	81	6	4	4	NUM
dti-2343	81	7	(	(	PUNCT
dti-2343	81	8	44.4	44.4	NUM
dti-2343	81	9	)	)	PUNCT
dti-2343	81	10	frequent	frequent	ADJ
dti-2343	81	11	fluid	fluid	NOUN
dti-2343	81	12	recurrences	recurrence	NOUN
dti-2343	81	13	5	5	NUM
dti-2343	81	14	(	(	PUNCT
dti-2343	81	15	55.6	55.6	NUM
dti-2343	81	16	)	)	PUNCT
dti-2343	81	17	µm	µm	NOUN
dti-2343	81	18	=	=	SYM
dti-2343	81	19	micrometers	micrometer	NOUN
dti-2343	81	20	;	;	PUNCT
dti-2343	81	21	cst	cst	PROPN
dti-2343	81	22	=	=	PROPN
dti-2343	81	23	retinal	retinal	ADJ
dti-2343	81	24	central	central	ADJ
dti-2343	81	25	subfield	subfield	NOUN
dti-2343	81	26	thickness	thickness	NOUN
dti-2343	81	27	;	;	PUNCT
dti-2343	81	28	irf	irf	PROPN
dti-2343	81	29	=	=	PROPN
dti-2343	81	30	intraretinal	intraretinal	ADJ
dti-2343	81	31	fluid	fluid	NOUN
dti-2343	81	32	;	;	PUNCT
dti-2343	81	33	max	max	PROPN
dti-2343	81	34	=	=	SYM
dti-2343	81	35	maximum	maximum	PROPN
dti-2343	81	36	;	;	PUNCT
dti-2343	81	37	min	min	NOUN
dti-2343	81	38	=	=	SYM
dti-2343	81	39	minimum	minimum	NOUN
dti-2343	81	40	;	;	PUNCT
dti-2343	81	41	no	no	INTJ
dti-2343	81	42	.	.	PUNCT
dti-2343	82	1	=	=	NOUN
dti-2343	82	2	number	number	NOUN
dti-2343	82	3	;	;	PUNCT
dti-2343	82	4	rpe	rpe	PROPN
dti-2343	82	5	=	=	SYM
dti-2343	82	6	retinal	retinal	ADJ
dti-2343	82	7	pigment	pigment	NOUN
dti-2343	82	8	epithelium	epithelium	NOUN
dti-2343	82	9	;	;	PUNCT
dti-2343	82	10	sd	sd	NOUN
dti-2343	82	11	=	=	SYM
dti-2343	82	12	standard	standard	ADJ
dti-2343	82	13	deviation	deviation	NOUN
dti-2343	82	14	;	;	PUNCT
dti-2343	82	15	shrm	shrm	PROPN
dti-2343	82	16	=	=	SYM
dti-2343	82	17	subretinal	subretinal	ADJ
dti-2343	82	18	hyperreflective	hyperreflective	ADJ
dti-2343	82	19	material	material	NOUN
dti-2343	82	20	;	;	PUNCT
dti-2343	82	21	srf	srf	ADJ
dti-2343	82	22	=	=	ADJ
dti-2343	82	23	subretinal	subretinal	ADJ
dti-2343	82	24	fluid	fluid	NOUN
dti-2343	82	25	;	;	PUNCT
dti-2343	82	26	va	va	X
dti-2343	82	27	=	=	PROPN
dti-2343	82	28	visual	visual	ADJ
dti-2343	82	29	acuity	acuity	NOUN
dti-2343	82	30	;	;	PUNCT
dti-2343	83	1	vegf	vegf	NOUN
dti-2343	83	2	=	=	PUNCT
dti-2343	83	3	vascular	vascular	ADJ
dti-2343	83	4	endothelial	endothelial	ADJ
dti-2343	83	5	growth	growth	NOUN
dti-2343	83	6	factor	factor	NOUN
dti-2343	83	7	.	.	PUNCT
dti-2343	84	1	zuccarini	zuccarini	PROPN
dti-2343	84	2	et	et	PROPN
dti-2343	84	3	al	al	PROPN
dti-2343	84	4	drug	drug	PROPN
dti-2343	84	5	target	target	NOUN
dti-2343	84	6	insights	insight	NOUN
dti-2343	84	7	2022	2022	NUM
dti-2343	84	8	;	;	PUNCT
dti-2343	84	9	16	16	NUM
dti-2343	84	10	:	:	SYM
dti-2343	84	11	9	9	NUM
dti-2343	84	12	©	©	ADP
dti-2343	84	13	2022	2022	NUM
dti-2343	84	14	the	the	DET
dti-2343	84	15	authors	author	NOUN
dti-2343	84	16	.	.	PUNCT
dti-2343	85	1	published	publish	VERB
dti-2343	85	2	by	by	ADP
dti-2343	85	3	aboutscience	aboutscience	NOUN
dti-2343	85	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2343	85	5	constituting	constitute	VERB
dti-2343	85	6	a	a	DET
dti-2343	85	7	significant	significant	ADJ
dti-2343	85	8	improvement	improvement	NOUN
dti-2343	85	9	of	of	ADP
dti-2343	85	10	treatment	treatment	NOUN
dti-2343	85	11	burden	burden	NOUN
dti-2343	85	12	.	.	PUNCT
dti-2343	86	1	this	this	PRON
dti-2343	86	2	is	be	AUX
dti-2343	86	3	also	also	ADV
dti-2343	86	4	clearer	clear	ADJ
dti-2343	86	5	considering	consider	VERB
dti-2343	86	6	that	that	SCONJ
dti-2343	86	7	retinal	retinal	ADJ
dti-2343	86	8	fluid	fluid	NOUN
dti-2343	86	9	was	be	AUX
dti-2343	86	10	not	not	PART
dti-2343	86	11	successfully	successfully	ADV
dti-2343	86	12	controlled	control	VERB
dti-2343	86	13	with	with	ADP
dti-2343	86	14	injections	injection	NOUN
dti-2343	86	15	every	every	DET
dti-2343	86	16	8	8	NUM
dti-2343	86	17	weeks	week	NOUN
dti-2343	86	18	before	before	SCONJ
dti-2343	86	19	the	the	DET
dti-2343	86	20	switch	switch	NOUN
dti-2343	86	21	to	to	PART
dti-2343	86	22	brolucizumab	brolucizumab	VERB
dti-2343	86	23	.	.	PUNCT
dti-2343	87	1	in	in	ADP
dti-2343	87	2	our	our	PRON
dti-2343	87	3	group	group	NOUN
dti-2343	87	4	of	of	ADP
dti-2343	87	5	patients	patient	NOUN
dti-2343	87	6	,	,	PUNCT
dti-2343	87	7	we	we	PRON
dti-2343	87	8	also	also	ADV
dti-2343	87	9	observed	observe	VERB
dti-2343	87	10	a	a	DET
dti-2343	87	11	significant	significant	ADJ
dti-2343	87	12	improvement	improvement	NOUN
dti-2343	87	13	in	in	ADP
dti-2343	87	14	terms	term	NOUN
dti-2343	87	15	of	of	ADP
dti-2343	87	16	va	va	PROPN
dti-2343	87	17	.	.	PUNCT
dti-2343	88	1	this	this	PRON
dti-2343	88	2	appears	appear	VERB
dti-2343	88	3	to	to	PART
dti-2343	88	4	contradict	contradict	VERB
dti-2343	88	5	a	a	DET
dti-2343	88	6	recent	recent	ADJ
dti-2343	88	7	case	case	NOUN
dti-2343	88	8	series	series	NOUN
dti-2343	88	9	of	of	ADP
dti-2343	88	10	six	six	NUM
dti-2343	88	11	patients	patient	NOUN
dti-2343	88	12	who	who	PRON
dti-2343	88	13	did	do	AUX
dti-2343	88	14	not	not	PART
dti-2343	88	15	show	show	VERB
dti-2343	88	16	any	any	DET
dti-2343	88	17	increase	increase	NOUN
dti-2343	88	18	in	in	ADP
dti-2343	88	19	va	va	PROPN
dti-2343	88	20	(	(	PUNCT
dti-2343	88	21	26	26	NUM
dti-2343	88	22	)	)	PUNCT
dti-2343	88	23	,	,	PUNCT
dti-2343	88	24	and	and	CCONJ
dti-2343	88	25	a	a	DET
dti-2343	88	26	retrospective	retrospective	ADJ
dti-2343	88	27	analysis	analysis	NOUN
dti-2343	88	28	of	of	ADP
dti-2343	88	29	172	172	NUM
dti-2343	88	30	eyes	eye	NOUN
dti-2343	88	31	,	,	PUNCT
dti-2343	88	32	in	in	ADP
dti-2343	88	33	which	which	PRON
dti-2343	88	34	there	there	PRON
dti-2343	88	35	was	be	VERB
dti-2343	88	36	no	no	DET
dti-2343	88	37	improvement	improvement	NOUN
dti-2343	88	38	in	in	ADP
dti-2343	88	39	va	va	NOUN
dti-2343	88	40	after	after	ADP
dti-2343	88	41	one	one	NUM
dti-2343	88	42	to	to	PART
dti-2343	88	43	three	three	NUM
dti-2343	88	44	brolucizumab	brolucizumab	NOUN
dti-2343	88	45	injections	injection	NOUN
dti-2343	88	46	(	(	PUNCT
dti-2343	88	47	28	28	NUM
dti-2343	88	48	)	)	PUNCT
dti-2343	88	49	.	.	PUNCT
dti-2343	89	1	there	there	PRON
dti-2343	89	2	are	be	VERB
dti-2343	89	3	two	two	NUM
dti-2343	89	4	possible	possible	ADJ
dti-2343	89	5	explanations	explanation	NOUN
dti-2343	89	6	for	for	ADP
dti-2343	89	7	our	our	PRON
dti-2343	89	8	observation	observation	NOUN
dti-2343	89	9	:	:	PUNCT
dti-2343	89	10	the	the	DET
dti-2343	89	11	low	low	ADJ
dti-2343	89	12	number	number	NOUN
dti-2343	89	13	of	of	ADP
dti-2343	89	14	cases	case	NOUN
dti-2343	89	15	in	in	ADP
dti-2343	89	16	this	this	DET
dti-2343	89	17	case	case	NOUN
dti-2343	89	18	series	series	NOUN
dti-2343	89	19	,	,	PUNCT
dti-2343	89	20	and	and	CCONJ
dti-2343	89	21	the	the	DET
dti-2343	89	22	fact	fact	NOUN
dti-2343	89	23	that	that	SCONJ
dti-2343	89	24	our	our	PRON
dti-2343	89	25	patients	patient	NOUN
dti-2343	89	26	were	be	AUX
dti-2343	89	27	treated	treat	VERB
dti-2343	89	28	for	for	ADP
dti-2343	89	29	a	a	DET
dti-2343	89	30	shorter	short	ADJ
dti-2343	89	31	follow	follow	NOUN
dti-2343	89	32	-	-	PUNCT
dti-2343	89	33	up	up	NOUN
dti-2343	89	34	compared	compare	VERB
dti-2343	89	35	with	with	ADP
dti-2343	89	36	the	the	DET
dti-2343	89	37	other	other	ADJ
dti-2343	89	38	studies	study	NOUN
dti-2343	89	39	(	(	PUNCT
dti-2343	89	40	9.9	9.9	NUM
dti-2343	89	41	months	month	NOUN
dti-2343	89	42	and	and	CCONJ
dti-2343	89	43	at	at	ADV
dti-2343	89	44	least	least	ADJ
dti-2343	89	45	2	2	NUM
dti-2343	89	46	years	year	NOUN
dti-2343	89	47	,	,	PUNCT
dti-2343	89	48	respectively	respectively	ADV
dti-2343	89	49	)	)	PUNCT
dti-2343	89	50	.	.	PUNCT
dti-2343	90	1	no	no	DET
dti-2343	90	2	inflammatory	inflammatory	ADJ
dti-2343	90	3	adverse	adverse	ADJ
dti-2343	90	4	events	event	NOUN
dti-2343	90	5	were	be	AUX
dti-2343	90	6	reported	report	VERB
dti-2343	90	7	in	in	ADP
dti-2343	90	8	our	our	PRON
dti-2343	90	9	patients	patient	NOUN
dti-2343	90	10	,	,	PUNCT
dti-2343	90	11	which	which	PRON
dti-2343	90	12	may	may	AUX
dti-2343	90	13	also	also	ADV
dti-2343	90	14	be	be	AUX
dti-2343	90	15	due	due	ADJ
dti-2343	90	16	to	to	ADP
dti-2343	90	17	the	the	DET
dti-2343	90	18	small	small	ADJ
dti-2343	90	19	sample	sample	NOUN
dti-2343	90	20	size	size	NOUN
dti-2343	90	21	and	and	CCONJ
dti-2343	90	22	short	short	ADJ
dti-2343	90	23	follow	follow	NOUN
dti-2343	90	24	-	-	PUNCT
dti-2343	90	25	up	up	NOUN
dti-2343	90	26	.	.	PUNCT
dti-2343	91	1	an	an	DET
dti-2343	91	2	independent	independent	ADJ
dti-2343	91	3	safety	safety	NOUN
dti-2343	91	4	review	review	NOUN
dti-2343	91	5	committee	committee	NOUN
dti-2343	91	6	,	,	PUNCT
dti-2343	91	7	analyzing	analyze	VERB
dti-2343	91	8	inflammatory	inflammatory	ADJ
dti-2343	91	9	ocular	ocular	ADJ
dti-2343	91	10	adverse	adverse	ADJ
dti-2343	91	11	events	event	NOUN
dti-2343	91	12	in	in	ADP
dti-2343	91	13	the	the	DET
dti-2343	91	14	hawk	hawk	NOUN
dti-2343	91	15	and	and	CCONJ
dti-2343	91	16	harrier	harrier	NOUN
dti-2343	91	17	trials	trial	NOUN
dti-2343	91	18	,	,	PUNCT
dti-2343	91	19	observed	observe	VERB
dti-2343	91	20	an	an	DET
dti-2343	91	21	incidence	incidence	NOUN
dti-2343	91	22	of	of	ADP
dti-2343	91	23	retinal	retinal	ADJ
dti-2343	91	24	vasculitis	vasculitis	NOUN
dti-2343	91	25	and	and	CCONJ
dti-2343	91	26	retinal	retinal	ADJ
dti-2343	91	27	vascular	vascular	ADJ
dti-2343	91	28	occlusion	occlusion	NOUN
dti-2343	91	29	of	of	ADP
dti-2343	91	30	3	3	NUM
dti-2343	91	31	%	%	NOUN
dti-2343	91	32	and	and	CCONJ
dti-2343	91	33	2	2	NUM
dti-2343	91	34	%	%	NOUN
dti-2343	91	35	,	,	PUNCT
dti-2343	91	36	respectively	respectively	ADV
dti-2343	91	37	,	,	PUNCT
dti-2343	91	38	with	with	ADP
dti-2343	91	39	a	a	DET
dti-2343	91	40	risk	risk	NOUN
dti-2343	91	41	of	of	ADP
dti-2343	91	42	severe	severe	ADJ
dti-2343	91	43	visual	visual	ADJ
dti-2343	91	44	loss	loss	NOUN
dti-2343	91	45	in	in	ADP
dti-2343	91	46	approximately	approximately	ADV
dti-2343	91	47	1	1	NUM
dti-2343	91	48	in	in	ADP
dti-2343	91	49	every	every	DET
dti-2343	91	50	200	200	NUM
dti-2343	91	51	patients	patient	NOUN
dti-2343	91	52	(	(	PUNCT
dti-2343	91	53	31	31	NUM
dti-2343	91	54	)	)	PUNCT
dti-2343	91	55	.	.	PUNCT
dti-2343	92	1	in	in	ADP
dti-2343	92	2	this	this	DET
dti-2343	92	3	context	context	NOUN
dti-2343	92	4	,	,	PUNCT
dti-2343	92	5	it	it	PRON
dti-2343	92	6	is	be	AUX
dti-2343	92	7	important	important	ADJ
dti-2343	92	8	to	to	PART
dti-2343	92	9	consider	consider	VERB
dti-2343	92	10	the	the	DET
dti-2343	92	11	balance	balance	NOUN
dti-2343	92	12	between	between	ADP
dti-2343	92	13	the	the	DET
dti-2343	92	14	risk	risk	NOUN
dti-2343	92	15	of	of	ADP
dti-2343	92	16	adverse	adverse	ADJ
dti-2343	92	17	events	event	NOUN
dti-2343	92	18	and	and	CCONJ
dti-2343	92	19	the	the	DET
dti-2343	92	20	benefits	benefit	NOUN
dti-2343	92	21	.	.	PUNCT
dti-2343	93	1	in	in	ADP
dti-2343	93	2	our	our	PRON
dti-2343	93	3	case	case	NOUN
dti-2343	93	4	fig	fig	NOUN
dti-2343	93	5	.	.	PUNCT
dti-2343	93	6	1	1	NUM
dti-2343	93	7	kaplan	kaplan	PROPN
dti-2343	93	8	-	-	PUNCT
dti-2343	93	9	meier	meier	PROPN
dti-2343	93	10	plot	plot	NOUN
dti-2343	93	11	for	for	ADP
dti-2343	93	12	time	time	NOUN
dti-2343	93	13	to	to	PART
dti-2343	93	14	disease	disease	NOUN
dti-2343	93	15	inactivation	inactivation	NOUN
dti-2343	93	16	in	in	ADP
dti-2343	93	17	the	the	DET
dti-2343	93	18	nine	nine	NUM
dti-2343	93	19	patients	patient	NOUN
dti-2343	93	20	.	.	PUNCT
dti-2343	94	1	the	the	DET
dti-2343	94	2	median	median	NOUN
dti-2343	94	3	(	(	PUNCT
dti-2343	94	4	50th	50th	ADJ
dti-2343	94	5	percentile	percentile	NOUN
dti-2343	94	6	)	)	PUNCT
dti-2343	94	7	is	be	AUX
dti-2343	94	8	indicated	indicate	VERB
dti-2343	94	9	in	in	ADP
dti-2343	94	10	red	red	PROPN
dti-2343	94	11	.	.	PUNCT
dti-2343	94	12	0	0	NUM
dti-2343	94	13	0,0	0,0	NUM
dti-2343	94	14	0,1	0,1	NUM
dti-2343	94	15	0,2	0,2	NUM
dti-2343	94	16	0,3	0,3	NUM
dti-2343	94	17	0,4	0,4	NUM
dti-2343	94	18	0,5	0,5	NUM
dti-2343	94	19	0,6	0,6	NUM
dti-2343	94	20	0,7	0,7	NUM
dti-2343	94	21	0,8	0,8	NUM
dti-2343	94	22	0,9	0,9	NUM
dti-2343	94	23	1,0	1,0	NUM
dti-2343	94	24	42	42	NUM
dti-2343	94	25	86	86	NUM
dti-2343	94	26	1210	1210	NUM
dti-2343	94	27	1614	1614	NUM
dti-2343	94	28	2018	2018	NUM
dti-2343	94	29	2422	2422	NUM
dti-2343	94	30	2826	2826	NUM
dti-2343	94	31	30	30	NUM
dti-2343	94	32	3432	3432	NUM
dti-2343	94	33	3836	3836	NUM
dti-2343	94	34	4240	4240	NUM
dti-2343	95	1	c	c	X
dti-2343	95	2	um	um	INTJ
dti-2343	95	3	ul	ul	INTJ
dti-2343	95	4	at	at	ADP
dti-2343	95	5	iv	iv	NUM
dti-2343	95	6	e	e	NOUN
dti-2343	95	7	in	in	ADP
dti-2343	95	8	ci	ci	PROPN
dti-2343	95	9	de	de	PROPN
dti-2343	95	10	nc	nc	PROPN
dti-2343	95	11	e	e	PROPN
dti-2343	95	12	of	of	ADP
dti-2343	95	13	in	in	ADP
dti-2343	95	14	ac	ac	PROPN
dti-2343	95	15	tiv	tiv	PROPN
dti-2343	95	16	e	e	PROPN
dti-2343	95	17	di	di	X
dti-2343	95	18	se	se	PROPN
dti-2343	95	19	as	as	ADP
dti-2343	95	20	e	e	PROPN
dti-2343	95	21	days	day	NOUN
dti-2343	95	22	from	from	ADP
dti-2343	95	23	injection	injection	NOUN
dti-2343	95	24	fig	fig	NOUN
dti-2343	95	25	.	.	PUNCT
dti-2343	96	1	2	2	NUM
dti-2343	96	2	representative	representative	NOUN
dti-2343	96	3	case	case	NOUN
dti-2343	96	4	of	of	ADP
dti-2343	96	5	a	a	DET
dti-2343	96	6	woman	woman	NOUN
dti-2343	96	7	,	,	PUNCT
dti-2343	96	8	90	90	NUM
dti-2343	96	9	years	year	NOUN
dti-2343	96	10	old	old	ADJ
dti-2343	96	11	,	,	PUNCT
dti-2343	96	12	treated	treat	VERB
dti-2343	96	13	with	with	ADP
dti-2343	96	14	three	three	NUM
dti-2343	96	15	intravitreal	intravitreal	ADJ
dti-2343	96	16	injections	injection	NOUN
dti-2343	96	17	of	of	ADP
dti-2343	96	18	aflibercept	aflibercept	NOUN
dti-2343	96	19	during	during	ADP
dti-2343	96	20	the	the	DET
dti-2343	96	21	previous	previous	ADJ
dti-2343	96	22	9	9	NUM
dti-2343	96	23	months	month	NOUN
dti-2343	96	24	.	.	PUNCT
dti-2343	97	1	spectral	spectral	ADJ
dti-2343	97	2	domain	domain	NOUN
dti-2343	97	3	optical	optical	ADJ
dti-2343	97	4	coherence	coherence	NOUN
dti-2343	97	5	tomography	tomography	NOUN
dti-2343	97	6	(	(	PUNCT
dti-2343	97	7	sd	sd	NOUN
dti-2343	97	8	-	-	PUNCT
dti-2343	97	9	oct	oct	NOUN
dti-2343	97	10	)	)	PUNCT
dti-2343	97	11	b	b	NOUN
dti-2343	97	12	-	-	PUNCT
dti-2343	97	13	scans	scan	NOUN
dti-2343	97	14	at	at	ADP
dti-2343	97	15	different	different	ADJ
dti-2343	97	16	time	time	NOUN
dti-2343	97	17	points	point	NOUN
dti-2343	97	18	:	:	PUNCT
dti-2343	97	19	a	a	X
dti-2343	97	20	)	)	PUNCT
dti-2343	97	21	baseline	baseline	NOUN
dti-2343	97	22	(	(	PUNCT
dti-2343	97	23	before	before	ADP
dti-2343	97	24	brolucizumab	brolucizumab	PROPN
dti-2343	97	25	injection	injection	NOUN
dti-2343	97	26	)	)	PUNCT
dti-2343	97	27	.	.	PUNCT
dti-2343	98	1	b	b	X
dti-2343	98	2	)	)	PUNCT
dti-2343	98	3	follow	follow	VERB
dti-2343	98	4	-	-	PUNCT
dti-2343	98	5	up	up	NOUN
dti-2343	98	6	1	1	NUM
dti-2343	98	7	month	month	NOUN
dti-2343	98	8	after	after	ADP
dti-2343	98	9	injection	injection	NOUN
dti-2343	98	10	.	.	PUNCT
dti-2343	99	1	c	c	X
dti-2343	99	2	)	)	PUNCT
dti-2343	99	3	follow	follow	VERB
dti-2343	99	4	-	-	PUNCT
dti-2343	99	5	up	up	NOUN
dti-2343	99	6	2	2	NUM
dti-2343	99	7	months	month	NOUN
dti-2343	99	8	after	after	ADP
dti-2343	99	9	injection	injection	NOUN
dti-2343	99	10	.	.	PUNCT
dti-2343	100	1	single	single	ADJ
dti-2343	100	2	brolucizumab	brolucizumab	NOUN
dti-2343	100	3	intravitreal	intravitreal	ADJ
dti-2343	100	4	injection	injection	NOUN
dti-2343	100	5	for	for	ADP
dti-2343	100	6	namd	namd	NOUN
dti-2343	100	7	treatment10	treatment10	NOUN
dti-2343	100	8	©	©	ADP
dti-2343	100	9	2022	2022	NUM
dti-2343	100	10	the	the	DET
dti-2343	100	11	authors	author	NOUN
dti-2343	100	12	.	.	PUNCT
dti-2343	101	1	drug	drug	NOUN
dti-2343	101	2	target	target	NOUN
dti-2343	101	3	insights	insight	NOUN
dti-2343	101	4	issn	issn	VERB
dti-2343	101	5	1177	1177	NUM
dti-2343	101	6	-	-	SYM
dti-2343	101	7	3928	3928	NUM
dti-2343	101	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2343	101	9	series	series	NOUN
dti-2343	101	10	,	,	PUNCT
dti-2343	101	11	the	the	DET
dti-2343	101	12	decision	decision	NOUN
dti-2343	101	13	to	to	PART
dti-2343	101	14	initiate	initiate	VERB
dti-2343	101	15	brolucizumab	brolucizumab	NOUN
dti-2343	101	16	treatment	treatment	NOUN
dti-2343	101	17	was	be	AUX
dti-2343	101	18	made	make	VERB
dti-2343	101	19	for	for	ADP
dti-2343	101	20	patients	patient	NOUN
dti-2343	101	21	who	who	PRON
dti-2343	101	22	were	be	AUX
dti-2343	101	23	not	not	PART
dti-2343	101	24	responding	respond	VERB
dti-2343	101	25	anymore	anymore	ADV
dti-2343	101	26	to	to	ADP
dti-2343	101	27	other	other	ADJ
dti-2343	101	28	anti	anti	ADJ
dti-2343	101	29	-	-	ADJ
dti-2343	101	30	vegfs	vegfs	ADJ
dti-2343	101	31	despite	despite	SCONJ
dti-2343	101	32	regular	regular	ADJ
dti-2343	101	33	treatment	treatment	NOUN
dti-2343	101	34	.	.	PUNCT
dti-2343	102	1	notwithstanding	notwithstanding	ADP
dti-2343	102	2	,	,	PUNCT
dti-2343	102	3	close	close	ADJ
dti-2343	102	4	contact	contact	NOUN
dti-2343	102	5	with	with	ADP
dti-2343	102	6	the	the	DET
dti-2343	102	7	patient	patient	NOUN
dti-2343	102	8	is	be	AUX
dti-2343	102	9	needed	need	VERB
dti-2343	102	10	during	during	ADP
dti-2343	102	11	follow	follow	NOUN
dti-2343	102	12	-	-	PUNCT
dti-2343	102	13	up	up	NOUN
dti-2343	102	14	,	,	PUNCT
dti-2343	102	15	as	as	SCONJ
dti-2343	102	16	it	it	PRON
dti-2343	102	17	is	be	AUX
dti-2343	102	18	expected	expect	VERB
dti-2343	102	19	that	that	SCONJ
dti-2343	102	20	adverse	adverse	ADJ
dti-2343	102	21	inflammatory	inflammatory	ADJ
dti-2343	102	22	events	event	NOUN
dti-2343	102	23	can	can	AUX
dti-2343	102	24	be	be	AUX
dti-2343	102	25	successfully	successfully	ADV
dti-2343	102	26	managed	manage	VERB
dti-2343	102	27	if	if	SCONJ
dti-2343	102	28	they	they	PRON
dti-2343	102	29	are	be	AUX
dti-2343	102	30	recognized	recognize	VERB
dti-2343	102	31	and	and	CCONJ
dti-2343	102	32	treated	treat	VERB
dti-2343	102	33	promptly	promptly	ADV
dti-2343	102	34	.	.	PUNCT
dti-2343	103	1	this	this	DET
dti-2343	103	2	retrospective	retrospective	ADJ
dti-2343	103	3	case	case	NOUN
dti-2343	103	4	series	series	NOUN
dti-2343	103	5	has	have	VERB
dti-2343	103	6	some	some	DET
dti-2343	103	7	limitations	limitation	NOUN
dti-2343	103	8	.	.	PUNCT
dti-2343	104	1	despite	despite	SCONJ
dti-2343	104	2	the	the	DET
dti-2343	104	3	important	important	ADJ
dti-2343	104	4	improvements	improvement	NOUN
dti-2343	104	5	observed	observe	VERB
dti-2343	104	6	,	,	PUNCT
dti-2343	104	7	the	the	DET
dti-2343	104	8	sample	sample	NOUN
dti-2343	104	9	size	size	NOUN
dti-2343	104	10	was	be	AUX
dti-2343	104	11	small	small	ADJ
dti-2343	104	12	,	,	PUNCT
dti-2343	104	13	and	and	CCONJ
dti-2343	104	14	the	the	DET
dti-2343	104	15	measured	measure	VERB
dti-2343	104	16	changes	change	NOUN
dti-2343	104	17	had	have	VERB
dti-2343	104	18	wide	wide	ADJ
dti-2343	104	19	ranges	range	NOUN
dti-2343	104	20	.	.	PUNCT
dti-2343	105	1	to	to	PART
dti-2343	105	2	better	well	ADV
dti-2343	105	3	characterize	characterize	VERB
dti-2343	105	4	the	the	DET
dti-2343	105	5	long	long	ADJ
dti-2343	105	6	-	-	PUNCT
dti-2343	105	7	term	term	NOUN
dti-2343	105	8	efficacy	efficacy	NOUN
dti-2343	105	9	and	and	CCONJ
dti-2343	105	10	safety	safety	NOUN
dti-2343	105	11	profile	profile	NOUN
dti-2343	105	12	of	of	ADP
dti-2343	105	13	brolucizumab	brolucizumab	NOUN
dti-2343	105	14	in	in	ADP
dti-2343	105	15	clinical	clinical	ADJ
dti-2343	105	16	practice	practice	NOUN
dti-2343	105	17	,	,	PUNCT
dti-2343	105	18	patients	patient	NOUN
dti-2343	105	19	undergoing	undergo	VERB
dti-2343	105	20	a	a	DET
dti-2343	105	21	treatment	treatment	NOUN
dti-2343	105	22	switch	switch	NOUN
dti-2343	105	23	to	to	PART
dti-2343	105	24	brolucizumab	brolucizumab	NOUN
dti-2343	105	25	should	should	AUX
dti-2343	105	26	be	be	AUX
dti-2343	105	27	followed	follow	VERB
dti-2343	105	28	for	for	ADP
dti-2343	105	29	longer	long	ADJ
dti-2343	105	30	.	.	PUNCT
dti-2343	106	1	furthermore	furthermore	ADV
dti-2343	106	2	,	,	PUNCT
dti-2343	106	3	naïve	naïve	ADJ
dti-2343	106	4	patients	patient	NOUN
dti-2343	106	5	not	not	PART
dti-2343	106	6	undergoing	undergo	VERB
dti-2343	106	7	treatment	treatment	NOUN
dti-2343	106	8	with	with	ADP
dti-2343	106	9	other	other	ADJ
dti-2343	106	10	anti	anti	ADJ
dti-2343	106	11	-	-	ADJ
dti-2343	106	12	vegfs	vegfs	ADJ
dti-2343	106	13	should	should	AUX
dti-2343	106	14	be	be	AUX
dti-2343	106	15	recruited	recruit	VERB
dti-2343	106	16	to	to	PART
dti-2343	106	17	verify	verify	VERB
dti-2343	106	18	the	the	DET
dti-2343	106	19	anatomical	anatomical	ADJ
dti-2343	106	20	superiority	superiority	NOUN
dti-2343	106	21	of	of	ADP
dti-2343	106	22	brolucizumab	brolucizumab	NOUN
dti-2343	106	23	and	and	CCONJ
dti-2343	106	24	to	to	PART
dti-2343	106	25	optimize	optimize	VERB
dti-2343	106	26	the	the	DET
dti-2343	106	27	treatment	treatment	NOUN
dti-2343	106	28	of	of	ADP
dti-2343	106	29	namd	namd	NOUN
dti-2343	106	30	by	by	ADP
dti-2343	106	31	reducing	reduce	VERB
dti-2343	106	32	the	the	DET
dti-2343	106	33	treatment	treatment	NOUN
dti-2343	106	34	burden	burden	NOUN
dti-2343	106	35	for	for	ADP
dti-2343	106	36	both	both	DET
dti-2343	106	37	patients	patient	NOUN
dti-2343	106	38	and	and	CCONJ
dti-2343	106	39	clinicians	clinician	NOUN
dti-2343	106	40	(	(	PUNCT
dti-2343	106	41	24,25	24,25	NUM
dti-2343	106	42	)	)	PUNCT
dti-2343	106	43	.	.	PUNCT
dti-2343	107	1	conclusion	conclusion	NOUN
dti-2343	107	2	in	in	ADP
dti-2343	107	3	conclusion	conclusion	NOUN
dti-2343	107	4	,	,	PUNCT
dti-2343	107	5	a	a	DET
dti-2343	107	6	single	single	ADJ
dti-2343	107	7	injection	injection	NOUN
dti-2343	107	8	of	of	ADP
dti-2343	107	9	brolucizumab	brolucizumab	NOUN
dti-2343	107	10	was	be	AUX
dti-2343	107	11	shown	show	VERB
dti-2343	107	12	to	to	PART
dti-2343	107	13	be	be	AUX
dti-2343	107	14	rapid	rapid	ADJ
dti-2343	107	15	and	and	CCONJ
dti-2343	107	16	effective	effective	ADJ
dti-2343	107	17	in	in	ADP
dti-2343	107	18	fluid	fluid	ADJ
dti-2343	107	19	resolution	resolution	NOUN
dti-2343	107	20	,	,	PUNCT
dti-2343	107	21	thus	thus	ADV
dti-2343	107	22	representing	represent	VERB
dti-2343	107	23	a	a	DET
dti-2343	107	24	valuable	valuable	ADJ
dti-2343	107	25	therapeutic	therapeutic	ADJ
dti-2343	107	26	option	option	NOUN
dti-2343	107	27	for	for	ADP
dti-2343	107	28	controlling	control	VERB
dti-2343	107	29	disease	disease	NOUN
dti-2343	107	30	activity	activity	NOUN
dti-2343	107	31	in	in	ADP
dti-2343	107	32	namd	namd	ADJ
dti-2343	107	33	patients	patient	NOUN
dti-2343	107	34	.	.	PUNCT
dti-2343	108	1	indeed	indeed	ADV
dti-2343	108	2	,	,	PUNCT
dti-2343	108	3	the	the	DET
dti-2343	108	4	first	first	ADJ
dti-2343	108	5	month	month	NOUN
dti-2343	108	6	after	after	SCONJ
dti-2343	108	7	the	the	DET
dti-2343	108	8	injection	injection	NOUN
dti-2343	108	9	was	be	AUX
dti-2343	108	10	shown	show	VERB
dti-2343	108	11	to	to	PART
dti-2343	108	12	be	be	AUX
dti-2343	108	13	very	very	ADV
dti-2343	108	14	important	important	ADJ
dti-2343	108	15	to	to	PART
dti-2343	108	16	predict	predict	VERB
dti-2343	108	17	the	the	DET
dti-2343	108	18	response	response	NOUN
dti-2343	108	19	to	to	ADP
dti-2343	108	20	the	the	DET
dti-2343	108	21	anti	anti	ADJ
dti-2343	108	22	-	-	ADJ
dti-2343	108	23	vegf	vegf	ADJ
dti-2343	108	24	drug	drug	NOUN
dti-2343	108	25	of	of	ADP
dti-2343	108	26	the	the	DET
dti-2343	108	27	single	single	ADJ
dti-2343	108	28	patient	patient	NOUN
dti-2343	108	29	and	and	CCONJ
dti-2343	108	30	brolucizumab	brolucizumab	NOUN
dti-2343	108	31	showed	show	VERB
dti-2343	108	32	a	a	DET
dti-2343	108	33	rapid	rapid	ADJ
dti-2343	108	34	and	and	CCONJ
dti-2343	108	35	intense	intense	ADJ
dti-2343	108	36	response	response	NOUN
dti-2343	108	37	.	.	PUNCT
dti-2343	109	1	acknowledgments	acknowledgment	NOUN
dti-2343	109	2	we	we	PRON
dti-2343	109	3	thank	thank	VERB
dti-2343	109	4	gabriele	gabriele	PROPN
dti-2343	109	5	massimetti	massimetti	PROPN
dti-2343	109	6	,	,	PUNCT
dti-2343	109	7	department	department	NOUN
dti-2343	109	8	of	of	ADP
dti-2343	109	9	clinical	clinical	ADJ
dti-2343	109	10	and	and	CCONJ
dti-2343	109	11	experimental	experimental	ADJ
dti-2343	109	12	medicine	medicine	NOUN
dti-2343	109	13	,	,	PUNCT
dti-2343	109	14	university	university	NOUN
dti-2343	109	15	of	of	ADP
dti-2343	109	16	pisa	pisa	PROPN
dti-2343	109	17	,	,	PUNCT
dti-2343	109	18	pisa	pisa	PROPN
dti-2343	109	19	,	,	PUNCT
dti-2343	109	20	for	for	ADP
dti-2343	109	21	the	the	DET
dti-2343	109	22	statistical	statistical	ADJ
dti-2343	109	23	support	support	NOUN
dti-2343	109	24	.	.	PUNCT
dti-2343	110	1	medical	medical	ADJ
dti-2343	110	2	writing	writing	NOUN
dti-2343	110	3	support	support	NOUN
dti-2343	110	4	was	be	AUX
dti-2343	110	5	provided	provide	VERB
dti-2343	110	6	by	by	ADP
dti-2343	110	7	corrado	corrado	NOUN
dti-2343	110	8	minetti	minetti	NOUN
dti-2343	110	9	on	on	ADP
dti-2343	110	10	behalf	behalf	NOUN
dti-2343	110	11	of	of	ADP
dti-2343	110	12	health	health	NOUN
dti-2343	110	13	publishing	publishing	PROPN
dti-2343	110	14	&	&	CCONJ
dti-2343	110	15	services	services	PROPN
dti-2343	110	16	srl	srl	PROPN
dti-2343	110	17	,	,	PUNCT
dti-2343	110	18	which	which	PRON
dti-2343	110	19	was	be	AUX
dti-2343	110	20	funded	fund	VERB
dti-2343	110	21	by	by	ADP
dti-2343	110	22	novartis	novartis	PROPN
dti-2343	110	23	farma	farma	PROPN
dti-2343	110	24	spa	spa	PROPN
dti-2343	110	25	.	.	PUNCT
dti-2343	111	1	disclosures	disclosure	NOUN
dti-2343	111	2	statement	statement	NOUN
dti-2343	111	3	of	of	ADP
dti-2343	111	4	ethics	ethic	NOUN
dti-2343	111	5	:	:	PUNCT
dti-2343	111	6	this	this	DET
dti-2343	111	7	retrospective	retrospective	ADJ
dti-2343	111	8	study	study	NOUN
dti-2343	111	9	was	be	AUX
dti-2343	111	10	conducted	conduct	VERB
dti-2343	111	11	in	in	ADP
dti-2343	111	12	accordance	accordance	NOUN
dti-2343	111	13	with	with	ADP
dti-2343	111	14	the	the	DET
dti-2343	111	15	ethical	ethical	ADJ
dti-2343	111	16	standards	standard	NOUN
dti-2343	111	17	set	set	VERB
dti-2343	111	18	forth	forth	ADP
dti-2343	111	19	in	in	ADP
dti-2343	111	20	the	the	DET
dti-2343	111	21	1964	1964	NUM
dti-2343	111	22	declaration	declaration	NOUN
dti-2343	111	23	of	of	ADP
dti-2343	111	24	helsinki	helsinki	PROPN
dti-2343	111	25	and	and	CCONJ
dti-2343	111	26	its	its	PRON
dti-2343	111	27	subsequent	subsequent	ADJ
dti-2343	111	28	amendments	amendment	NOUN
dti-2343	111	29	.	.	PUNCT
dti-2343	112	1	a	a	DET
dti-2343	112	2	notification	notification	NOUN
dti-2343	112	3	letter	letter	NOUN
dti-2343	112	4	was	be	AUX
dti-2343	112	5	sent	send	VERB
dti-2343	112	6	to	to	ADP
dti-2343	112	7	the	the	DET
dti-2343	112	8	local	local	ADJ
dti-2343	112	9	ethical	ethical	PROPN
dti-2343	112	10	committee	committee	NOUN
dti-2343	112	11	(	(	PUNCT
dti-2343	112	12	comitato	comitato	PROPN
dti-2343	112	13	etico	etico	PROPN
dti-2343	112	14	area	area	NOUN
dti-2343	112	15	vasta	vasta	PROPN
dti-2343	112	16	centro	centro	NOUN
dti-2343	112	17	at	at	ADP
dti-2343	112	18	the	the	DET
dti-2343	112	19	careggi	careggi	PROPN
dti-2343	112	20	university	university	PROPN
dti-2343	112	21	hospital	hospital	NOUN
dti-2343	112	22	,	,	PUNCT
dti-2343	112	23	florence	florence	NOUN
dti-2343	112	24	,	,	PUNCT
dti-2343	112	25	italy	italy	PROPN
dti-2343	112	26	)	)	PUNCT
dti-2343	112	27	,	,	PUNCT
dti-2343	112	28	as	as	SCONJ
dti-2343	112	29	required	require	VERB
dti-2343	112	30	by	by	ADP
dti-2343	112	31	italian	italian	ADJ
dti-2343	112	32	regulations	regulation	NOUN
dti-2343	112	33	.	.	PUNCT
dti-2343	113	1	written	write	VERB
dti-2343	113	2	informed	informed	ADJ
dti-2343	113	3	consent	consent	NOUN
dti-2343	113	4	for	for	ADP
dti-2343	113	5	both	both	PRON
dti-2343	113	6	medical	medical	ADJ
dti-2343	113	7	treatment	treatment	NOUN
dti-2343	113	8	and	and	CCONJ
dti-2343	113	9	publications	publication	NOUN
dti-2343	113	10	of	of	ADP
dti-2343	113	11	their	their	PRON
dti-2343	113	12	data	datum	NOUN
dti-2343	113	13	was	be	AUX
dti-2343	113	14	obtained	obtain	VERB
dti-2343	113	15	from	from	ADP
dti-2343	113	16	all	all	DET
dti-2343	113	17	participants	participant	NOUN
dti-2343	113	18	.	.	PUNCT
dti-2343	114	1	conflict	conflict	NOUN
dti-2343	114	2	of	of	ADP
dti-2343	114	3	interest	interest	NOUN
dti-2343	114	4	:	:	PUNCT
dti-2343	114	5	the	the	DET
dti-2343	114	6	authors	author	NOUN
dti-2343	114	7	have	have	VERB
dti-2343	114	8	no	no	DET
dti-2343	114	9	conflicts	conflict	NOUN
dti-2343	114	10	of	of	ADP
dti-2343	114	11	interest	interest	NOUN
dti-2343	114	12	to	to	PART
dti-2343	114	13	declare	declare	VERB
dti-2343	114	14	.	.	PUNCT
dti-2343	115	1	funding	funding	NOUN
dti-2343	115	2	sources	source	NOUN
dti-2343	115	3	:	:	PUNCT
dti-2343	115	4	this	this	DET
dti-2343	115	5	manuscript	manuscript	NOUN
dti-2343	115	6	did	do	AUX
dti-2343	115	7	not	not	PART
dti-2343	115	8	receive	receive	VERB
dti-2343	115	9	any	any	DET
dti-2343	115	10	funding	funding	NOUN
dti-2343	115	11	.	.	PUNCT
dti-2343	116	1	author	author	NOUN
dti-2343	116	2	contributions	contribution	NOUN
dti-2343	116	3	:	:	PUNCT
dti-2343	116	4	study	study	NOUN
dti-2343	116	5	design	design	NOUN
dti-2343	116	6	:	:	PUNCT
dti-2343	116	7	silvio	silvio	NOUN
dti-2343	116	8	zuccarini	zuccarini	PROPN
dti-2343	116	9	.	.	PUNCT
dti-2343	117	1	data	data	PROPN
dti-2343	117	2	collection	collection	NOUN
dti-2343	117	3	:	:	PUNCT
dti-2343	117	4	fabrizio	fabrizio	PROPN
dti-2343	117	5	puce	puce	PROPN
dti-2343	117	6	,	,	PUNCT
dti-2343	117	7	alessandro	alessandro	PROPN
dti-2343	117	8	crisà	crisà	NOUN
dti-2343	117	9	.	.	PUNCT
dti-2343	118	1	all	all	DET
dti-2343	118	2	authors	author	NOUN
dti-2343	118	3	contributed	contribute	VERB
dti-2343	118	4	to	to	ADP
dti-2343	118	5	writing	writing	NOUN
dti-2343	118	6	,	,	PUNCT
dti-2343	118	7	reviewing	review	VERB
dti-2343	118	8	,	,	PUNCT
dti-2343	118	9	and	and	CCONJ
dti-2343	118	10	editing	edit	VERB
dti-2343	118	11	the	the	DET
dti-2343	118	12	manuscript	manuscript	NOUN
dti-2343	118	13	.	.	PUNCT
dti-2343	119	1	data	datum	NOUN
dti-2343	119	2	availability	availability	NOUN
dti-2343	119	3	statement	statement	NOUN
dti-2343	119	4	:	:	PUNCT
dti-2343	119	5	data	datum	NOUN
dti-2343	119	6	generated	generate	VERB
dti-2343	119	7	or	or	CCONJ
dti-2343	119	8	analyzed	analyze	VERB
dti-2343	119	9	during	during	ADP
dti-2343	119	10	this	this	DET
dti-2343	119	11	study	study	NOUN
dti-2343	119	12	are	be	AUX
dti-2343	119	13	included	include	VERB
dti-2343	119	14	in	in	ADP
dti-2343	119	15	this	this	DET
dti-2343	119	16	article	article	NOUN
dti-2343	119	17	.	.	PUNCT
dti-2343	120	1	further	further	ADJ
dti-2343	120	2	enquiries	enquiry	NOUN
dti-2343	120	3	can	can	AUX
dti-2343	120	4	be	be	AUX
dti-2343	120	5	directed	direct	VERB
dti-2343	120	6	to	to	ADP
dti-2343	120	7	the	the	DET
dti-2343	120	8	corresponding	corresponding	ADJ
dti-2343	120	9	author	author	NOUN
dti-2343	120	10	.	.	PUNCT
dti-2343	121	1	references	reference	NOUN
dti-2343	121	2	1	1	NUM
dti-2343	121	3	.	.	PUNCT
dti-2343	122	1	grossniklaus	grossniklaus	PROPN
dti-2343	122	2	he	he	PRON
dti-2343	122	3	,	,	PUNCT
dti-2343	122	4	green	green	PROPN
dti-2343	122	5	wr	wr	PROPN
dti-2343	122	6	.	.	PUNCT
dti-2343	122	7	choroidal	choroidal	ADJ
dti-2343	122	8	neovascularization	neovascularization	NOUN
dti-2343	122	9	.	.	PUNCT
dti-2343	122	10	 	 	SPACE
dti-2343	123	1	am	be	AUX
dti-2343	123	2	j	j	PROPN
dti-2343	123	3	ophthalmol	ophthalmol	NOUN
dti-2343	123	4	.	.	PUNCT
dti-2343	124	1	2004;137(3):496	2004;137(3):496	NUM
dti-2343	124	2	-	-	SYM
dti-2343	124	3	503	503	NUM
dti-2343	124	4	.	.	PUNCT
dti-2343	125	1	crossref	crossref	PROPN
dti-2343	125	2	pubmed	pubmed	PROPN
dti-2343	125	3	2	2	PROPN
dti-2343	125	4	.	.	PROPN
dti-2343	125	5	spaide	spaide	PROPN
dti-2343	125	6	rf	rf	PROPN
dti-2343	125	7	,	,	PUNCT
dti-2343	125	8	jaffe	jaffe	PROPN
dti-2343	125	9	gj	gj	PROPN
dti-2343	125	10	,	,	PUNCT
dti-2343	125	11	sarraf	sarraf	NOUN
dti-2343	125	12	d	d	PROPN
dti-2343	125	13	,	,	PUNCT
dti-2343	125	14	et	et	PROPN
dti-2343	125	15	al	al	PROPN
dti-2343	125	16	.	.	PUNCT
dti-2343	126	1	consensus	consensus	NOUN
dti-2343	126	2	nomenclature	nomenclature	NOUN
dti-2343	126	3	for	for	ADP
dti-2343	126	4	reporting	report	VERB
dti-2343	126	5	neovascular	neovascular	ADJ
dti-2343	126	6	age	age	NOUN
dti-2343	126	7	-	-	PUNCT
dti-2343	126	8	related	relate	VERB
dti-2343	126	9	macular	macular	NOUN
dti-2343	126	10	degeneration	degeneration	NOUN
dti-2343	126	11	data	datum	NOUN
dti-2343	126	12	:	:	PUNCT
dti-2343	126	13	consensus	consensus	NOUN
dti-2343	126	14	on	on	ADP
dti-2343	126	15	neovascular	neovascular	PROPN
dti-2343	126	16	age	age	NOUN
dti-2343	126	17	-	-	PUNCT
dti-2343	126	18	related	relate	VERB
dti-2343	126	19	macular	macular	ADJ
dti-2343	126	20	degeneration	degeneration	NOUN
dti-2343	126	21	nomenclature	nomenclature	NOUN
dti-2343	126	22	study	study	NOUN
dti-2343	126	23	group	group	NOUN
dti-2343	126	24	.	.	PUNCT
dti-2343	127	1	ophthalmology	ophthalmology	NOUN
dti-2343	127	2	.	.	PUNCT
dti-2343	128	1	2020	2020	NUM
dti-2343	128	2	;	;	PUNCT
dti-2343	128	3	127(5):616	127(5):616	NUM
dti-2343	128	4	-	-	SYM
dti-2343	128	5	636	636	NUM
dti-2343	128	6	.	.	PUNCT
dti-2343	129	1	crossref	crossref	PROPN
dti-2343	129	2	pubmed	pubmed	PROPN
dti-2343	129	3	3	3	PROPN
dti-2343	129	4	.	.	PUNCT
dti-2343	130	1	schmidt	schmidt	VERB
dti-2343	130	2	-	-	PUNCT
dti-2343	130	3	erfurth	erfurth	NOUN
dti-2343	130	4	u	u	NOUN
dti-2343	130	5	,	,	PUNCT
dti-2343	130	6	waldstein	waldstein	PROPN
dti-2343	130	7	sm	sm	PROPN
dti-2343	130	8	.	.	PUNCT
dti-2343	131	1	a	a	DET
dti-2343	131	2	paradigm	paradigm	NOUN
dti-2343	131	3	shift	shift	NOUN
dti-2343	131	4	in	in	ADP
dti-2343	131	5	imaging	image	VERB
dti-2343	131	6	biomarkers	biomarker	NOUN
dti-2343	131	7	in	in	ADP
dti-2343	131	8	neovascular	neovascular	NOUN
dti-2343	131	9	age	age	NOUN
dti-2343	131	10	-	-	PUNCT
dti-2343	131	11	related	relate	VERB
dti-2343	131	12	macular	macular	ADJ
dti-2343	131	13	degeneration	degeneration	NOUN
dti-2343	131	14	.	.	PUNCT
dti-2343	132	1	prog	prog	PROPN
dti-2343	132	2	retin	retin	PROPN
dti-2343	132	3	eye	eye	NOUN
dti-2343	132	4	res	re	NOUN
dti-2343	132	5	.	.	PUNCT
dti-2343	133	1	2016;50:1	2016;50:1	PROPN
dti-2343	133	2	-	-	SYM
dti-2343	133	3	24	24	NUM
dti-2343	133	4	.	.	PUNCT
dti-2343	134	1	crossref	crossref	PROPN
dti-2343	134	2	pubmed	pubmed	PROPN
dti-2343	134	3	4	4	PROPN
dti-2343	134	4	.	.	PROPN
dti-2343	134	5	wykoff	wykoff	PROPN
dti-2343	134	6	cc	cc	PROPN
dti-2343	134	7	,	,	PUNCT
dti-2343	134	8	clark	clark	PROPN
dti-2343	134	9	wl	wl	PROPN
dti-2343	134	10	,	,	PUNCT
dti-2343	134	11	nielsen	nielsen	PROPN
dti-2343	134	12	js	js	PROPN
dti-2343	134	13	,	,	PUNCT
dti-2343	134	14	brill	brill	PROPN
dti-2343	134	15	jv	jv	NOUN
dti-2343	134	16	,	,	PUNCT
dti-2343	134	17	greene	greene	PROPN
dti-2343	134	18	ls	ls	PROPN
dti-2343	134	19	,	,	PUNCT
dti-2343	134	20	heggen	heggen	PROPN
dti-2343	134	21	cl	cl	NOUN
dti-2343	134	22	.	.	PUNCT
dti-2343	135	1	optimizing	optimize	VERB
dti-2343	135	2	anti	anti	ADJ
dti-2343	135	3	-	-	ADJ
dti-2343	135	4	vegf	vegf	ADJ
dti-2343	135	5	treatment	treatment	NOUN
dti-2343	135	6	outcomes	outcome	NOUN
dti-2343	135	7	for	for	ADP
dti-2343	135	8	patients	patient	NOUN
dti-2343	135	9	with	with	ADP
dti-2343	135	10	neovascular	neovascular	NOUN
dti-2343	135	11	age	age	NOUN
dti-2343	135	12	-	-	PUNCT
dti-2343	135	13	related	relate	VERB
dti-2343	135	14	macular	macular	ADJ
dti-2343	135	15	degeneration	degeneration	NOUN
dti-2343	135	16	.	.	PUNCT
dti-2343	136	1	j	j	PROPN
dti-2343	136	2	manag	manag	PROPN
dti-2343	136	3	care	care	PROPN
dti-2343	136	4	spec	spec	PROPN
dti-2343	136	5	pharm	pharm	PROPN
dti-2343	136	6	.	.	PUNCT
dti-2343	137	1	2018	2018	NUM
dti-2343	137	2	feb;24(2	feb;24(2	NUM
dti-2343	137	3	-	-	PUNCT
dti-2343	137	4	a	a	DET
dti-2343	137	5	suppl):s3	suppl):s3	NOUN
dti-2343	137	6	-	-	PUNCT
dti-2343	137	7	s15	s15	NOUN
dti-2343	137	8	.	.	PUNCT
dti-2343	138	1	crossref	crossref	PROPN
dti-2343	138	2	pubmed	pubmed	PROPN
dti-2343	138	3	5	5	NUM
dti-2343	138	4	.	.	PUNCT
dti-2343	139	1	rasmussen	rasmussen	PROPN
dti-2343	139	2	a	a	PROPN
dti-2343	139	3	,	,	PUNCT
dti-2343	139	4	brandi	brandi	PROPN
dti-2343	139	5	s	s	PROPN
dti-2343	139	6	,	,	PUNCT
dti-2343	139	7	fuchs	fuchs	PROPN
dti-2343	139	8	j	j	PROPN
dti-2343	139	9	,	,	PUNCT
dti-2343	139	10	et	et	PROPN
dti-2343	139	11	al	al	PROPN
dti-2343	139	12	.	.	PROPN
dti-2343	140	1	visual	visual	ADJ
dti-2343	140	2	outcomes	outcome	NOUN
dti-2343	140	3	in	in	ADP
dti-2343	140	4	relation	relation	NOUN
dti-2343	140	5	to	to	ADP
dti-2343	140	6	time	time	NOUN
dti-2343	140	7	to	to	ADP
dti-2343	140	8	treatment	treatment	NOUN
dti-2343	140	9	in	in	ADP
dti-2343	140	10	neovascular	neovascular	NOUN
dti-2343	140	11	age	age	NOUN
dti-2343	140	12	-	-	PUNCT
dti-2343	140	13	related	relate	VERB
dti-2343	140	14	macular	macular	ADJ
dti-2343	140	15	degeneration	degeneration	NOUN
dti-2343	140	16	.	.	PUNCT
dti-2343	141	1	acta	acta	PROPN
dti-2343	141	2	ophthalmol	ophthalmol	PROPN
dti-2343	141	3	.	.	PUNCT
dti-2343	142	1	2015;93(7):616	2015;93(7):616	NOUN
dti-2343	142	2	-	-	SYM
dti-2343	142	3	620	620	NUM
dti-2343	142	4	.	.	PUNCT
dti-2343	143	1	crossref	crossref	PROPN
dti-2343	143	2	pubmed	pubmed	PROPN
dti-2343	143	3	6	6	NUM
dti-2343	143	4	.	.	PUNCT
dti-2343	144	1	real	real	ADJ
dti-2343	144	2	jp	jp	PROPN
dti-2343	144	3	,	,	PUNCT
dti-2343	144	4	granero	granero	PROPN
dti-2343	144	5	ge	ge	PROPN
dti-2343	144	6	,	,	PUNCT
dti-2343	144	7	de	de	PROPN
dti-2343	144	8	santis	santis	PROPN
dti-2343	144	9	mo	mo	PROPN
dti-2343	144	10	,	,	PUNCT
dti-2343	144	11	et	et	PROPN
dti-2343	144	12	al	al	PROPN
dti-2343	144	13	.	.	PUNCT
dti-2343	144	14	rate	rate	NOUN
dti-2343	144	15	of	of	ADP
dti-2343	144	16	vision	vision	NOUN
dti-2343	144	17	loss	loss	NOUN
dti-2343	144	18	in	in	ADP
dti-2343	144	19	neovascular	neovascular	NOUN
dti-2343	144	20	age	age	NOUN
dti-2343	144	21	-	-	PUNCT
dti-2343	144	22	related	relate	VERB
dti-2343	144	23	macular	macular	NOUN
dti-2343	144	24	degeneration	degeneration	NOUN
dti-2343	144	25	explored	explore	VERB
dti-2343	144	26	.	.	PUNCT
dti-2343	145	1	graefes	graefe	NOUN
dti-2343	145	2	arch	arch	PROPN
dti-2343	145	3	clin	clin	PROPN
dti-2343	145	4	exp	exp	PROPN
dti-2343	145	5	ophthalmol	ophthalmol	PROPN
dti-2343	145	6	.	.	PUNCT
dti-2343	146	1	2015;253(11):1859	2015;253(11):1859	NUM
dti-2343	146	2	-	-	SYM
dti-2343	146	3	1865	1865	NUM
dti-2343	146	4	.	.	PUNCT
dti-2343	147	1	crossref	crossref	PROPN
dti-2343	147	2	pubmed	pubmed	PROPN
dti-2343	147	3	7	7	PROPN
dti-2343	147	4	.	.	PUNCT
dti-2343	148	1	arnold	arnold	PROPN
dti-2343	148	2	jj	jj	PROPN
dti-2343	148	3	,	,	PUNCT
dti-2343	148	4	markey	markey	PROPN
dti-2343	148	5	cm	cm	PROPN
dti-2343	148	6	,	,	PUNCT
dti-2343	148	7	kurstjens	kurstjen	NOUN
dti-2343	148	8	np	np	PROPN
dti-2343	148	9	,	,	PUNCT
dti-2343	148	10	guymer	guymer	NOUN
dti-2343	148	11	rh	rh	PROPN
dti-2343	148	12	.	.	PUNCT
dti-2343	149	1	the	the	DET
dti-2343	149	2	role	role	NOUN
dti-2343	149	3	of	of	ADP
dti-2343	149	4	sub	sub	ADJ
dti-2343	149	5	-	-	ADJ
dti-2343	149	6	retinal	retinal	ADJ
dti-2343	149	7	fluid	fluid	NOUN
dti-2343	149	8	in	in	ADP
dti-2343	149	9	determining	determine	VERB
dti-2343	149	10	treatment	treatment	NOUN
dti-2343	149	11	outcomes	outcome	NOUN
dti-2343	149	12	in	in	ADP
dti-2343	149	13	patients	patient	NOUN
dti-2343	149	14	with	with	ADP
dti-2343	149	15	neovascular	neovascular	NOUN
dti-2343	149	16	age	age	NOUN
dti-2343	149	17	-	-	PUNCT
dti-2343	149	18	related	relate	VERB
dti-2343	149	19	macular	macular	ADJ
dti-2343	149	20	degeneration	degeneration	NOUN
dti-2343	149	21	—	—	PUNCT
dti-2343	149	22	a	a	DET
dti-2343	149	23	phase	phase	NOUN
dti-2343	149	24	iv	iv	NUM
dti-2343	149	25	randomised	randomise	VERB
dti-2343	149	26	clinical	clinical	ADJ
dti-2343	149	27	trial	trial	NOUN
dti-2343	149	28	with	with	ADP
dti-2343	149	29	ranibizumab	ranibizumab	NOUN
dti-2343	149	30	:	:	PUNCT
dti-2343	149	31	the	the	DET
dti-2343	149	32	fluid	fluid	ADJ
dti-2343	149	33	study	study	NOUN
dti-2343	149	34	.	.	PUNCT
dti-2343	150	1	bmc	bmc	PROPN
dti-2343	150	2	ophthalmol	ophthalmol	PROPN
dti-2343	150	3	.	.	PUNCT
dti-2343	151	1	2016;16(1):31	2016;16(1):31	NUM
dti-2343	151	2	.	.	PUNCT
dti-2343	151	3	crossref	crossref	PROPN
dti-2343	151	4	pubmed	pubmed	PROPN
dti-2343	151	5	8	8	PROPN
dti-2343	151	6	.	.	PUNCT
dti-2343	152	1	lanzetta	lanzetta	PROPN
dti-2343	152	2	p	p	NOUN
dti-2343	152	3	,	,	PUNCT
dti-2343	152	4	loewenstein	loewenstein	VERB
dti-2343	152	5	a	a	PRON
dti-2343	152	6	;	;	PUNCT
dti-2343	152	7	vision	vision	PROPN
dti-2343	152	8	academy	academy	PROPN
dti-2343	152	9	steering	steering	PROPN
dti-2343	152	10	committee	committee	NOUN
dti-2343	152	11	.	.	PUNCT
dti-2343	153	1	fundamental	fundamental	ADJ
dti-2343	153	2	principles	principle	NOUN
dti-2343	153	3	of	of	ADP
dti-2343	153	4	an	an	DET
dti-2343	153	5	anti	anti	ADJ
dti-2343	153	6	-	-	ADJ
dti-2343	153	7	vegf	vegf	ADJ
dti-2343	153	8	treatment	treatment	NOUN
dti-2343	153	9	regimen	regiman	NOUN
dti-2343	153	10	:	:	PUNCT
dti-2343	153	11	optimal	optimal	ADJ
dti-2343	153	12	application	application	NOUN
dti-2343	153	13	of	of	ADP
dti-2343	153	14	intravitreal	intravitreal	ADJ
dti-2343	153	15	anti	anti	ADJ
dti-2343	153	16	-	-	ADJ
dti-2343	153	17	vascular	vascular	ADJ
dti-2343	153	18	endothelial	endothelial	ADJ
dti-2343	153	19	growth	growth	NOUN
dti-2343	153	20	factor	factor	NOUN
dti-2343	153	21	therapy	therapy	NOUN
dti-2343	153	22	of	of	ADP
dti-2343	153	23	macular	macular	ADJ
dti-2343	153	24	diseases	disease	NOUN
dti-2343	153	25	.	.	PUNCT
dti-2343	154	1	graefes	graefe	NOUN
dti-2343	154	2	arch	arch	PROPN
dti-2343	154	3	clin	clin	PROPN
dti-2343	154	4	exp	exp	PROPN
dti-2343	154	5	ophthalmol	ophthalmol	PROPN
dti-2343	154	6	.	.	PUNCT
dti-2343	155	1	2017;255(7):1259	2017;255(7):1259	NUM
dti-2343	155	2	-	-	SYM
dti-2343	155	3	1273	1273	NUM
dti-2343	155	4	.	.	PUNCT
dti-2343	156	1	crossref	crossref	PROPN
dti-2343	156	2	pubmed	pubmed	PROPN
dti-2343	156	3	9	9	PROPN
dti-2343	156	4	.	.	PUNCT
dti-2343	157	1	gillies	gillie	NOUN
dti-2343	157	2	m	m	PROPN
dti-2343	157	3	,	,	PUNCT
dti-2343	157	4	arnold	arnold	PROPN
dti-2343	157	5	j	j	PROPN
dti-2343	157	6	,	,	PUNCT
dti-2343	157	7	bhandari	bhandari	PROPN
dti-2343	157	8	s	s	PROPN
dti-2343	157	9	,	,	PUNCT
dti-2343	157	10	et	et	PROPN
dti-2343	157	11	al	al	PROPN
dti-2343	157	12	.	.	PROPN
dti-2343	157	13	ten	ten	NUM
dti-2343	157	14	-	-	PUNCT
dti-2343	157	15	year	year	NOUN
dti-2343	157	16	treatment	treatment	NOUN
dti-2343	157	17	outcomes	outcome	NOUN
dti-2343	157	18	of	of	ADP
dti-2343	157	19	neovascular	neovascular	NOUN
dti-2343	157	20	age	age	NOUN
dti-2343	157	21	-	-	PUNCT
dti-2343	157	22	related	relate	VERB
dti-2343	157	23	macular	macular	ADJ
dti-2343	157	24	degeneration	degeneration	NOUN
dti-2343	157	25	from	from	ADP
dti-2343	157	26	two	two	NUM
dti-2343	157	27	regions	region	NOUN
dti-2343	157	28	.	.	PUNCT
dti-2343	158	1	am	be	AUX
dti-2343	158	2	j	j	PROPN
dti-2343	158	3	ophthalmol	ophthalmol	NOUN
dti-2343	158	4	.	.	PUNCT
dti-2343	159	1	2020;210:116	2020;210:116	NUM
dti-2343	159	2	-	-	SYM
dti-2343	159	3	124	124	NUM
dti-2343	159	4	.	.	PUNCT
dti-2343	160	1	crossref	crossref	PROPN
dti-2343	160	2	pubmed	pubmed	PROPN
dti-2343	160	3	10	10	PROPN
dti-2343	160	4	.	.	PUNCT
dti-2343	161	1	chandra	chandra	PROPN
dti-2343	161	2	s	s	PROPN
dti-2343	161	3	,	,	PUNCT
dti-2343	161	4	arpa	arpa	PROPN
dti-2343	161	5	c	c	PROPN
dti-2343	161	6	,	,	PUNCT
dti-2343	161	7	menon	menon	PROPN
dti-2343	161	8	d	d	PROPN
dti-2343	161	9	,	,	PUNCT
dti-2343	161	10	et	et	PROPN
dti-2343	161	11	al	al	PROPN
dti-2343	161	12	.	.	PROPN
dti-2343	161	13	ten	ten	NUM
dti-2343	161	14	-	-	PUNCT
dti-2343	161	15	year	year	NOUN
dti-2343	161	16	outcomes	outcome	NOUN
dti-2343	161	17	of	of	ADP
dti-2343	161	18	antivascular	antivascular	ADJ
dti-2343	161	19	endothelial	endothelial	ADJ
dti-2343	161	20	growth	growth	NOUN
dti-2343	161	21	factor	factor	NOUN
dti-2343	161	22	therapy	therapy	NOUN
dti-2343	161	23	in	in	ADP
dti-2343	161	24	neovascular	neovascular	NOUN
dti-2343	161	25	age	age	NOUN
dti-2343	161	26	-	-	PUNCT
dti-2343	161	27	related	relate	VERB
dti-2343	161	28	macular	macular	ADJ
dti-2343	161	29	degeneration	degeneration	NOUN
dti-2343	161	30	.	.	PUNCT
dti-2343	162	1	eye	eye	NOUN
dti-2343	162	2	(	(	PUNCT
dti-2343	162	3	lond	lond	PROPN
dti-2343	162	4	)	)	PUNCT
dti-2343	162	5	.	.	PUNCT
dti-2343	163	1	2020;34(10):1888	2020;34(10):1888	X
dti-2343	163	2	-	-	PROPN
dti-2343	163	3	1896	1896	NUM
dti-2343	163	4	.	.	PUNCT
dti-2343	164	1	crossref	crossref	PROPN
dti-2343	164	2	pubmed	pubmed	PROPN
dti-2343	164	3	11	11	NUM
dti-2343	164	4	.	.	PUNCT
dti-2343	165	1	heier	heier	PROPN
dti-2343	165	2	js	js	PROPN
dti-2343	165	3	,	,	PUNCT
dti-2343	165	4	brown	brown	ADJ
dti-2343	165	5	dm	dm	PROPN
dti-2343	165	6	,	,	PUNCT
dti-2343	165	7	chong	chong	PROPN
dti-2343	165	8	v	v	PROPN
dti-2343	165	9	,	,	PUNCT
dti-2343	165	10	et	et	PROPN
dti-2343	165	11	al	al	PROPN
dti-2343	165	12	;	;	PUNCT
dti-2343	165	13	view	view	NOUN
dti-2343	165	14	1	1	NUM
dti-2343	165	15	and	and	CCONJ
dti-2343	165	16	view	view	VERB
dti-2343	165	17	2	2	NUM
dti-2343	165	18	study	study	NOUN
dti-2343	165	19	groups	group	NOUN
dti-2343	165	20	.	.	PUNCT
dti-2343	166	1	intravitreal	intravitreal	ADJ
dti-2343	166	2	aflibercept	aflibercept	PROPN
dti-2343	166	3	(	(	PUNCT
dti-2343	166	4	vegf	vegf	PROPN
dti-2343	166	5	trap	trap	NOUN
dti-2343	166	6	-	-	PUNCT
dti-2343	166	7	eye	eye	NOUN
dti-2343	166	8	)	)	PUNCT
dti-2343	166	9	in	in	ADP
dti-2343	166	10	wet	wet	ADJ
dti-2343	166	11	agerelated	agerelate	VERB
dti-2343	166	12	macular	macular	ADJ
dti-2343	166	13	degeneration	degeneration	NOUN
dti-2343	166	14	.	.	PUNCT
dti-2343	167	1	ophthalmology	ophthalmology	NOUN
dti-2343	167	2	.	.	PUNCT
dti-2343	168	1	2012;119(12	2012;119(12	NUM
dti-2343	168	2	):	):	PUNCT
dti-2343	168	3	2537	2537	NUM
dti-2343	168	4	-	-	SYM
dti-2343	168	5	2548	2548	NUM
dti-2343	168	6	.	.	PUNCT
dti-2343	169	1	crossref	crossref	PROPN
dti-2343	169	2	pubmed	pubmed	PROPN
dti-2343	169	3	12	12	NUM
dti-2343	169	4	.	.	PUNCT
dti-2343	170	1	guymer	guymer	PROPN
dti-2343	170	2	rh	rh	PROPN
dti-2343	170	3	,	,	PUNCT
dti-2343	170	4	markey	markey	PROPN
dti-2343	170	5	cm	cm	PROPN
dti-2343	170	6	,	,	PUNCT
dti-2343	170	7	mcallister	mcallister	PROPN
dti-2343	170	8	il	il	PROPN
dti-2343	170	9	,	,	PUNCT
dti-2343	170	10	et	et	PROPN
dti-2343	170	11	al	al	PROPN
dti-2343	170	12	;	;	PUNCT
dti-2343	170	13	fluid	fluid	ADJ
dti-2343	170	14	investigators	investigator	NOUN
dti-2343	170	15	.	.	PUNCT
dti-2343	171	1	tolerating	tolerate	VERB
dti-2343	171	2	subretinal	subretinal	ADJ
dti-2343	171	3	fluid	fluid	NOUN
dti-2343	171	4	in	in	ADP
dti-2343	171	5	neovascular	neovascular	PROPN
dti-2343	171	6	age	age	NOUN
dti-2343	171	7	-	-	PUNCT
dti-2343	171	8	related	relate	VERB
dti-2343	171	9	macular	macular	ADJ
dti-2343	171	10	degeneration	degeneration	NOUN
dti-2343	171	11	treated	treat	VERB
dti-2343	171	12	with	with	ADP
dti-2343	171	13	ranibizumab	ranibizumab	NOUN
dti-2343	171	14	using	use	VERB
dti-2343	171	15	a	a	DET
dti-2343	171	16	treatand	treatand	NOUN
dti-2343	171	17	-	-	PUNCT
dti-2343	171	18	extend	extend	NOUN
dti-2343	171	19	regimen	regimen	NOUN
dti-2343	171	20	:	:	PUNCT
dti-2343	171	21	fluid	fluid	ADJ
dti-2343	171	22	study	study	NOUN
dti-2343	171	23	24	24	NUM
dti-2343	171	24	-	-	PUNCT
dti-2343	171	25	month	month	NOUN
dti-2343	171	26	results	result	NOUN
dti-2343	171	27	.	.	PUNCT
dti-2343	172	1	ophthalmology	ophthalmology	NOUN
dti-2343	172	2	.	.	PUNCT
dti-2343	173	1	2019;126(5):723	2019;126(5):723	NUM
dti-2343	173	2	-	-	SYM
dti-2343	173	3	734	734	NUM
dti-2343	173	4	.	.	PUNCT
dti-2343	174	1	crossref	crossref	PROPN
dti-2343	174	2	pubmed	pubmed	PROPN
dti-2343	174	3	13	13	NUM
dti-2343	174	4	.	.	PUNCT
dti-2343	175	1	bhandari	bhandari	PROPN
dti-2343	175	2	s	s	PROPN
dti-2343	175	3	,	,	PUNCT
dti-2343	175	4	nguyen	nguyen	NOUN
dti-2343	175	5	v	v	PROPN
dti-2343	175	6	,	,	PUNCT
dti-2343	175	7	arnold	arnold	PROPN
dti-2343	175	8	j	j	PROPN
dti-2343	175	9	,	,	PUNCT
dti-2343	175	10	et	et	PROPN
dti-2343	175	11	al	al	PROPN
dti-2343	175	12	.	.	PUNCT
dti-2343	175	13	treatment	treatment	NOUN
dti-2343	175	14	outcomes	outcome	NOUN
dti-2343	175	15	of	of	ADP
dti-2343	175	16	ranibizumab	ranibizumab	NOUN
dti-2343	175	17	versus	versus	ADP
dti-2343	175	18	aflibercept	aflibercept	NOUN
dti-2343	175	19	for	for	ADP
dti-2343	175	20	neovascular	neovascular	NOUN
dti-2343	175	21	age	age	NOUN
dti-2343	175	22	-	-	PUNCT
dti-2343	175	23	related	relate	VERB
dti-2343	175	24	macular	macular	ADJ
dti-2343	175	25	degeneration	degeneration	NOUN
dti-2343	175	26	:	:	PUNCT
dti-2343	175	27	data	datum	NOUN
dti-2343	175	28	from	from	ADP
dti-2343	175	29	the	the	DET
dti-2343	175	30	fight	fight	ADJ
dti-2343	175	31	retinal	retinal	ADJ
dti-2343	175	32	blindness	blindness	NOUN
dti-2343	175	33	!	!	PUNCT
dti-2343	176	1	registry	registry	NOUN
dti-2343	176	2	.	.	PUNCT
dti-2343	177	1	ophthalmology	ophthalmology	NOUN
dti-2343	177	2	.	.	PUNCT
dti-2343	178	1	2020;127(3):369	2020;127(3):369	NUM
dti-2343	178	2	-	-	SYM
dti-2343	178	3	376	376	NUM
dti-2343	178	4	.	.	PUNCT
dti-2343	179	1	crossref	crossref	PROPN
dti-2343	179	2	pubmed	pubmed	PROPN
dti-2343	179	3	14	14	PROPN
dti-2343	179	4	.	.	PUNCT
dti-2343	180	1	essex	essex	PROPN
dti-2343	180	2	rw	rw	PROPN
dti-2343	180	3	,	,	PUNCT
dti-2343	180	4	nguyen	nguyen	PROPN
dti-2343	180	5	v	v	PROPN
dti-2343	180	6	,	,	PUNCT
dti-2343	180	7	walton	walton	PROPN
dti-2343	180	8	r	r	PROPN
dti-2343	180	9	,	,	PUNCT
dti-2343	180	10	et	et	PROPN
dti-2343	180	11	al	al	PROPN
dti-2343	180	12	;	;	PUNCT
dti-2343	180	13	fight	fight	VERB
dti-2343	180	14	retinal	retinal	ADJ
dti-2343	180	15	blindness	blindness	NOUN
dti-2343	180	16	study	study	NOUN
dti-2343	180	17	group	group	NOUN
dti-2343	180	18	.	.	PUNCT
dti-2343	181	1	treatment	treatment	NOUN
dti-2343	181	2	patterns	pattern	NOUN
dti-2343	181	3	and	and	CCONJ
dti-2343	181	4	visual	visual	ADJ
dti-2343	181	5	outcomes	outcome	NOUN
dti-2343	181	6	during	during	ADP
dti-2343	181	7	the	the	DET
dti-2343	181	8	maintenance	maintenance	NOUN
dti-2343	181	9	phase	phase	NOUN
dti-2343	181	10	of	of	ADP
dti-2343	181	11	treat	treat	NOUN
dti-2343	181	12	-	-	PUNCT
dti-2343	181	13	and	and	CCONJ
dti-2343	181	14	-	-	PUNCT
dti-2343	181	15	extend	extend	NOUN
dti-2343	181	16	therapy	therapy	NOUN
dti-2343	181	17	for	for	ADP
dti-2343	181	18	age	age	NOUN
dti-2343	181	19	-	-	PUNCT
dti-2343	181	20	related	relate	VERB
dti-2343	181	21	macular	macular	ADJ
dti-2343	181	22	degeneration	degeneration	NOUN
dti-2343	181	23	.	.	PUNCT
dti-2343	182	1	ophthalmology	ophthalmology	NOUN
dti-2343	182	2	.	.	PUNCT
dti-2343	183	1	2016	2016	NUM
dti-2343	183	2	;	;	PUNCT
dti-2343	184	1	123(11):2393	123(11):2393	PROPN
dti-2343	184	2	-	-	SYM
dti-2343	184	3	2400	2400	NUM
dti-2343	184	4	.	.	PUNCT
dti-2343	185	1	crossref	crossref	PROPN
dti-2343	185	2	pubmed	pubmed	PROPN
dti-2343	185	3	15	15	PROPN
dti-2343	185	4	.	.	PUNCT
dti-2343	186	1	nguyen	nguyen	PROPN
dti-2343	186	2	v	v	PROPN
dti-2343	186	3	,	,	PUNCT
dti-2343	186	4	vaze	vaze	NOUN
dti-2343	186	5	a	a	PRON
dti-2343	186	6	,	,	PUNCT
dti-2343	186	7	fraser	fraser	NOUN
dti-2343	186	8	-	-	PUNCT
dti-2343	186	9	bell	bell	NOUN
dti-2343	186	10	s	s	PROPN
dti-2343	186	11	,	,	PUNCT
dti-2343	186	12	et	et	PROPN
dti-2343	186	13	al	al	PROPN
dti-2343	186	14	;	;	PUNCT
dti-2343	186	15	fight	fight	VERB
dti-2343	186	16	retinal	retinal	ADJ
dti-2343	186	17	blindness	blindness	NOUN
dti-2343	186	18	!	!	PUNCT
dti-2343	187	1	study	study	NOUN
dti-2343	187	2	group	group	NOUN
dti-2343	187	3	.	.	PUNCT
dti-2343	188	1	outcomes	outcome	NOUN
dti-2343	188	2	of	of	ADP
dti-2343	188	3	suspending	suspend	VERB
dti-2343	188	4	vegf	vegf	NOUN
dti-2343	188	5	inhibitors	inhibitor	NOUN
dti-2343	188	6	for	for	ADP
dti-2343	188	7	neovascular	neovascular	NOUN
dti-2343	188	8	age	age	NOUN
dti-2343	188	9	-	-	PUNCT
dti-2343	188	10	related	relate	VERB
dti-2343	188	11	macular	macular	ADJ
dti-2343	188	12	degeneration	degeneration	NOUN
dti-2343	188	13	when	when	SCONJ
dti-2343	188	14	lesions	lesion	NOUN
dti-2343	188	15	have	have	AUX
dti-2343	188	16	been	be	AUX
dti-2343	188	17	inactive	inactive	ADJ
dti-2343	188	18	for	for	ADP
dti-2343	188	19	3	3	NUM
dti-2343	188	20	months	month	NOUN
dti-2343	188	21	.	.	PUNCT
dti-2343	189	1	ophthalmol	ophthalmol	PROPN
dti-2343	189	2	retina	retina	NOUN
dti-2343	189	3	.	.	PUNCT
dti-2343	190	1	2019;3(8	2019;3(8	NUM
dti-2343	190	2	):	):	PUNCT
dti-2343	190	3	623	623	NUM
dti-2343	190	4	-	-	SYM
dti-2343	190	5	628	628	NUM
dti-2343	190	6	.	.	PUNCT
dti-2343	191	1	crossref	crossref	PROPN
dti-2343	191	2	pubmed	pubmed	PROPN
dti-2343	191	3	16	16	NUM
dti-2343	191	4	.	.	PUNCT
dti-2343	192	1	rusakevich	rusakevich	PROPN
dti-2343	192	2	am	be	AUX
dti-2343	192	3	,	,	PUNCT
dti-2343	192	4	zhou	zhou	PROPN
dti-2343	192	5	b	b	PROPN
dti-2343	192	6	,	,	PUNCT
dti-2343	192	7	wong	wong	PROPN
dti-2343	192	8	tp	tp	PROPN
dti-2343	192	9	,	,	PUNCT
dti-2343	192	10	wykoff	wykoff	PROPN
dti-2343	192	11	cc	cc	PROPN
dti-2343	192	12	.	.	PROPN
dti-2343	192	13	quarterly	quarterly	ADJ
dti-2343	192	14	antivascular	antivascular	ADJ
dti-2343	192	15	endothelial	endothelial	ADJ
dti-2343	192	16	growth	growth	NOUN
dti-2343	192	17	factor	factor	NOUN
dti-2343	192	18	dosing	dose	VERB
dti-2343	192	19	for	for	ADP
dti-2343	192	20	neovascular	neovascular	NOUN
dti-2343	192	21	age	age	NOUN
dti-2343	192	22	-	-	PUNCT
dti-2343	192	23	related	relate	VERB
dti-2343	192	24	macular	macular	ADJ
dti-2343	192	25	degeneration	degeneration	NOUN
dti-2343	192	26	:	:	PUNCT
dti-2343	192	27	real	real	ADJ
dti-2343	192	28	-	-	PUNCT
dti-2343	192	29	world	world	NOUN
dti-2343	192	30	clinical	clinical	ADJ
dti-2343	192	31	outcomes	outcome	NOUN
dti-2343	192	32	.	.	PUNCT
dti-2343	193	1	ophthalmic	ophthalmic	ADJ
dti-2343	193	2	surg	surg	NOUN
dti-2343	193	3	lasers	laser	NOUN
dti-2343	193	4	imaging	imaging	NOUN
dti-2343	193	5	retina	retina	NOUN
dti-2343	193	6	.	.	PUNCT
dti-2343	194	1	2019;50(9	2019;50(9	NUM
dti-2343	194	2	):	):	PUNCT
dti-2343	194	3	e250	e250	PROPN
dti-2343	194	4	-	-	PUNCT
dti-2343	194	5	e256	e256	PROPN
dti-2343	194	6	.	.	PUNCT
dti-2343	194	7	crossref	crossref	PROPN
dti-2343	194	8	pubmed	pubmed	PROPN
dti-2343	194	9	https://doi.org/10.1016/j.ajo.2003.09.042	https://doi.org/10.1016/j.ajo.2003.09.042	PROPN
dti-2343	194	10	https://www.ncbi.nlm.nih.gov/pubmed/15013874	https://www.ncbi.nlm.nih.gov/pubmed/15013874	X
dti-2343	194	11	https://doi.org/10.1016/j.ophtha.2019.11.004	https://doi.org/10.1016/j.ophtha.2019.11.004	VERB
dti-2343	194	12	https://www.ncbi.nlm.nih.gov/pubmed/31864668	https://www.ncbi.nlm.nih.gov/pubmed/31864668	NUM
dti-2343	194	13	https://doi.org/10.1016/j.preteyeres.2015.07.007	https://doi.org/10.1016/j.preteyeres.2015.07.007	ADJ
dti-2343	194	14	https://www.ncbi.nlm.nih.gov/pubmed/26307399	https://www.ncbi.nlm.nih.gov/pubmed/26307399	NUM
dti-2343	194	15	https://doi.org/10.18553/jmcp.2018.24.2-a.s3	https://doi.org/10.18553/jmcp.2018.24.2-a.s3	NUM
dti-2343	194	16	https://pubmed.ncbi.nlm.nih.gov/29383980/	https://pubmed.ncbi.nlm.nih.gov/29383980/	PROPN
dti-2343	194	17	https://doi.org/10.1111/aos.12781	https://doi.org/10.1111/aos.12781	PROPN
dti-2343	194	18	https://www.ncbi.nlm.nih.gov/pubmed/26073051	https://www.ncbi.nlm.nih.gov/pubmed/26073051	NUM
dti-2343	194	19	https://doi.org/10.1007/s00417-014-2885-y	https://doi.org/10.1007/s00417-014-2885-y	PROPN
dti-2343	194	20	https://www.ncbi.nlm.nih.gov/pubmed/25491161	https://www.ncbi.nlm.nih.gov/pubmed/25491161	X
dti-2343	194	21	https://doi.org/10.1186/s12886-016-0207-3	https://doi.org/10.1186/s12886-016-0207-3	NOUN
dti-2343	194	22	https://www.ncbi.nlm.nih.gov/pubmed/27009515	https://www.ncbi.nlm.nih.gov/pubmed/27009515	NUM
dti-2343	194	23	https://doi.org/10.1007/s00417-017-3647-4	https://doi.org/10.1007/s00417-017-3647-4	NUM
dti-2343	194	24	https://www.ncbi.nlm.nih.gov/pubmed/28527040	https://www.ncbi.nlm.nih.gov/pubmed/28527040	NUM
dti-2343	194	25	https://doi.org/10.1016/j.ajo.2019.10.007	https://doi.org/10.1016/j.ajo.2019.10.007	VERB
dti-2343	194	26	https://www.ncbi.nlm.nih.gov/pubmed/31606444	https://www.ncbi.nlm.nih.gov/pubmed/31606444	PRON
dti-2343	194	27	https://doi.org/10.1038/s41433-020-0764-9	https://doi.org/10.1038/s41433-020-0764-9	NUM
dti-2343	194	28	https://www.ncbi.nlm.nih.gov/pubmed/31980748	https://www.ncbi.nlm.nih.gov/pubmed/31980748	NUM
dti-2343	194	29	https://doi.org/10.1016/j.ophtha.2012.09.006	https://doi.org/10.1016/j.ophtha.2012.09.006	PROPN
dti-2343	194	30	https://www.ncbi.nlm.nih.gov/pubmed/23084240	https://www.ncbi.nlm.nih.gov/pubmed/23084240	NUM
dti-2343	194	31	https://doi.org/10.1016/j.ophtha.2018.11.025	https://doi.org/10.1016/j.ophtha.2018.11.025	PROPN
dti-2343	194	32	https://www.ncbi.nlm.nih.gov/pubmed/30502372	https://www.ncbi.nlm.nih.gov/pubmed/30502372	X
dti-2343	194	33	https://doi.org/10.1016/j.ophtha.2019.10.006	https://doi.org/10.1016/j.ophtha.2019.10.006	PROPN
dti-2343	194	34	https://www.ncbi.nlm.nih.gov/pubmed/31757494	https://www.ncbi.nlm.nih.gov/pubmed/31757494	NUM
dti-2343	194	35	https://doi.org/10.1016/j.ophtha.2016.07.012	https://doi.org/10.1016/j.ophtha.2016.07.012	PROPN
dti-2343	194	36	https://www.ncbi.nlm.nih.gov/pubmed/27554034	https://www.ncbi.nlm.nih.gov/pubmed/27554034	NUM
dti-2343	194	37	https://doi.org/10.1016/j.oret.2019.05.013	https://doi.org/10.1016/j.oret.2019.05.013	PROPN
dti-2343	194	38	https://www.ncbi.nlm.nih.gov/pubmed/31281103	https://www.ncbi.nlm.nih.gov/pubmed/31281103	NUM
dti-2343	194	39	https://doi.org/10.3928/23258160-20190905-17	https://doi.org/10.3928/23258160-20190905-17	NOUN
dti-2343	194	40	https://www.ncbi.nlm.nih.gov/pubmed/31589766	https://www.ncbi.nlm.nih.gov/pubmed/31589766	PROPN
dti-2343	194	41	zuccarini	zuccarini	PROPN
dti-2343	194	42	et	et	PROPN
dti-2343	194	43	al	al	PROPN
dti-2343	194	44	drug	drug	PROPN
dti-2343	194	45	target	target	NOUN
dti-2343	194	46	insights	insight	NOUN
dti-2343	194	47	2022	2022	NUM
dti-2343	194	48	;	;	PUNCT
dti-2343	194	49	16	16	NUM
dti-2343	194	50	:	:	SYM
dti-2343	194	51	11	11	NUM
dti-2343	194	52	©	©	ADP
dti-2343	194	53	2022	2022	NUM
dti-2343	194	54	the	the	DET
dti-2343	194	55	authors	author	NOUN
dti-2343	194	56	.	.	PUNCT
dti-2343	195	1	published	publish	VERB
dti-2343	195	2	by	by	ADP
dti-2343	195	3	aboutscience	aboutscience	NOUN
dti-2343	195	4	www.aboutscience.eu	www.aboutscience.eu	PROPN
dti-2343	195	5	17	17	NUM
dti-2343	195	6	.	.	PUNCT
dti-2343	196	1	monés	monés	PROPN
dti-2343	196	2	j	j	PROPN
dti-2343	196	3	,	,	PUNCT
dti-2343	196	4	singh	singh	PROPN
dti-2343	196	5	rp	rp	NOUN
dti-2343	196	6	,	,	PUNCT
dti-2343	196	7	bandello	bandello	PROPN
dti-2343	196	8	f	f	PROPN
dti-2343	196	9	,	,	PUNCT
dti-2343	196	10	souied	souie	VERB
dti-2343	196	11	e	e	NOUN
dti-2343	196	12	,	,	PUNCT
dti-2343	196	13	liu	liu	PROPN
dti-2343	196	14	x	x	PROPN
dti-2343	196	15	,	,	PUNCT
dti-2343	196	16	gale	gale	PROPN
dti-2343	196	17	r.	r.	NOUN
dti-2343	196	18	undertreatment	undertreatment	NOUN
dti-2343	196	19	of	of	ADP
dti-2343	196	20	neovascular	neovascular	NOUN
dti-2343	196	21	age	age	NOUN
dti-2343	196	22	-	-	PUNCT
dti-2343	196	23	related	relate	VERB
dti-2343	196	24	macular	macular	ADJ
dti-2343	196	25	degeneration	degeneration	NOUN
dti-2343	196	26	after	after	ADP
dti-2343	196	27	10	10	NUM
dti-2343	196	28	years	year	NOUN
dti-2343	196	29	of	of	ADP
dti-2343	196	30	anti	anti	ADJ
dti-2343	196	31	-	-	ADJ
dti-2343	196	32	vascular	vascular	ADJ
dti-2343	196	33	endothelial	endothelial	ADJ
dti-2343	196	34	growth	growth	NOUN
dti-2343	196	35	factor	factor	NOUN
dti-2343	196	36	therapy	therapy	NOUN
dti-2343	196	37	in	in	ADP
dti-2343	196	38	the	the	DET
dti-2343	196	39	real	real	ADJ
dti-2343	196	40	world	world	NOUN
dti-2343	196	41	:	:	PUNCT
dti-2343	196	42	the	the	DET
dti-2343	196	43	need	need	NOUN
dti-2343	196	44	for	for	ADP
dti-2343	196	45	a	a	DET
dti-2343	196	46	change	change	NOUN
dti-2343	196	47	of	of	ADP
dti-2343	196	48	mindset	mindset	NOUN
dti-2343	196	49	.	.	PUNCT
dti-2343	197	1	ophthalmologica	ophthalmologica	NOUN
dti-2343	197	2	.	.	PUNCT
dti-2343	198	1	2020;243(1):1	2020;243(1):1	NUM
dti-2343	198	2	-	-	SYM
dti-2343	198	3	8	8	NUM
dti-2343	198	4	.	.	PUNCT
dti-2343	199	1	crossref	crossref	PROPN
dti-2343	199	2	pubmed	pubmed	PROPN
dti-2343	199	3	18	18	NUM
dti-2343	199	4	.	.	PUNCT
dti-2343	200	1	gillies	gillies	PROPN
dti-2343	200	2	mc	mc	PROPN
dti-2343	200	3	,	,	PUNCT
dti-2343	200	4	campain	campain	NOUN
dti-2343	200	5	a	a	PRON
dti-2343	200	6	,	,	PUNCT
dti-2343	200	7	barthelmes	barthelme	NOUN
dti-2343	200	8	d	d	NOUN
dti-2343	200	9	,	,	PUNCT
dti-2343	200	10	et	et	PROPN
dti-2343	200	11	al	al	PROPN
dti-2343	200	12	;	;	PUNCT
dti-2343	200	13	fight	fight	VERB
dti-2343	200	14	retinal	retinal	ADJ
dti-2343	200	15	blindness	blindness	NOUN
dti-2343	200	16	study	study	NOUN
dti-2343	200	17	group	group	NOUN
dti-2343	200	18	.	.	PUNCT
dti-2343	201	1	long	long	ADJ
dti-2343	201	2	-	-	PUNCT
dti-2343	201	3	term	term	NOUN
dti-2343	201	4	outcomes	outcome	NOUN
dti-2343	201	5	of	of	ADP
dti-2343	201	6	treatment	treatment	NOUN
dti-2343	201	7	of	of	ADP
dti-2343	201	8	neovascular	neovascular	NOUN
dti-2343	201	9	age	age	NOUN
dti-2343	201	10	-	-	PUNCT
dti-2343	201	11	related	relate	VERB
dti-2343	201	12	macular	macular	ADJ
dti-2343	201	13	degeneration	degeneration	NOUN
dti-2343	201	14	:	:	PUNCT
dti-2343	201	15	data	datum	NOUN
dti-2343	201	16	from	from	ADP
dti-2343	201	17	an	an	DET
dti-2343	201	18	observational	observational	ADJ
dti-2343	201	19	study	study	NOUN
dti-2343	201	20	.	.	PUNCT
dti-2343	202	1	ophthalmology	ophthalmology	NOUN
dti-2343	202	2	.	.	PUNCT
dti-2343	203	1	2015;122(9):1837	2015;122(9):1837	NUM
dti-2343	203	2	-	-	SYM
dti-2343	203	3	1845	1845	NUM
dti-2343	203	4	.	.	PUNCT
dti-2343	204	1	crossref	crossref	PROPN
dti-2343	204	2	pubmed	pubmed	PROPN
dti-2343	204	3	19	19	NUM
dti-2343	204	4	.	.	PUNCT
dti-2343	205	1	binder	binder	PROPN
dti-2343	205	2	s.	s.	PROPN
dti-2343	205	3	loss	loss	NOUN
dti-2343	205	4	of	of	ADP
dti-2343	205	5	reactivity	reactivity	NOUN
dti-2343	205	6	in	in	ADP
dti-2343	205	7	intravitreal	intravitreal	ADJ
dti-2343	205	8	anti	anti	ADJ
dti-2343	205	9	-	-	ADJ
dti-2343	205	10	vegf	vegf	ADJ
dti-2343	205	11	therapy	therapy	NOUN
dti-2343	205	12	:	:	PUNCT
dti-2343	205	13	tachyphylaxis	tachyphylaxis	NOUN
dti-2343	205	14	or	or	CCONJ
dti-2343	205	15	tolerance	tolerance	NOUN
dti-2343	205	16	?	?	PUNCT
dti-2343	206	1	br	br	PROPN
dti-2343	207	1	j	j	PROPN
dti-2343	207	2	ophthalmol	ophthalmol	PROPN
dti-2343	207	3	.	.	PUNCT
dti-2343	208	1	2012;96(1):1	2012;96(1):1	NUM
dti-2343	208	2	-	-	SYM
dti-2343	208	3	2	2	NUM
dti-2343	208	4	.	.	PUNCT
dti-2343	209	1	crossref	crossref	PROPN
dti-2343	209	2	pubmed	pubmed	PROPN
dti-2343	209	3	20	20	NUM
dti-2343	209	4	.	.	PUNCT
dti-2343	210	1	chakravarthy	chakravarthy	PROPN
dti-2343	210	2	u	u	NOUN
dti-2343	210	3	,	,	PUNCT
dti-2343	210	4	bezlyak	bezlyak	NOUN
dti-2343	210	5	v	v	NOUN
dti-2343	210	6	,	,	PUNCT
dti-2343	210	7	sagkriotis	sagkriotis	PROPN
dti-2343	210	8	a	a	PRON
dti-2343	210	9	,	,	PUNCT
dti-2343	210	10	et	et	PROPN
dti-2343	210	11	al	al	PROPN
dti-2343	210	12	.	.	PROPN
dti-2343	210	13	effectiveness	effectiveness	NOUN
dti-2343	210	14	of	of	ADP
dti-2343	210	15	continued	continue	VERB
dti-2343	210	16	ranibizumab	ranibizumab	NOUN
dti-2343	210	17	therapy	therapy	NOUN
dti-2343	210	18	in	in	ADP
dti-2343	210	19	neovascular	neovascular	NOUN
dti-2343	210	20	age	age	NOUN
dti-2343	210	21	-	-	PUNCT
dti-2343	210	22	related	relate	VERB
dti-2343	210	23	macular	macular	ADJ
dti-2343	210	24	degeneration	degeneration	NOUN
dti-2343	210	25	versus	versus	ADP
dti-2343	210	26	switch	switch	NOUN
dti-2343	210	27	to	to	ADP
dti-2343	210	28	aflibercept	aflibercept	VERB
dti-2343	210	29	:	:	PUNCT
dti-2343	210	30	real	real	ADJ
dti-2343	210	31	world	world	NOUN
dti-2343	210	32	evidence	evidence	NOUN
dti-2343	210	33	.	.	PUNCT
dti-2343	211	1	ophthalmol	ophthalmol	PROPN
dti-2343	211	2	retina	retina	NOUN
dti-2343	211	3	.	.	PUNCT
dti-2343	212	1	2019;3(1):8	2019;3(1):8	PROPN
dti-2343	212	2	-	-	PUNCT
dti-2343	212	3	15.e1	15.e1	PROPN
dti-2343	212	4	.	.	PUNCT
dti-2343	212	5	crossref	crossref	PROPN
dti-2343	212	6	pubmed	pubmed	PROPN
dti-2343	212	7	21	21	NUM
dti-2343	212	8	.	.	PUNCT
dti-2343	213	1	nguyen	nguyen	PROPN
dti-2343	213	2	cl	cl	PROPN
dti-2343	213	3	,	,	PUNCT
dti-2343	213	4	gillies	gillie	NOUN
dti-2343	213	5	mc	mc	PROPN
dti-2343	213	6	,	,	PUNCT
dti-2343	213	7	nguyen	nguyen	PROPN
dti-2343	213	8	v	v	PROPN
dti-2343	213	9	,	,	PUNCT
dti-2343	213	10	et	et	PROPN
dti-2343	213	11	al	al	PROPN
dti-2343	213	12	;	;	PUNCT
dti-2343	213	13	fight	fight	VERB
dti-2343	213	14	retinal	retinal	ADJ
dti-2343	213	15	blindness	blindness	NOUN
dti-2343	213	16	!	!	PUNCT
dti-2343	214	1	study	study	NOUN
dti-2343	214	2	group	group	NOUN
dti-2343	214	3	.	.	PUNCT
dti-2343	215	1	characterization	characterization	NOUN
dti-2343	215	2	of	of	ADP
dti-2343	215	3	poor	poor	ADJ
dti-2343	215	4	visual	visual	ADJ
dti-2343	215	5	outcomes	outcome	NOUN
dti-2343	215	6	of	of	ADP
dti-2343	215	7	neovascular	neovascular	NOUN
dti-2343	215	8	age	age	NOUN
dti-2343	215	9	-	-	PUNCT
dti-2343	215	10	related	relate	VERB
dti-2343	215	11	macular	macular	ADJ
dti-2343	215	12	degeneration	degeneration	NOUN
dti-2343	215	13	treated	treat	VERB
dti-2343	215	14	with	with	ADP
dti-2343	215	15	antivascular	antivascular	ADJ
dti-2343	215	16	endothelial	endothelial	ADJ
dti-2343	215	17	growth	growth	NOUN
dti-2343	215	18	factor	factor	NOUN
dti-2343	215	19	agents	agent	NOUN
dti-2343	215	20	.	.	PUNCT
dti-2343	216	1	ophthalmology	ophthalmology	NOUN
dti-2343	216	2	.	.	PUNCT
dti-2343	217	1	2019;126(5):735	2019;126(5):735	NUM
dti-2343	217	2	-	-	SYM
dti-2343	217	3	742	742	NUM
dti-2343	217	4	.	.	PUNCT
dti-2343	218	1	crossref	crossref	PROPN
dti-2343	218	2	pubmed	pubmed	PROPN
dti-2343	218	3	22	22	NUM
dti-2343	218	4	.	.	PUNCT
dti-2343	219	1	salcedo	salcedo	PROPN
dti-2343	219	2	-	-	PUNCT
dti-2343	219	3	villanueva	villanueva	PROPN
dti-2343	219	4	g	g	PROPN
dti-2343	219	5	,	,	PUNCT
dti-2343	219	6	feria	feria	PROPN
dti-2343	219	7	-	-	PUNCT
dti-2343	219	8	anzaldo	anzaldo	PROPN
dti-2343	219	9	e	e	PROPN
dti-2343	219	10	,	,	PUNCT
dti-2343	219	11	romo	romo	NOUN
dti-2343	219	12	-	-	PUNCT
dti-2343	219	13	aguas	aguas	PROPN
dti-2343	219	14	jc	jc	PROPN
dti-2343	219	15	,	,	PUNCT
dti-2343	219	16	et	et	PROPN
dti-2343	219	17	al	al	PROPN
dti-2343	219	18	.	.	PUNCT
dti-2343	220	1	anti	anti	ADJ
dti-2343	220	2	-	-	ADJ
dti-2343	220	3	vegf	vegf	ADJ
dti-2343	220	4	treatment	treatment	NOUN
dti-2343	220	5	switch	switch	NOUN
dti-2343	220	6	in	in	ADP
dti-2343	220	7	neovascular	neovascular	NOUN
dti-2343	220	8	age	age	NOUN
dti-2343	220	9	-	-	PUNCT
dti-2343	220	10	related	relate	VERB
dti-2343	220	11	macular	macular	ADJ
dti-2343	220	12	degeneration	degeneration	NOUN
dti-2343	220	13	:	:	PUNCT
dti-2343	220	14	a	a	DET
dti-2343	220	15	comparison	comparison	NOUN
dti-2343	220	16	of	of	ADP
dti-2343	220	17	aflibercept	aflibercept	PRON
dti-2343	220	18	versus	versus	ADP
dti-2343	220	19	ranibizumab	ranibizumab	NOUN
dti-2343	220	20	after	after	ADP
dti-2343	220	21	a	a	DET
dti-2343	220	22	single	single	ADJ
dti-2343	220	23	-	-	PUNCT
dti-2343	220	24	dose	dose	NOUN
dti-2343	220	25	switch	switch	NOUN
dti-2343	220	26	.	.	PUNCT
dti-2343	221	1	int	int	NOUN
dti-2343	221	2	ophthalmol	ophthalmol	PROPN
dti-2343	221	3	.	.	PUNCT
dti-2343	222	1	2019;39(9):20232031	2019;39(9):20232031	NOUN
dti-2343	222	2	.	.	PUNCT
dti-2343	223	1	crossref	crossref	PROPN
dti-2343	223	2	pubmed	pubmed	PROPN
dti-2343	223	3	23	23	NUM
dti-2343	223	4	.	.	PUNCT
dti-2343	224	1	dugel	dugel	PROPN
dti-2343	224	2	pu	pu	PROPN
dti-2343	224	3	,	,	PUNCT
dti-2343	224	4	singh	singh	PROPN
dti-2343	224	5	rp	rp	NOUN
dti-2343	224	6	,	,	PUNCT
dti-2343	224	7	koh	koh	PROPN
dti-2343	224	8	a	a	X
dti-2343	224	9	,	,	PUNCT
dti-2343	224	10	et	et	PROPN
dti-2343	224	11	al	al	PROPN
dti-2343	224	12	.	.	PROPN
dti-2343	224	13	hawk	hawk	PROPN
dti-2343	224	14	and	and	CCONJ
dti-2343	224	15	harrier	harrier	PROPN
dti-2343	224	16	:	:	PUNCT
dti-2343	224	17	ninetysix	ninetysix	ADJ
dti-2343	224	18	-	-	PUNCT
dti-2343	224	19	week	week	NOUN
dti-2343	224	20	outcomes	outcome	NOUN
dti-2343	224	21	from	from	ADP
dti-2343	224	22	the	the	DET
dti-2343	224	23	phase	phase	NOUN
dti-2343	224	24	3	3	NUM
dti-2343	224	25	trials	trial	NOUN
dti-2343	224	26	of	of	ADP
dti-2343	224	27	brolucizumab	brolucizumab	NOUN
dti-2343	224	28	for	for	ADP
dti-2343	224	29	neovascular	neovascular	NOUN
dti-2343	224	30	age	age	NOUN
dti-2343	224	31	-	-	PUNCT
dti-2343	224	32	related	relate	VERB
dti-2343	224	33	macular	macular	ADJ
dti-2343	224	34	degeneration	degeneration	NOUN
dti-2343	224	35	.	.	PUNCT
dti-2343	225	1	ophthalmology	ophthalmology	NOUN
dti-2343	225	2	.	.	PUNCT
dti-2343	226	1	2021;128(1):89	2021;128(1):89	NUM
dti-2343	226	2	-	-	SYM
dti-2343	226	3	99	99	NUM
dti-2343	226	4	.	.	PUNCT
dti-2343	227	1	crossref	crossref	PROPN
dti-2343	227	2	pubmed	pubmed	PROPN
dti-2343	227	3	24	24	NUM
dti-2343	227	4	.	.	PUNCT
dti-2343	228	1	dugel	dugel	PROPN
dti-2343	228	2	pu	pu	PROPN
dti-2343	228	3	,	,	PUNCT
dti-2343	228	4	koh	koh	PROPN
dti-2343	228	5	a	a	X
dti-2343	228	6	,	,	PUNCT
dti-2343	228	7	ogura	ogura	PROPN
dti-2343	228	8	y	y	PROPN
dti-2343	228	9	,	,	PUNCT
dti-2343	228	10	et	et	PROPN
dti-2343	228	11	al	al	PROPN
dti-2343	228	12	;	;	PUNCT
dti-2343	228	13	hawk	hawk	NOUN
dti-2343	228	14	and	and	CCONJ
dti-2343	228	15	harrier	harrier	PROPN
dti-2343	228	16	study	study	NOUN
dti-2343	228	17	investigators	investigator	NOUN
dti-2343	228	18	.	.	PUNCT
dti-2343	229	1	hawk	hawk	NOUN
dti-2343	229	2	and	and	CCONJ
dti-2343	229	3	harrier	harrier	NOUN
dti-2343	229	4	:	:	PUNCT
dti-2343	229	5	phase	phase	NOUN
dti-2343	229	6	3	3	NUM
dti-2343	229	7	,	,	PUNCT
dti-2343	229	8	multicenter	multicenter	NOUN
dti-2343	229	9	,	,	PUNCT
dti-2343	229	10	randomized	randomize	VERB
dti-2343	229	11	,	,	PUNCT
dti-2343	229	12	double	double	ADJ
dti-2343	229	13	-	-	PUNCT
dti-2343	229	14	masked	mask	VERB
dti-2343	229	15	trials	trial	NOUN
dti-2343	229	16	of	of	ADP
dti-2343	229	17	brolucizumab	brolucizumab	NOUN
dti-2343	229	18	for	for	ADP
dti-2343	229	19	neovascular	neovascular	NOUN
dti-2343	229	20	age	age	NOUN
dti-2343	229	21	-	-	PUNCT
dti-2343	229	22	related	relate	VERB
dti-2343	229	23	macular	macular	ADJ
dti-2343	229	24	degeneration	degeneration	NOUN
dti-2343	229	25	.	.	PUNCT
dti-2343	230	1	ophthalmology	ophthalmology	NOUN
dti-2343	230	2	.	.	PUNCT
dti-2343	231	1	2020;127(1):72	2020;127(1):72	NUM
dti-2343	231	2	-	-	SYM
dti-2343	231	3	84	84	NUM
dti-2343	231	4	.	.	PUNCT
dti-2343	232	1	crossref	crossref	PROPN
dti-2343	232	2	pubmed	pubmed	PROPN
dti-2343	232	3	25	25	NUM
dti-2343	232	4	.	.	PUNCT
dti-2343	233	1	sharma	sharma	PROPN
dti-2343	233	2	a	a	PROPN
dti-2343	233	3	,	,	PUNCT
dti-2343	233	4	kumar	kumar	PROPN
dti-2343	233	5	n	n	PROPN
dti-2343	233	6	,	,	PUNCT
dti-2343	233	7	parachuri	parachuri	PROPN
dti-2343	233	8	n	n	PROPN
dti-2343	233	9	,	,	PUNCT
dti-2343	233	10	et	et	PROPN
dti-2343	233	11	al	al	PROPN
dti-2343	233	12	.	.	PROPN
dti-2343	233	13	brolucizumab	brolucizumab	PROPN
dti-2343	233	14	-	-	PUNCT
dti-2343	233	15	early	early	ADJ
dti-2343	233	16	realworld	realworld	PROPN
dti-2343	233	17	experience	experience	NOUN
dti-2343	233	18	:	:	PUNCT
dti-2343	233	19	brew	brew	VERB
dti-2343	233	20	study	study	NOUN
dti-2343	233	21	.	.	PUNCT
dti-2343	234	1	eye	eye	NOUN
dti-2343	234	2	(	(	PUNCT
dti-2343	234	3	lond	lond	PROPN
dti-2343	234	4	)	)	PUNCT
dti-2343	234	5	.	.	PUNCT
dti-2343	235	1	2021;35(4):10451047	2021;35(4):10451047	NUM
dti-2343	235	2	.	.	PUNCT
dti-2343	236	1	crossref	crossref	PROPN
dti-2343	236	2	pubmed	pubmed	PROPN
dti-2343	236	3	26	26	NUM
dti-2343	236	4	.	.	PUNCT
dti-2343	237	1	avaylon	avaylon	PROPN
dti-2343	237	2	j	j	PROPN
dti-2343	237	3	,	,	PUNCT
dti-2343	237	4	lee	lee	PROPN
dti-2343	237	5	s	s	PART
dti-2343	237	6	,	,	PUNCT
dti-2343	237	7	gallemore	gallemore	VERB
dti-2343	237	8	rp	rp	NOUN
dti-2343	237	9	.	.	PUNCT
dti-2343	237	10	case	case	NOUN
dti-2343	237	11	series	series	NOUN
dti-2343	237	12	on	on	ADP
dti-2343	237	13	initial	initial	ADJ
dti-2343	237	14	responses	response	NOUN
dti-2343	237	15	to	to	PART
dti-2343	237	16	intravitreal	intravitreal	ADJ
dti-2343	237	17	brolucizumab	brolucizumab	NOUN
dti-2343	237	18	in	in	ADP
dti-2343	237	19	patients	patient	NOUN
dti-2343	237	20	with	with	ADP
dti-2343	237	21	recalcitrant	recalcitrant	ADJ
dti-2343	237	22	chronic	chronic	ADJ
dti-2343	237	23	wet	wet	ADJ
dti-2343	237	24	age	age	NOUN
dti-2343	237	25	-	-	PUNCT
dti-2343	237	26	related	relate	VERB
dti-2343	237	27	macular	macular	ADJ
dti-2343	237	28	degeneration	degeneration	NOUN
dti-2343	237	29	.	.	PUNCT
dti-2343	238	1	int	int	PROPN
dti-2343	238	2	med	med	PROPN
dti-2343	238	3	case	case	NOUN
dti-2343	238	4	rep	rep	PROPN
dti-2343	238	5	j.	j.	PROPN
dti-2343	238	6	2020;13:145	2020;13:145	PROPN
dti-2343	238	7	-	-	SYM
dti-2343	238	8	152	152	NUM
dti-2343	238	9	.	.	PUNCT
dti-2343	239	1	crossref	crossref	PROPN
dti-2343	239	2	pubmed	pubmed	PROPN
dti-2343	239	3	27	27	NUM
dti-2343	239	4	.	.	PUNCT
dti-2343	240	1	seguin	seguin	PROPN
dti-2343	240	2	-	-	PUNCT
dti-2343	240	3	greenstein	greenstein	PROPN
dti-2343	240	4	s	s	PROPN
dti-2343	240	5	,	,	PUNCT
dti-2343	240	6	lightman	lightman	PROPN
dti-2343	240	7	s	s	PROPN
dti-2343	240	8	,	,	PUNCT
dti-2343	240	9	tomkins	tomkins	PROPN
dti-2343	240	10	-	-	PUNCT
dti-2343	240	11	netzer	netzer	PROPN
dti-2343	240	12	o.	o.	PROPN
dti-2343	240	13	a	a	DET
dti-2343	240	14	metaanalysis	metaanalysis	NOUN
dti-2343	240	15	of	of	ADP
dti-2343	240	16	studies	study	NOUN
dti-2343	240	17	evaluating	evaluate	VERB
dti-2343	240	18	visual	visual	ADJ
dti-2343	240	19	and	and	CCONJ
dti-2343	240	20	anatomical	anatomical	ADJ
dti-2343	240	21	outcomes	outcome	NOUN
dti-2343	240	22	in	in	ADP
dti-2343	240	23	patients	patient	NOUN
dti-2343	240	24	with	with	ADP
dti-2343	240	25	treatment	treatment	NOUN
dti-2343	240	26	resistant	resistant	ADJ
dti-2343	240	27	neovascular	neovascular	NOUN
dti-2343	240	28	age	age	NOUN
dti-2343	240	29	-	-	PUNCT
dti-2343	240	30	related	relate	VERB
dti-2343	240	31	macular	macular	ADJ
dti-2343	240	32	degeneration	degeneration	NOUN
dti-2343	240	33	following	follow	VERB
dti-2343	240	34	switching	switch	VERB
dti-2343	240	35	to	to	ADP
dti-2343	240	36	treatment	treatment	NOUN
dti-2343	240	37	with	with	ADP
dti-2343	240	38	aflibercept	aflibercept	NOUN
dti-2343	240	39	.	.	PUNCT
dti-2343	241	1	j	j	PROPN
dti-2343	241	2	ophthalmol	ophthalmol	PROPN
dti-2343	241	3	.	.	PUNCT
dti-2343	242	1	2016;2016:4095852	2016;2016:4095852	NUM
dti-2343	242	2	.	.	PUNCT
dti-2343	243	1	crossref	crossref	PROPN
dti-2343	243	2	pubmed	pubmed	PROPN
dti-2343	243	3	28	28	PROPN
dti-2343	243	4	.	.	PUNCT
dti-2343	244	1	enríquez	enríquez	PROPN
dti-2343	244	2	ab	ab	PROPN
dti-2343	244	3	,	,	PUNCT
dti-2343	244	4	baumal	baumal	ADJ
dti-2343	244	5	cr	cr	PROPN
dti-2343	244	6	,	,	PUNCT
dti-2343	244	7	crane	crane	NOUN
dti-2343	244	8	am	am	NOUN
dti-2343	244	9	,	,	PUNCT
dti-2343	244	10	et	et	PROPN
dti-2343	244	11	al	al	PROPN
dti-2343	244	12	.	.	PUNCT
dti-2343	245	1	early	early	ADJ
dti-2343	245	2	experience	experience	NOUN
dti-2343	245	3	with	with	ADP
dti-2343	245	4	brolucizumab	brolucizumab	NOUN
dti-2343	245	5	treatment	treatment	NOUN
dti-2343	245	6	of	of	ADP
dti-2343	245	7	neovascular	neovascular	NOUN
dti-2343	245	8	age	age	NOUN
dti-2343	245	9	-	-	PUNCT
dti-2343	245	10	related	relate	VERB
dti-2343	245	11	macular	macular	ADJ
dti-2343	245	12	degeneration	degeneration	NOUN
dti-2343	245	13	.	.	PUNCT
dti-2343	246	1	jama	jama	PROPN
dti-2343	246	2	ophthalmol	ophthalmol	PROPN
dti-2343	246	3	.	.	PUNCT
dti-2343	247	1	2021;139(4):441	2021;139(4):441	NUM
dti-2343	247	2	-	-	SYM
dti-2343	247	3	448	448	NUM
dti-2343	247	4	.	.	PUNCT
dti-2343	248	1	crossref	crossref	PROPN
dti-2343	248	2	pubmed	pubmed	PROPN
dti-2343	248	3	29	29	NUM
dti-2343	248	4	.	.	PUNCT
dti-2343	249	1	bontzos	bontzos	PROPN
dti-2343	249	2	g	g	PROPN
dti-2343	249	3	,	,	PUNCT
dti-2343	249	4	bagheri	bagheri	PROPN
dti-2343	249	5	s	s	PROPN
dti-2343	249	6	,	,	PUNCT
dti-2343	249	7	ioanidi	ioanidi	ADJ
dti-2343	249	8	l	l	NOUN
dti-2343	249	9	,	,	PUNCT
dti-2343	249	10	et	et	PROPN
dti-2343	249	11	al	al	PROPN
dti-2343	249	12	.	.	PUNCT
dti-2343	249	13	nonresponders	nonresponder	NOUN
dti-2343	249	14	to	to	PART
dti-2343	249	15	ranibizumab	ranibizumab	VERB
dti-2343	249	16	anti	anti	ADJ
dti-2343	249	17	-	-	ADJ
dti-2343	249	18	vegf	vegf	ADJ
dti-2343	249	19	treatment	treatment	NOUN
dti-2343	249	20	are	be	AUX
dti-2343	249	21	actually	actually	ADV
dti-2343	249	22	short	short	ADJ
dti-2343	249	23	-	-	PUNCT
dti-2343	249	24	term	term	NOUN
dti-2343	249	25	responders	responder	NOUN
dti-2343	249	26	:	:	PUNCT
dti-2343	249	27	a	a	DET
dti-2343	249	28	prospective	prospective	ADJ
dti-2343	249	29	spectral	spectral	ADJ
dti-2343	249	30	-	-	PUNCT
dti-2343	249	31	domain	domain	NOUN
dti-2343	249	32	oct	oct	PROPN
dti-2343	249	33	study	study	NOUN
dti-2343	249	34	.	.	PUNCT
dti-2343	250	1	ophthalmol	ophthalmol	PROPN
dti-2343	250	2	retina	retina	PROPN
dti-2343	250	3	.	.	PUNCT
dti-2343	251	1	2020;4(12):1138	2020;4(12):1138	NUM
dti-2343	251	2	-	-	SYM
dti-2343	251	3	1145	1145	NUM
dti-2343	251	4	.	.	PUNCT
dti-2343	252	1	crossref	crossref	PROPN
dti-2343	252	2	pubmed	pubmed	PROPN
dti-2343	252	3	30	30	NUM
dti-2343	252	4	.	.	PUNCT
dti-2343	253	1	zola	zola	PROPN
dti-2343	253	2	m	m	PROPN
dti-2343	253	3	,	,	PUNCT
dti-2343	253	4	d’alessandro	d’alessandro	PROPN
dti-2343	253	5	e	e	NOUN
dti-2343	253	6	,	,	PUNCT
dti-2343	253	7	sherif	sherif	PROPN
dti-2343	253	8	m	m	PROPN
dti-2343	253	9	,	,	PUNCT
dti-2343	253	10	et	et	PROPN
dti-2343	253	11	al	al	PROPN
dti-2343	253	12	.	.	PUNCT
dti-2343	254	1	refractory	refractory	PROPN
dti-2343	254	2	neovascular	neovascular	PROPN
dti-2343	254	3	age	age	NOUN
dti-2343	254	4	-	-	PUNCT
dti-2343	254	5	related	relate	VERB
dti-2343	254	6	macular	macular	ADJ
dti-2343	254	7	degeneration	degeneration	NOUN
dti-2343	254	8	:	:	PUNCT
dti-2343	254	9	time	time	NOUN
dti-2343	254	10	-	-	PUNCT
dti-2343	254	11	dependent	dependent	ADJ
dti-2343	254	12	changes	change	NOUN
dti-2343	254	13	of	of	ADP
dti-2343	254	14	central	central	ADJ
dti-2343	254	15	retinal	retinal	ADJ
dti-2343	254	16	thickness	thickness	NOUN
dti-2343	254	17	with	with	ADP
dti-2343	254	18	anti	anti	ADJ
dti-2343	254	19	-	-	ADJ
dti-2343	254	20	vegf	vegf	ADJ
dti-2343	254	21	treatment	treatment	NOUN
dti-2343	254	22	.	.	PUNCT
dti-2343	255	1	graefes	graefes	PROPN
dti-2343	255	2	arch	arch	PROPN
dti-2343	255	3	clin	clin	PROPN
dti-2343	255	4	exp	exp	PROPN
dti-2343	255	5	ophthalmol	ophthalmol	PROPN
dti-2343	255	6	.	.	PUNCT
dti-2343	256	1	2021	2021	NUM
dti-2343	256	2	jun;259(6):1477	jun;259(6):1477	NOUN
dti-2343	256	3	-	-	PUNCT
dti-2343	256	4	1486	1486	NUM
dti-2343	256	5	crossref	crossref	PROPN
dti-2343	256	6	pubmed	pubmed	PROPN
dti-2343	256	7	31	31	NUM
dti-2343	256	8	.	.	PUNCT
dti-2343	257	1	monés	monés	PROPN
dti-2343	257	2	j	j	PROPN
dti-2343	257	3	,	,	PUNCT
dti-2343	257	4	srivastava	srivastava	PROPN
dti-2343	257	5	sk	sk	PROPN
dti-2343	257	6	,	,	PUNCT
dti-2343	257	7	jaffe	jaffe	PROPN
dti-2343	257	8	gj	gj	PROPN
dti-2343	257	9	,	,	PUNCT
dti-2343	257	10	et	et	PROPN
dti-2343	257	11	al	al	PROPN
dti-2343	257	12	.	.	PROPN
dti-2343	257	13	risk	risk	NOUN
dti-2343	257	14	of	of	ADP
dti-2343	257	15	inflammation	inflammation	NOUN
dti-2343	257	16	,	,	PUNCT
dti-2343	257	17	retinal	retinal	ADJ
dti-2343	257	18	vasculitis	vasculitis	NOUN
dti-2343	257	19	,	,	PUNCT
dti-2343	257	20	and	and	CCONJ
dti-2343	257	21	retinal	retinal	ADJ
dti-2343	257	22	occlusion	occlusion	NOUN
dti-2343	257	23	-	-	PUNCT
dti-2343	257	24	related	relate	VERB
dti-2343	257	25	events	event	NOUN
dti-2343	257	26	with	with	ADP
dti-2343	257	27	brolucizumab	brolucizumab	NOUN
dti-2343	257	28	:	:	PUNCT
dti-2343	257	29	post	post	X
dti-2343	257	30	hoc	hoc	X
dti-2343	257	31	review	review	NOUN
dti-2343	257	32	of	of	ADP
dti-2343	257	33	hawk	hawk	NOUN
dti-2343	257	34	and	and	CCONJ
dti-2343	257	35	harrier	harrier	NOUN
dti-2343	257	36	.	.	PUNCT
dti-2343	258	1	ophthalmology	ophthalmology	PROPN
dti-2343	258	2	.	.	PUNCT
dti-2343	259	1	2021	2021	NUM
dti-2343	259	2	jul;128(7):1050	jul;128(7):1050	PROPN
dti-2343	259	3	-	-	PUNCT
dti-2343	259	4	1059	1059	NUM
dti-2343	259	5	.	.	PUNCT
dti-2343	260	1	crossref	crossref	PROPN
dti-2343	260	2	pubmed	pubmed	PROPN
dti-2343	260	3	https://doi.org/10.1159/000502747	https://doi.org/10.1159/000502747	PROPN
dti-2343	260	4	https://www.ncbi.nlm.nih.gov/pubmed/31743912	https://www.ncbi.nlm.nih.gov/pubmed/31743912	PROPN
dti-2343	260	5	https://doi.org/10.1016/j.ophtha.2015.05.010	https://doi.org/10.1016/j.ophtha.2015.05.010	PROPN
dti-2343	260	6	https://www.ncbi.nlm.nih.gov/pubmed/26096346	https://www.ncbi.nlm.nih.gov/pubmed/26096346	VERB
dti-2343	260	7	https://doi.org/10.1136/bjophthalmol-2011-301236	https://doi.org/10.1136/bjophthalmol-2011-301236	PROPN
dti-2343	260	8	https://www.ncbi.nlm.nih.gov/pubmed/22157632	https://www.ncbi.nlm.nih.gov/pubmed/22157632	NUM
dti-2343	260	9	https://doi.org/10.1016/j.oret.2018.09.001	https://doi.org/10.1016/j.oret.2018.09.001	PROPN
dti-2343	260	10	https://www.ncbi.nlm.nih.gov/pubmed/30929819	https://www.ncbi.nlm.nih.gov/pubmed/30929819	NUM
dti-2343	260	11	https://doi.org/10.1016/j.ophtha.2018.11.036	https://doi.org/10.1016/j.ophtha.2018.11.036	NOUN
dti-2343	260	12	https://www.ncbi.nlm.nih.gov/pubmed/30529685	https://www.ncbi.nlm.nih.gov/pubmed/30529685	CCONJ
dti-2343	260	13	https://doi.org/10.1007/s10792-018-1038-4	https://doi.org/10.1007/s10792-018-1038-4	NUM
dti-2343	260	14	https://www.ncbi.nlm.nih.gov/pubmed/30386955	https://www.ncbi.nlm.nih.gov/pubmed/30386955	VERB
dti-2343	260	15	https://doi.org/10.1016/j.ophtha.2020.06.028	https://doi.org/10.1016/j.ophtha.2020.06.028	ADJ
dti-2343	260	16	https://www.ncbi.nlm.nih.gov/pubmed/32574761	https://www.ncbi.nlm.nih.gov/pubmed/32574761	NUM
dti-2343	260	17	https://doi.org/10.1016/j.ophtha.2019.04.017	https://doi.org/10.1016/j.ophtha.2019.04.017	NUM
dti-2343	260	18	https://www.ncbi.nlm.nih.gov/pubmed/30986442	https://www.ncbi.nlm.nih.gov/pubmed/30986442	NUM
dti-2343	261	1	https://doi.org/10.1038/s41433-020-1111-x	https://doi.org/10.1038/s41433-020-1111-x	PROPN
dti-2343	261	2	https://www.ncbi.nlm.nih.gov/pubmed/32709960	https://www.ncbi.nlm.nih.gov/pubmed/32709960	PROPN
dti-2343	261	3	https://doi.org/10.2147/imcrj.s252260	https://doi.org/10.2147/imcrj.s252260	PROPN
dti-2343	261	4	https://www.ncbi.nlm.nih.gov/pubmed/32494207	https://www.ncbi.nlm.nih.gov/pubmed/32494207	PROPN
dti-2343	261	5	https://doi.org/10.1155/2016/4095852	https://doi.org/10.1155/2016/4095852	PROPN
dti-2343	261	6	https://www.ncbi.nlm.nih.gov/pubmed/27042342	https://www.ncbi.nlm.nih.gov/pubmed/27042342	X
dti-2343	262	1	https://doi.org/10.1001/jamaophthalmol.2020.7085	https://doi.org/10.1001/jamaophthalmol.2020.7085	PROPN
dti-2343	262	2	https://www.ncbi.nlm.nih.gov/pubmed/33630045	https://www.ncbi.nlm.nih.gov/pubmed/33630045	PRON
dti-2343	262	3	https://doi.org/10.1016/j.oret.2019.11.004	https://doi.org/10.1016/j.oret.2019.11.004	NOUN
dti-2343	262	4	https://www.ncbi.nlm.nih.gov/pubmed/31937473	https://www.ncbi.nlm.nih.gov/pubmed/31937473	NUM
dti-2343	262	5	https://www.ncbi.nlm.nih.gov/pubmed/31937473	https://www.ncbi.nlm.nih.gov/pubmed/31937473	NUM
dti-2343	262	6	https://doi.org/10.1007/s00417-020-05000-3	https://doi.org/10.1007/s00417-020-05000-3	NUM
dti-2343	262	7	https://www.ncbi.nlm.nih.gov/pubmed/33245426	https://www.ncbi.nlm.nih.gov/pubmed/33245426	NUM
dti-2343	262	8	https://doi.org/10.1016/j.ophtha.2020.11.011	https://doi.org/10.1016/j.ophtha.2020.11.011	NOUN
dti-2343	262	9	https://www.ncbi.nlm.nih.gov/pubmed/33207259	https://www.ncbi.nlm.nih.gov/pubmed/33207259	NUM